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ABSTRACT'
The incidence and mortality from cardiovascular disease (CVD) in patients with 
chronic kidney disease (CKD) far exceeds that seen in the general population. 
Whilst a number of risk factors and associations have been identified in patients 
with CKD that may contribute to the increased risk of CVD, our understanding of 
the underlying pathophysiology remains poor. 
 
It has previously been reported that uraemic animals sustain larger myocardial 
infarcts and that this ‘reduced ischaemia tolerance’ may in part explain the excess 
mortality from CVD seen in CKD patients. The aim of this work was to establish 
an in vivo model of uraemic myocardial infarction in order to further explore the 
pathophysiology of uraemic CVD with particular focus on ameliorating 
myocardial ischaemia-reperfusion injury using ischaemic and pharmacological 
preconditioning.  
 
An increase in myocardial infarct size was demonstrated in the sub-total 
nephrectomy model of chronic uraemia, confirming previous reports in the 
literature. However, infarct size was not found to be increased in adenine diet 
induced renal failure. In addition, it was demonstrated for the first time, that the 
techniques of ischaemic preconditioning (IPC) and remote ischaemic 
preconditioning (RIPC) are both efficacious and not attenuated by chronic 
uraemia induced by sub-total nephrectomy or adenine diet (IPC only). 
Investigations were undertaken using an agent (a HIF stabiliser, FG4497) to 
induce pharmacological preconditioning in both animals with renal insufficiency 
and those without. These studies demonstrate that stabilisation of hypoxia 
inducible factor (HIF) may be a promising strategy to induce pharmacological 
preconditioning. 
 
It is hoped that this work may lay the foundations for future investigations to 
determine why sub-totally nephrectomised rats have larger infarcts whilst those 
with adenine induced renal failure, with a substantially greater degree of renal 
dysfunction, do not. Moreover, it is hoped that; by demonstrating that uraemia 
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does not prevent or attenuate the myocardial protection afforded by ischaemic 
preconditioning, the recruitment of patients with CKD will be encouraged to 
clinical trials of both ischaemic preconditioning and other therapies to limit 
myocardial infarction.
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1.1 General)comments)
Cardiovascular disease is the leading cause of death for patients with moderate to 
severe chronic kidney disease (CKD, stages 3-5), and remains amongst the most 
common cause of death for recipients of renal transplants.1,2 Whilst the majority of 
deaths of individuals with CKD attributible to cardiovascular casues are the result 
of heart failure or sudden cardiac death, the rate of acute myocardial infarction 
(AMI) amongst patients with CKD is more than twice that of patients without 
CKD.3 There is a graduated risk of death for patients with kidney disease post 
AMI. Hospital mortality is in the order of 26-32%,4,5 some 15 times the rate for 
patients without CKD (2% in-hospital mortality) and is associated with greater 
than twice the risk of in-hospital mortality compared with diabetic patients 
without CKD.6 One year survival for dialysis patients post MI is a little over 40%7 
and despite significant advances in the management of AMI over the last 30 years, 
there has been little change in the prognosis for patients with CKD post AMI. Up 
to one third of patients presenting with an acute coronary syndrome (ACS) have 
CKD stage 3-5.4,8,9 
 
Despite making up a sizeable proportion of patients presenting with both ST 
elevation (STEMI) and non-ST elevation myocardial infarction (NSTEMI) such 
patients are routinely excluded from clinical trials10,11 resulting in a dearth of 
prospective data on which to base clinical practice guidelines. A consistent 
feature of observational studies has been the recognition that patients with CKD 
are less likely to receive reperfusion or revascularization therapies. This 
underutilization of such treatments, so called “therapeutic nihilism”, was thought 
to explain much of the excess mortality seen following AMI in patients with 
impaired renal function and indeed this maybe a contributing factor.4 However 
emergent data from a number of registry studies suggests that even when 
optimally treated, outcomes for patients with CKD receiving primary PCI for AMI 
remain poor. Even those patients with relatively mild CKD (Stage 3 eGFR 30-59 
ml/min) have roughly seven times the rate of in hospital mortality than patients 
without CKD.8 Furthermore, reperfusion therapy seems to have little impact on in-
hospital mortality for patients with CKD and PCI, for those with the most severe 
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degrees of renal dysfunction, may actually be harmful.9,12 However, in recipients 
of reperfusion therapy, who survive to hospital discharge, the long-term prognosis 
appears to be improved by primary PCI and early revascularization.4 This 
apparent paradox may suggest that aspects of the contemporary management of 
acute myocardial ischaemia, such as the administration of glycoprotein IIa/IIIb 
(GpIIa/IIIb) inhibitors or dual antiplatelet therapy may be harmful and offset the 
early benefit of reperfusion therapy. Additionally in patients with stable coronary 
artery disease, PCI does not improve outcomes for patients with mild CKD over 
optimal medical management.13 
 
The factors determining the outcome for patients with CKD remain largely 
unstudied. The cause of the excess mortality seen in patients with CKD following 
AMI is likely to be multifactorial. Patients with CKD are significantly more likely 
to experience post-infarction heart failure and cardiac arrest.14 Individuals with 
CKD are at increased risk of bleeding and several studies have highlighted the 
increased risk of hemorrhagic complications post PCI in patients with CKD.15 
However, even when bleeding episodes are corrected for, the outcome for 
patients with CKD still remains significantly worse16 suggesting additional factors 
specific to patients with impaired renal function may be of importance. 
 
Discovered by Murray and colleagues in 1986,17 ischaemic preconditioning (IPC) 
describes the phenomenon whereby a brief episode/s of ‘sub-lethal’ ischaemia 
(i.e. of insufficient duration to result in tissue damage) followed by reperfusion, 
confers resistance to a subsequent more prolonged or lethal episode of ischaemia-
reperfusion. ‘Conditioning strategies’, are arguably the most powerful 
cytoprotective therapies yet discovered, and may be considered benchmarks 
against which to determine the relative efficacy of potential drug therapies.
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1.2 Introduction)
There has been a steady improvement in both short and long term survival for 
patients developing end stage renal disease (ESRD) requiring renal replacement 
therapy (RRT) over the last decade (see Figure 1).  
 
The modest Improvement in absolute survival rates belie a significant 
improvement in relative survival, which is offset by increased access to dialysis 
with both older patients and individuals with greater degrees of associated co-
morbidity being offered renal replacement therapy. 
 
Nonetheless, the relative risk of death for individuals with ESRD remains 
unacceptably high. A 30-year-old individual starting dialysis has 30 times the risk 
of death compared with a 30 year old from the general population.  
 
Figure 1 – Data from UK Renal Registry indicating the fall in death rate for patients with ESRD. 
 
Survival rates for ESRD are worse than for many common cancers (Figure 2), a 
fact under appreciated by both the general population and broader medical 
community alike. 
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Figure 2 - Age standardised 5-year survival for the 20 most common cancers in England & Wales 
compared to ESRD. 
(Source: UK renal registry and Cancer Research UK.) 
 
Data from numerous registries confirms that, as in the general population, the 
leading cause of death for patients with ESRD treated is from cardiovascular 
disease (CVD).2 Cardiovascular mortality rates are estimated to be between ten to 
100-fold higher among dialysis patients than among age and sex-matched 
individuals from the general population.18 Over the last decade it has become 
increasingly recognised that there is a graded increase in the risk of cardiovascular 
mortality with declining renal function, as measured by glomerular filtration rate. 
The first to establish this association was Go et al19 who published their now 
seminal study of the Kaiser Permanente Renal Registry cohort, containing more 
than one million individuals, in 2004. They found the risk of death increased as 
GFR decreased below 60 ml/min/1.73 m2. For Stage 3a (eGFR 45 to 59 
ml/min/1.73 m2) the adjusted hazard ratio for death was 1.2, Stage 3b 1.8 (eGFR 
of 30 to 44 ml/min/1.73 m2), Stage 4 (eGFR of 15 to 29 ml/min/1.73 m2) 3.2 and 
stage 5 5.9 (eGFR of less than 15 ml/min/ 1.73 m2). The adjusted hazard ratio for 
cardiovascular events followed a similar pattern. These results were born out by a 
systematic review of 37 prospective studies20 comprising 1,366,126 individuals 
which permitted the comparison in outcome between participants with CKD and 
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those without. The unadjusted relative risk of mortality for participants with 
impaired kidney function was 0.94 to 5.0 and significantly >1.0 in 93% of the 
cohorts. 
 
More recently a meta analysis of fourteen community-based cohort studies21 
enrolling more than 100,000 subjects with urinary albumin creatinine 
measurements and over a million with urine dipstick readings paired with serum 
creatinine, has shown that both impaired renal function (GFR <60 ml/min) and 
albuminuria independently predict cardiovascular events and all cause mortality. 
Interestingly the presence of albuminuria acts as a risk multiplier, increasing the 
risk of cardiovascular mortality by a factor of two in all but the lowest echelons of 
eGFR, this difference is greater than that separating CKD stages. 
 
1.3 Famine)and)Feast)
There exists today a wealth of data which links reduced GFR to both an increased 
risk of CVD/ CV mortality and worse outcomes following presentation with an 
acute coronary syndrome. The systematic exclusion, both explicit and covert, of 
patients with CKD from large scale RCTs10,11 has led to a dearth of prospectively 
acquired data on which to make judgments and base clinical guidelines on the 
management of patients suffering an acute coronary syndrome. This was recently 
exemplified by the publication of the Caring for Australasians with Renal 
Impairment (CARI) guidelines for the management of “Coronary artery, 
cerebrovascular and peripheral vascular disease”.22 The guideline author was 
unable to find any level I (systematic review) or level II (randomised controlled 
trial) evidence (according to the National Health and Medical Research Council 
classification) on which to base his recommendations. 
 
Registry data indicates that around a quarter of patients presenting with an ACS 
have a GFR less than 60 ml/min/1.73m2.8,9 Moreover, in contrast to patients with 
an eGFR >60 ml/min/1.73m2, individuals with CKD do not seem to derive as 
much benefit from early reperfusion. Data from the GRACE (Global Registry of 
Acute Coronary Events) Registry,8 which consists of 12,532 patients presenting 
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with ST elevation myocardial infarction or new-onset left bundle branch block 
(LBBB) stratified according to their GFR calculated by the MDRD equation, 
normal (GFR greater or equal to 60 ml/min/1.73m2), moderate (59-30 
ml/min/1.73m2), or severe renal impairment (<30 ml/min/1.73m2), indicates that 
in patients with normal renal function; primary PCI was associated with a 
substantially reduced in-hospital mortality (OR 0.51, p=<0.001) compared with 
fibrinolysis. However, patients with moderate and severe renal failure did not 
experience a reduction in in-hospital mortality, although, in patients with 
moderate renal failure who survived to hospital discharge, mortality was 
significantly reduced at 6 months. The long-term survival benefit for patients with 
moderate renal dysfunction was tempered by a statistically significant increased 
risk of death at six months for patients with severe renal dysfunction (GFR less 
than 30 ml/ min/ 1.73m2) following both PCI and fibrinolysis. An increased risk of 
bleeding complications was observed for both fibrinolysis and primary PCI. 
However, unlike other studies, an increase in the risk of stroke was not seen. 
 
There was relatively few patients with severe renal dysfunction in this study, and 
therefore an increased risk of a Type II error, which precludes us from drawing the 
conclusion that primary PCI or fibrinolysis are truly harmful to patients with stages 
4 to 5 CKD. 
 
The Swedeheart registry23 has reported similar findings for patients with non-ST 
elevation myocardial infarction (NSTEMI) undergoing early revascularisation 
(within 14 days of presentation). A greater reduction in the benefit of early 
revascularisation was seen with advancing CKD stage, such that no benefit was 
seen in patients with an eGFR of <30 ml/ min/ 1.73m2. As in patients with STEMI, 
improved outcomes were seen at six months in survivors who were 
revascularised. Again the relatively small numbers of patients with advanced renal 
dysfunction (CKD stage 5, eGFR <15 ml/ min/ 1.73m2), render this data subject to 
Type II error. 
 
The registry data is also supported by post-hoc analysis of randomised controlled 
trials. The Controlled Abciximab and Device Investigation to Lower Late 
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Angioplasty Complications (CADILLAC) trial included 2082 patients presenting 
within 12 hours of acute myocardial infarction and randomised to PTCA 
±abciximab versus stenting ±abciximab with a 2X2 factorial design, prespecified 
exclusion criteria included a serum creatinine greater than 150 µmol/L (2 mg/dL). 
In a post-hoc analysis15 participants were divided into those with renal 
impairment, defined by a calculated creatinine clearance (CrCl, Cockcroft and 
Gault formula) of less than 60 mL/min. Mortality at 30 days and one year was 
found to be substantially greater, with the risk of death increasing incrementally 
with every 10 mL per minute decrease in baseline CrCl. Additionally, CrCl was 
found to be a powerful independent predictor of 30 day mortality (hazard ratio, 
5.77; p<0.0001) which was also associated with reduced one year survival 
(hazard ratio, 1.98; p=0.08). The risk of haemorrhagic complications (6.7% vs. 
2.8%, p=0.0003), transfusion requirements (8.9% vs. 3.6%, p=<0.0001), severe 
restenosis (>70%, 20.6% vs. 11.8%, p=0.024) and infarct artery reocclusion 
(14.7% vs. 7.3%, P=0.02) were all doubled for patients with a creatinine 
clearance of less than 60 ml per minute. 
 
This observational data raises several important points. Current optimal 
management of acute myocardial ischaemia is only applicable to 75% of patients. 
At the very least there is attenuation of the benefit of current revascularisation 
practices in patients with advanced renal failure presenting with acute coronary 
syndromes and raises the possibility that current practices may even be harmful to 
patients with an eGFR of less than 30 ml/ min/ 1.73m2. 
 
The risk benefit relationship for both percutaneous coronary intervention (PCI) 
and fibrinolytic therapy appears to be altered in patients with renal disease. A 
number of factors may be responsible. 
• Differences in the morphology of atherosclerotic plaques in patients with 
CKD have been described.24 
• PCI in patients with renal disease is accompanied by a higher rate of early 
and late complications of bleeding, restenosis, and death.25  
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Therefore, in the setting of CVD, the presence of renal disease may identify a 
segment of the population with a worse prognosis who may be less responsive to 
the benefits of certain interventions. 
 
1.4 Causes)of)increased)cardiovascular)disease)in)patients)with)CKD)and)
ESRD)
As previously alluded to; the high rate of cardiovascular mortality affecting 
individuals with CKD is the result of both an increased incidence and prevalence 
of CVD as well as increased case fatality.  
 
Over the past decade, much of the research conducted into the excess 
cardiovascular mortality experienced by individuals with ESRD and CKD has 
described the epidemiology and concentrated on the role of both established, 
‘traditional’ and ‘novel’ risk factors. 
1.4.1 Traditional*(Framingham)*risk*factors*
Much of the excess risk of cardiovascular disease seen in patients with CKD may 
be explained by clustering of so-called ‘traditional risk factors’ i.e. those originally 
identified in the Framingham heart study (see Table 1) 
 26 
26,27@28,29@ 27 @30 3,27 31@32,33@34,35 
Table 1 – Traditional cardiovascular risk factors in CKD. 
Risk Factor Comment References 
Older age Age is recognised as a major non-modifiable risk factor for cardiovascular disease. 
The prevalence of CKD increases with age. 
The greatest increase in incident dialysis patients has been in the over 65s. 
 
26, 27 
Menopause Cardiovascular mortality is reduced by 2% for every year menopause is delayed. 
Patients with ESRD experience earlier cessation of menses, Median age 48 compared with 52 in general 
population. 
 
28, 29 
Male sex More men are commenced on RRT than women, the disparity increases with age. 27 
Hypertension Hypertension is almost ubiquitous in patients with CKD with an estimated prevalence of 80%. 
Hypertension is the single most important driver of progression in CKD and the most important predictor of 
cardiovascular mortality. 
 
30 
Diabetes Mellitus Diabetes is by far the single most common cause of ESRD in the UK, 22% of incident dialysis patients. 
A further 8% of incident dialysis patients in the UK have diabetes as a secondary diagnosis. 
In the USA, diabetes is the cause of ESRD in 54% of incident dialysis patients. 
 
3, 27 
Smoking In the USA around 20% of the population are estimated to be current smokers, with a similar prevalence of 
smoking seen in dialysis patients in the UK. 
Of incident dialysis patients Approximately 17% are estimated to be current smokers. 
Smoking significantly increases the risk of developing heart failure for patients with ESRD. 
 
31 
Physical inactivity All cause and cardiovascular mortality is inversely related to physical activity. 
Dialysis patients tend to have sedentary lifestyles and report limitations in physical activity. 
 
32, 33 
Hypercholesterolaemia Hypercholesterolaemia is inconsistently associated with increased cardiovascular risk in patients with ESRD. 
Additionally several large clinical trials have failed to demonstrate reduction in mortality with statin therapy in 
patients with CKD/ESRD. 
 
34, 35 
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Many of these established risk factors are seen at increased frequency in patients 
with CKD at various stages of their disease (stages 3-5 CKD, incident dialysis 
patients,36 maintenance dialysis patients and recipients of renal allografts). 
 
The extent to which the excess risk of CVD seen in patients with CKD may be 
accounted for by these traditional risk factors has been the subject of several 
studies that have applied risk prediction equations, developed in the general 
population, and compared the predictions with the actual incidence and 
prevalence of CVD in patients with ESRD and CKD. In general such equations 
have tended to underestimate the cardiovascular risk observed in patients with 
renal failure. Moreover the relationship between some traditional risk factors, in 
particular hypercholesterolaemia and hypertension, appears to be perturbed in 
patients on haemodialysis.37 
 
Sarnak and colleagues38 examined a sub-group of patients from the Modification 
of Diet in Renal Disease (MDRD) study using the coronary point score. Despite a 
high prevalence of ‘traditional’ risk factors, the predicted risk was significantly less 
than the observed incidence of de novo CVD. 
 
It has previously been asserted that; “There is no reason to believe that traditional 
cardiac risk factors defined in the general population would not be important in 
CKD.” However, attempts to reduce the rates of cardiovascular disease by treating 
modifiable risk factors (most notably hypercholesterolaemia) have been singularly 
unsuccessful.34,35 
1.5 Non'Traditional/Risk/Factors/
Numerous non-traditional risk factors for CVD such as; anaemia, sympathetic 
overactivity, hyperhomocysteinaemia, inflammation, vascular calcification, 
coronary artery calcification, increased pulse wave velocity, serum phosphorus, 
fibroblast growth factor-23 (FGF-23), L-carnitine deficiency, left ventricular 
hypertrophy, iron therapy and oxidative stress have been identified and the list 
continues to grow. 
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Many of these factors are either observed at an increased frequency in patients 
with CKD or are peculiar to patients with CKD. There is considerable interplay 
between these risk factors, such as vascular calcification, pulse wave velocity and 
LVH and many of them may not be regarded as causal or even independent. 
1.6 Is/ CVD/ in/ patients/with/ CKD/ the/ same/ disease/ as/ that/ seen/ in/ the/
general/population?/
A key question that remains to be definitively resolved is whether CVD in the 
general population is the same disease as that seen in patients with CKD and 
ESRD. 
 
When considering this question we can draw on several observations that suggest 
that the drivers of CVD and CV mortality in patients with co-existent CKD may 
differ from those in the general population. 
 
1. Risk prediction equations developed from the general population 
underestimate the risk of CVD in patients with CKD. 
2. Treatments, proven in the general population to reduce the incidence and 
mortality, from CVD appear to be less efficacious in patients with CKD, 
especially the more advanced stages (CKD 5d). 
3. The majority of cardiovascular deaths are not the result of myocardial 
infarction, traditionally thought of as the result of obstructive coronary 
disease. 
Moreover, of those individuals that do suffer an AMI, patients with ESRD are 
more likely to experience a Non-ST-segment elevation myocardial infarction 
(NSTEMI) than ST-segment elevation MI (STEMI).14 
 
CVD affecting patients with CKD and ESRD may be a heterogenous condition in 
that risk of cardiovascular disease may not be equal across all patient groups with 
kidney disease. Evidence for this hypothesis may be drawn from a number of 
sources. 
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Firstly, albuminuria is more predictive of CVD risk than absolute GFR. 
Albuminuria is often regarded as a surrogate marker of endothelial dysfunction. 
Secondly, cardiovascular risk is not uniform in patients with CKD but is rather 
influenced by the cause of renal dysfunction. Nakayama and colleagues39 recently 
published their 12 month observational study which included 2692 patients. 
Subjects were grouped according to eGFR and aetiology of renal disease (primary 
renal disease, diabetic nephropathy, hypertensive nephropathy and other 
nephropathies) and followed up for at least 12 months with a composite end-point 
of cardiovascular events and all cause mortality. An increased risk of mortality 
with declining eGFR was observed (however this disappeared in multivariate 
analysis). Furthermore, in comparison to patients with primary renal disease, 
patients with diabetic nephropathy had almost 12 times the risk of the primary 
endpoint where as the odds ratio for hypertensive nephropathy was 2.87 and 
other nephropathies 3.59. The impact of cause of ESRD on the incidence of CVD 
is the subject of further investigation in another Japanese prospective cohort 
study.40 Whether individuals who experience an abrupt decline in renal function 
leading to ESRD have the same CVD risk as individuals who have a more 
protracted journey towards ESRD remains to be elucidated. 
 
For many years accelerated atherosclerosis was thought to be the primary 
determinant. However, whilst patients with ESRD undoubtedly have an increased 
burden of atherosclerotic vascular disease, several observations make it unlikely 
that increased rates of atherosclerosis can be solely responsible for the greatly 
increased risk of cardiovascular death seen. 
 
Firstly, although rates of acute myocardial infarction are approximately three to 
ten fold higher in patients with CKD 3-5 than individuals without CKD,3 acute 
myocardial infarction is only the third most common cause of cardiovascular 
death in dialysed patients. Rates of death due to congestive heart failure (CHF) 
and sudden cardiac death are considerably greater (3-20 fold increase and 4-17 
fold increased risk, respectively). In the 4D study cohort,34 8.2% of patients died 
from coronary heart disease (CHD) whereas other cardiac causes accounted for 
35% of deaths. Moreover, there is an early increase in relative risk of cardiac 
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death, with the most marked increase seen in the young.18 The premature 
development of cardiovascular disease is thought to account for the dramatic 
attenuation of life expectancy seen in children who develop ESRD.41 However, it 
does not appear that this is mediated by atherosclerosis. 
 
Secondly, statins, which are thought in large part to exert their protective effects 
by reducing atherosclerosis and stabilizing atherosclerotic plaques appear to have 
little impact on cardiovascular mortalility in individuals with CKD, despite 
reducing LDL cholesterol.34,35,42 
 
Lastly, ST-elevation myocardial infarction (STEMI) is observed almost half as 
frequently in patients with ESRD as compared with patients with normal kidney 
function.14 ST elevation is usually regarded as indicative of transmural/ full 
thickness ischaemia whereas Non-ST-elevation myocardial infarction is thought to 
represent sub-endocardial ischaemia. These observations may indicate a greater 
importance of ‘demand’ ischaemia, caused by reduced coronary flow reserve and 
LVH, in patients with ESRD compared with individuals with normal kidney 
function where ‘supply’ ischaemia is pre-eminent. 
1.7 Sudden/Cardiac/Death/
Sudden cardiac death (SCD) is broadly defined as death from a cardiac cause 
occurring within 1 hr of symptom onset in an otherwise well individual.43 SCD is 
responsible for around 60% of cardiovascular deaths and around a quarter of all 
deaths, almost double the rate seen in the general population, making it the single 
most important cause of death for patients with ESRD. With a 6-7% yearly 
incidence, the risk of SCD in patients with ESRD exceeds even that seen in 'high 
risk' heart failure patients.3 However, precise estimates of the incidence of SCD in 
patients with CKD are confounded by the lack of a consensus definition. The risk 
of SCD increases by 10% for every 10 ml/min fall in GFR.44 Thus prevention of 
SCD is vital target to improve survival for individuals with CKD. 
 
The majority of SCD are the result of ventricular arrhythmias that are triggered by 
an event, which occurs in the context of a diseased myocardium. A number of 
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risk factors for SCD identified in the general population appear to also be 
important in patients with CKD (see Table 2, the pathogenesis of these factors are 
discussed later). However, the most important drivers of SCD in the general 
population namely coronary artery disease (CAD) and heart failure appear to be 
less important in ESRD.45 In recent years attention has focused on the deleterious 
effects of the dialysis treatment its self. 
 
Sudden death is evenly distributed throughout the week for patients in peritoneal 
dialysis. In contrast, there is an excess of sudden and cardiac deaths occurring on 
Monday and Tuesday for patients receiving thrice weekly dialysis and is highest in 
the 12 hours preceding and following the dialysis session after the weekend 
break.46 
 
The occurrence of silent myocardial ischaemia during dialysis sessions has been 
recognised for some time. In recent years, the work of professor MacIntyre’s group 
in Derby has highlighted this problem. Short intermittent haemodialysis sessions 
exert significant haemodynamic stress, as a result 20-30% of treatments are 
complicated by intradialytic hypotension.47 Patients with ESRD are predisposed to 
demand ischaemia as a result of a number of structural and functional 
abnormalities of the cardiovascular system. A well recognised consequence of 
myocardial ischaemia-reperfusion is transient ventricular dysfunction, myocardial 
stunning.48 Individuals who experience myocardial stunning associated with 
haemodialysis have an attendant increased relative risk of mortality.49 It is 
postulated that myocardial stunning can progress through hibernation to 
permanent loss of systolic function.50,51 myocardial stunning is independently 
associated with intradialytic hypotension and ultrafiltration (UF) volume. 
Strategies such as cooling the dialysate temperature and altering dialysate 
conductance are associated with a reduced risk of stunning. Whether these 
manoeuvres can reduce mortality is unknown. 
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Risk factors for sudden cardiac death 
Left ventricular hypertrophy (LVH) 
Coronary artery disease (CAD) 
Heart failure 
Intercardiomyocyte fibrosis 
Microvascular disease 
QTc dispersion 
Electrolyte shifts 
Sleep apnoea 
Sympathetic overactivity 
Vascular calcification 
Diabetes Melitus 
Disturbances of divalent ion metabolism 
 
Table 2 – Risk factors for sudden cardiac death 
1.8 The/Pathophysiology/of/Uraemic/Cardiovascular/Disease/
Although the excess risk of cardiovascular death experienced by patients with 
ESRD has been recognised for many years, our understanding of the 
pathophysiology that determines this greatly increased susceptibility to 
cardiovascular morbidity and mortality remains largely speculative. 
 
1.8.1 Uraemic+cardiomyopathy+
The existence of a specific ‘uraemic’ cardiomyopathy has been debated for more 
than thirty years52,53 with the protagonists either suggesting that one or more 
uraemia specific factors was responsible for the high levels of heart failure and 
cardiovascular mortality seen in patients with ESRD or that it was the result of the 
myriad of conditions associated with uraemia. This debate largely rested on 
semantics and there is now a broad consensus view that; whatever the 
aetiological factors responsible, the milieu of conditions predisposing to cardiac 
failure, which coexist as part of the uraemic syndrome, result in a distinct 
histopathological entity which may be described as uraemic cardiomyopathy. 
 
1.8.2 Hypertension+and+chronic+kidney+disease+
The association between hypertension and chronic kidney disease has been 
recognised since the time of Richard Bright in 1836.30 Hypertension is almost 
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ubiquitous amongst patients with CKD and those with ESRD. Estimates of 
prevalence are variable but it is thought that in the order of 80% of patients with 
CKD may have hypertension, making renal disease by far and away the most 
common form of secondary hypertension.30 
1.8.3 Pathophysiology+of+renal+hypertension+
There are 4 principal causes of hypertension in patients with CKD.30 
1) Intravascular volume expansion 
2) Activation of the RAS 
3) Sympathetic nervous system over activity 
4) Endothelial dysfunction 
Other factors that have been proposed include: baroreceptor dysfunction, 
oxidative stress, disturbances in divalent ion metabolism and parathyroid 
hormone, arterial remodeling, pre-existent essential hypertension, drug therapy 
(steroids, cyclosporin), erythropoietin therapy, serotonin, calcitonin gene related 
peptide and anti-phospholipid syndrome. 
 
Hypertension is the single most important factor contributing to progression of 
CKD and the most important predictor of cardiovascular disease in uraemic 
patients. 
 
1.8.4 Left+Ventricular+Hypertrophy+(LVH)+
The heart has an inherent capacity to undergo changes in size and shape in 
response to a variety of stimuli including haemodynamic stress, hormones, neural 
influences, and autacoid factors. The term “cardiac remodeling” is used to 
describe this plasticity of cardiac structure and is usually restricted to alterations in 
cardiac structure associated with disease states. 
 
Eighty four percent of patients starting dialysis have evidence of structural heart 
disease, with left ventricular hypertrophy being found in up to three quarters of 
incident haemodialysis patients.54,55 LVH is also common in earlier stages of CKD, 
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affecting up to 40% of patients, and increases in prevalence with declining GFR56 
and is the strongest independent predictor of cardiovascular mortality in patients 
with CKD.57 
 
Left ventricular hypertrophy may be regarded as an adaptive remodeling process, 
which compensates for an increase in workload placed on the heart by 
minimizing ventricular wall stress, which is associated with increased oxygen 
requirements. 
 
In crude terms LVH may be regarded as an increase in the mass of the left 
ventricle, it may be broadly categorised as concentric or eccentric. Conditions in 
which there is an increase in the after-load the ventricle must over come (e.g. 
arterial hypertension, aortic stenosis) require the generation of greater intra-cavity 
pressure during systole. This is achieved by arraying contractile units in parallel 
resulting in a relative increase in wall thickness and a fall in cavity volume 
(concentric LVH). In contrast, conditions associated with volume overload, e.g. 
anaemia or aortic incompetence, lengthening of the contractile units leads to a 
physiologically useful increase in systolic stroke volume, according to Starling’s 
Law. Unopposed, this process of left ventricular dilation leads to increased wall 
tension, resulting in an increase in oxygen requirements, and myocyte burnout. 
According to the Law of Laplace, the wall tension of a hollow spherical body is 
directly proportional to radius and pressure and inversely proportional to wall 
thickness. Thus, in states of left ventricular dilation, wall thickening and left 
ventricular hypertrophy are adaptations that occur secondarily in order to 
decrease wall tension and consequently oxygen requirements (eccentric LVH). 
The aetiology of LVH in patients with renal disease is multifactorial and has been 
traditionally thought of as being the result of factors affecting: 
♦ Preload/ volume overload 
♦ After-load/ pressure overload 
♦ Preload/ after-load independent factors 
Hypertension, which is the most frequent cause of LVH in the general 
population,58 is virtually ubiquitous in patients with ESRD59 and has a high 
prevalence in patients with earlier stages of CKD.60 
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1.8.5 The+role+of+anaemia+in+the+pathogenesis+of+left+ventricular+hypertrophy+
Anaemia causes tissue hypoxia, which results in peripheral vasodilatation and as 
a consequence a fall in systemic vascular resistance and blood pressure. This is 
perceived by the kidney as a reduction in effective blood flow which results in an 
increased sympathetic response, leading to tachycardia, increased stroke volume, 
renal vasoconstriction, reduced renal blood flow, stimulation of the renin-
angiotensin-aldosterone axis and consequent salt and water retention and a 
resultant expansion in extracellular fluid (ECF) volume.61 Anaemia is associated 
with left ventricular dilatation62 and eccentric LVH in patients on haemodialysis. 
 
1.8.6 Endothelial+dysfunction++
Endothelial cell dysfunction is well described in CKD and has been documented 
in a number of ways. Gerard London’s group were the first to directly demonstrate 
impaired endothelial function in patients with ESRD.63 They were able to show 
that ‘flow debt repayment’ (FDR), the ratio of the area under the curve between 
reperfusion and the end of hyperaemic flow to the ‘debt’; the area under the curve 
between onset of ischaemia and reperfusion, was increased in patients with ESRD, 
not as a result of a reduction in peak blood flow but because of shorter duration of 
hyperaemic flow. FDR is positively correlated with: 
♦ Serum albumin.  
♦ Common carotid artery (CCA) distensibility  
and negatively correlated with: 
♦ Common carotid artery (CCA) diameter 
♦ Duration of dialysis 
♦ Plasminogen activator inhibitor-1 (PAI-1) 
Subsequently it has been shown that endothelial function, as measured by flow 
mediated vasodilatation, is negatively associated with GFR and both are inversely 
correlated with plasma levels of asymmetric dimethyl arginine.64 Plasma ADMA 
levels have been found to be strongly predictive of cardiovascular outcomes in 
patients with ESRD.65 Other biomarkers of endothelial function (von Willebrand 
factor and soluble vascular cell adhesion molecule-1) have been found to be 
elevated in association with relatively mild degrees of renal dysfunction.66 
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Circulating levels of endothelial micro-particles are elevated in patients with 
ESRD and highly correlated with impaired flow-mediated vasodilatation and 
increased aortic pulse wave velocity. In vitro data suggests that micro-particles 
from patients with acute coronary syndromes affect endothelial function.67 
However, whether micro-particles are markers of or a cause of endothelial 
dysfunction continues to be debated. 
 
1.8.7 Pathological+arterial+remodelling+
In addition to functional alterations in the large arteries, a number of 
histopathological changes have also been described In experimental rat models of 
moderate renal insufficiency, including matrix accumulation resulting in 
increased wall thickness with accumulation of collagen, but not of elastin. These 
changes appear to be closely corealated with renal function.68 
 
1.8.7.1 Vascular calcification 
In recent years great interest has focused on the development of vascular 
calcification and in particular arterial medial calcification. Jono et al69 
demonstrated a phenotypic switch in vascular smooth-muscle cells (VSMC) to an 
osteoblast-like morphology in response to in vitro exposure to high phosphate 
containing media. The transformed cells displayed osteoblast-specific gene 
expression with transactivation of osteopontin, bone morphogenetic protein 
isoforms, osteocalcin, core binding factor alpha-1 (Cbfa-1) in association with 
deposition of membrane-bounded hydroxyapatite granules, similar to those found 
in plaques, but not convincingly in the media of coronary arteries. This finding is 
of course of great relevance in view of the observation by Block et al70 that a pre-
dialysis serum phosphate concentration of 2.10 mmol/L (>6.5 mg/dl) was 
associated with an increase in all-cause mortality and specifically an increased 
risk of cardiac death. The importance of hyperphosphataemia in cardiovascular 
disease appears not to be restricted to individuals with CKD. Narang et al71 found 
that; in patients with coronary heart disease, but without renal disease, serum 
phosphate concentration was a potent predictor of the severity of luminal 
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narrowing. More recently, this observation has been extended to individuals free 
from both CKD and CVD in a number of cohort studies; serum phosphate levels 
extending across the normal range have been found to be associated with incident 
CV events.72,73 
 
Both endothelial dysfunction and structural remodelling contribute to increased 
arterial stiffness, which results in increased after-load and ultimately contributes to 
the development of left ventricular hypertrophy (LVH). This process of arterial 
stiffening may be identified clinically as increased pulse pressure and pulse wave 
velocity. 
 
1.8.8 Accelerated+Atherosclerosis+
Lindner et al74 in their seminal publication were the first to highlight the increased 
burden of atherosclerotic vascular disease in patients with ESRD. Autopsy studies 
have confirmed a high frequency of coronary atheroma in patients with CKD.75,76 
Even mild reductions in GFR may contribute to a process of accelerated 
atherosclerosis, as seen when uninephrectomy is performed in the Apo E-/- 
mouse.77 
 
It is increasingly recognised that atherosclerosis is the net result of an imbalance 
between damage to the resident cells and repair by circulating bone marrow–
derived endothelial precursor cells (EPC).78 Against this background, it is of 
interest that the number and the function of such precursor cells is reduced in 
patients with renal failure.79 Furthermore, uraemic serum inhibits EPC 
differentiation and functional activity in vitro. Institution of renal replacement 
therapy (RRT) is associated with an increased numbers of EPC79 as is renal 
allograft function.80 The mechanism linking EPC number and function with renal 
function remains to be determined. However, it is interesting to note that 
erythropoietin treatment increases mobilisation of EPC from the bone marrow. 
Circulating EPC number has recently been shown to be associated with both 
cardiovascular events and mortality in patients with ESRD.81 These data suggest a 
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role for defective vascular repair and regeneration mechanisms in the excessive 
cardiovascular morbidity seen in patients with CKD. 
 
1.8.9 Myocardial+fibrosis+
Interstitial myocardial fibrosis is a singular feature of both experimental82 and 
clinical uraemia, being found in 91% of chronically uraemic patients, but not in 
non-hypertensive, non-diabetic controls.83 This form of fibrosis is frequently 
described as non-reparative fibrosis, as the increase in collagen deposition occurs 
in the absences of myocyte necrosis. Uraemia is the major determinant of 
intermyocardiocytic fibrosis, independent of hypertension, diabetes mellitus, 
anaemia, heart weight, and dialysis procedure. The severity of fibrosis in dialysed 
patients was found to be proportional to dialysis vintage and remained 
demonstrable for years following renal transplantation.  
 
A number of factors have been implicated in the pathogenesis of myocardial 
fibrosis associated with uraemia. Elevated plasma levels of cardiotonic steroids, 
cardenolides [e.g. endogenous ouabain (EO)] and bufadienolides [e.g. 
marinobufagenin (MBG) and telocinobufagin], have been found in sub-totally 
nephrectomised rats.84 Infusion of MBG to rats results in a cardiac phenotype 
similar to that induced by sub-total nephrectomy.84 In an extremely novel 
therapeutic strategy, immunization of rats against MBG, prior to sub-total 
nephrectomy (SNx) has been reported to attenuate the extent of myocardial 
fibrosis.84 
 
A key histological finding in hearts from animals with experimentally induced 
uraemia is an increase in the volume densities of both the cytoplasm and nucleus 
of the interstitial cells; the same changes are not seen in the endothelial cells and 
are regarded as indicative of an activating signal affecting the interstitial cells. 
Amann and colleagues85 determined the role of parathyroid hormone on markers 
of fibroblast activation and intermyocardiocyte fibrosis. 
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The volume density of interstitial tissue (excluding capillary volume) was 
increased at the expense of capillary volume, which was decreased, reflecting the 
encouragement of interstitial tissue upon capillary volume. Interstitial fibrosis was 
associated with swelling of interstitial cells, both cytoplasmic and nuclei: in 
contrast, nuclear and cytoplasmic volumes of endothelial cells were unchanged. 
This points to the presence of an activation signal, which is selective for interstitial 
cells. Similar fibrosis was not observed in other organs of uraemic animals. 
 
Amann et al86 demonstrated that intermyocyte fibrosis in sub-totally 
nephrectomised rats was exacerbated by a high phosphate diet, shedding light on 
the mechanism of enhanced myocardial fibrosis in uraemia and offering a 
biological explanation for the increased cardiovascular mortality associated with 
high pre-dialysis phosphate levels observed by Block and colleagues.70 In short; 
uraemia appears to activate interstitial fibroblasts to propagate the fibrotic process 
independently of arterial hypertension.82 
1.8.10 Consequences+of+myocardial+fibrosis+
There are several consequences of myocardial fibrosis; reduced ventricular 
compliance, disturbed electrical properties, increased oxygen diffusion distance 
and most importantly; disturbance of the electrical properties of the myocardium. 
The Interposition of high resistance interstitial tissue results in anisotropy leading 
to disordered propagation of the excitation front and facilitating re-entrant 
currents, a prerequisite for ventricular tachycardia. Disruption of the normal 
conducting pathways may be one factor contributing to the dramatic increased 
risk of sudden cardiac death in dialysis patients, particularly in dialysed diabetic 
patients.34 Among other factors, interstitial fibrosis must be considered as a 
potential cause of the electrical instability of the heart in uraemic patients. 
1.8.11 Cardiac+microvascular+disease+in+uraemia+
In addition to intermyocyte fibrosis, marked capillary drop-out or capillary 
rarefaction is found in the both the hearts of animals with experimentally induced 
uraemia87 and the hearts of patients with CKD. As with intermyocyte fibrosis the 
degree of capillary rarefaction is exaggerated in uraemic hearts compared to 
hypertrophied hearts from hypertensive control animals. Additionally, the 
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wall/lumen ratio of myocardial arterioles was found to be significantly increased 
following sub-total nephrectomy compared to sham operated control animals. 
Treatment of hypertension failed to normalise the wall/lumen ratio. These findings 
provide evidence for blood pressure-independent changes of arteriolar geometry 
in uraemia88 and have implications for coronary vascular resistance and flow 
reserve. Similar histological changes have been reported in myocardial biopsy 
specimens from patients with ‘syndrome X’. 
 
Enhanced susceptibility to ischaemia-reperfusion injury in the uraemic heart may 
be the result of a number of factors: 
♦ Left ventricular hypertrophy results in an increase in myocardial 
oxygen requirements. 
♦ Capillary rarefaction and myocardial fibrosis result in an increase in the 
oxygen diffusion distance. 
♦ Perturbations in cellular bioenergetics with a reduction in the cellular 
levels of high-energy phosphate bonds. 
The development of left ventricular hypertrophy, myocardial fibrosis and capillary 
rarefaction provides the anatomical basis for increased vulnerability to myocardial 
ischaemia. These pathological changes result in both an increase in myocardial 
oxygen demand and decrease in oxygen delivery as a function of reduced 
capillary density and increased oxygen diffusion distance. However, there is at 
least a fourth factor enhancing the uraemic heart’s susceptibility to ischaemia, 
namely perturbations at a cellular level in energy production. 
 
1.8.12 Bioenergetics+
Adenosine triphosphate (ATP) is the primary energy currency of all living 
organisms. It is an essential requirement for cell viability and function. In the 
heart, cleavage of the terminal phosphate (a phosphoryl bond) by ATPases, 
resulting in the production of adenosine diphosphate (ADP) and inorganic 
phosphate (Pi), provides the chemical energy required for contraction and all 
other energy requiring processes. The amount of ATP in the heart is relatively 
small (~10 mM, which is only sufficient for a few beats) compared with demand 
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(which may be as much as 10 000 times greater); even under resting conditions, 
there exists a high rate of ATP utilization, as a result the myocyte must continually 
re-synthesize ATP. Nonetheless, despite large and variable changes in ATP 
demand, the concentration of ATP ([ATP]) is maintained at a constant level. 
 
ATP synthesis through fatty acid oxidation in mitochondria is normally sufficient 
to meet the demands for chemical energy and is the preferred substrate for ATP 
synthesis in the heart. Under conditions of high ATP demand, the myocyte 
recruits additional pathways for ATP synthesis, namely glycolysis and the 
phosphotransferase reactions, catalysed by creatine kinase (CK) and adenylate 
kinase (AK). These pathways differ in the rate in which they can resupply ATP. 
Production of ATP by phosphoryl transfer, mediated by CK, is ~10 times faster 
than ATP synthesis in mitochondria (~0.7mM/s) which is ~20 times faster than 
glycolysis.89 The relative contributions of these pathways to overall ATP synthesis 
change rapidly in response to changes in response to substrate utilization. 
Raine et al90 investigated the effects of uraemia, induced by sub-total 
nephrectomy (SNx), on cardiac performance and energetics in an isolated 
working heart preparation. They observed a significantly reduced cardiac output 
at all levels of preload and afterload in the hearts from uraemic animals. In 
addition, using 31Phosphate-nuclear magnetic resonance (NMR), they reported 
that; basal phosphocreatine levels were reduced by nearly a third (32%), the 
phosphocreatine/ ATP ratio was reduced to the same degree (32%) and an 
increase in the calculated cytosolic free ADP. Moreover, under conditions of low 
flow ischaemia, there was a greater decrease in phosphocreatine levels in the 
uraemic hearts and an accompanying marked increase in release of inosine into 
the coronary effluent, indicative of enhanced losses from the total nucleotide pool 
and suggestive of an increased vulnerability to ischaemia. These findings have 
subsequently been confirmed in an in vivo model of experimental uraemia. 
 
1.8.13 Summary+of+pathophysiology+of+uraemic+cardiomyopathy+
In conclusion uraemic cardiomyopathy is characterized by the development of 
left ventricular hypertrophy, which is the result of numerous factors, but in the 
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context of chronic kidney disease is associated with a greater degree of 
intermyocyte fibrosis and capillary rarefaction resulting in increased vulnerability 
of the myocardium to ischaemia. In addition, electrolyte shifts as a result of 
dialysis contribute to create a ‘perfect storm’ for cardiac arrhythmogenesis.
 
1.9 Do/all/patients/with/CKD/have/the/same/cardiac/phenotype?/
It is likely that the cardiac phenotype of patients with CKD is heterogeneous, with 
some individuals having a pure “uraemic” phenotype, whilst other, perhaps older 
patients with ischaemic nephropathy and a history of atherosclerotic vascular 
disease have a predominantly “ischaemic” phenotype, whilst others have a 
“diabetic” phenotype. Some individuals may have features of one or more 
conditions and it may be that with time/ duration of renal failure the predominant 
phenotype changes. Newer imaging techniques may enable us to define the 
cardiac phenotype of individuals more accurately91 and therefore target 
interventions more effectively.
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1.10 Ischaemia'reperfusion/injury/
1.10.1 Ischaemia+
There are two principal consequences of ischaemia: 
♦ A reduction in the supply/ availability of metabolic substrates 
(principally O2) 
♦ Accumulation in the tissue of the products of cellular metabolism. 
Ischaemia may occur either as the result of a reduced absolute blood flow rate 
(low-flow or no-flow) or a relative reduction in the face of increased tissue 
demands. Arguably the latter may be most pertinent in the setting of uraemia, 
which is associated with twice the risk of Non-ST elevation myocardial infarction 
(NSTEMI). 
 
Even under experimental conditions, ischaemia is heterogenous. Blood flow 
through an occluded artery may be completely or only partially arrested; 
furthermore within ischaemic regions not all cells are equally ischaemic. 
Typically, a gradient of ischaemia exists from the sub-endocardial (most 
ischaemic) to the sub-epicardial regions (least ischaemic).92 Collateral circulation 
through interarterial connections plays a significant role in tissue resistance to 
ischaemia. The extent of collateralisation varies considerably between species and 
between individuals. Some animals, such as cats and dogs, have extensive 
preformed collaterals, whereas pigs, rabbits and rats have none. The healthy 
human heart has no significant collateral circulation but individuals with pre-
existing coronary artery disease may have considerable collateral blood supply. 
 
In severe experimental ischaemia (<10% flow) cell death begins to appear after 20 
min and the majority of severely ischaemic cardiomyocytes are dead after 60 min, 
in moderate ischaemia (10-35% flow) or in less severely ischaemic areas (mid and 
sub-epicardial ischaemic regions), cell survival is prolonged but cell death usually 
occurs after 3-6 hrs. Mildly ischaemic tissue (>35% flow) will typically survive. 
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There are a number of changes that occur at a cellular level in response to the 
sudden onset of ischaemia: 
♦ Cessation of aerobic metabolism 
♦ Switch to anaerobic metabolism 
♦ Depletion of phosphocreatine 
♦ Accumulation of glycolytic products (e.g. lactate) and nucleotide 
catabolites 
 
Some of the features of the ischaemic heart, reperfused late in the reversible 
phase, do not return to normal for hours to days whilst others revert rapidly, 
within seconds to minutes. 
 
1.10.2 Metabolic+changes+associated+with+low+flow/+total+ischaemia+
Oxygen in the form of oxy-haemoglobin and oxy-myoglobin is exhausted within 
8-10 seconds of the onset of total ischaemia, at which point oxidative 
phosphorylation ceases. There is a rapid rise in the NADH/NAD ratio and within 
15-20 seconds of the onset of ischaemia, anaerobic glycolysis predominates as 
the only significant source of high-energy phosphate. Initially the anaerobic 
glycolytic rate is around a quarter of the aerobic rate but within 60 seconds this 
too has markedly reduced due to inhibition of glyceraldehyde phosphate 
dehydrogenase (GPD) by an increasing NADH/NAD ratio and falling pH. NAD is 
a cofactor in the conversion of glyceraldehyde-3-phosphate to 1,3-
bisphosphoglycerate by GPD. Glycolysis proceeds at this reduced rate for 40-60 
min before it too stops. Cessation of glycolysis is attributed to falling ATP 
concentrations, which is required to convert glucose to glucose-6-phosphate and 
fructose-6-phsosphate to fructose-1,6-bisphosphate. 
 
In addition to oxygen, ischaemia deprives the heart of metabolic substrates. Only 
glucose is capable of being metabolised anaerobicaly, which in total ischaemia 
must be obtained from intracellular stores of glycogen. Glycogen is broken down 
into glucose though the action of glycogen phosphorylase. There are two isoforms 
of glycogen phosphorylase (GP). Under normoxic conditions GP exists in a 
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relatively inactive state (GPb), in the first few seconds of ischaemia; the 
substitution of a covalently bound phosphate group for a sulphate at Ser-14 
converts GPb into the more active isoform (GPa).93,94 
 
Lactate produced by anaerobic glycolysis accumulates in severely ischaemic 
tissue. In addition three further glycolytic intermediates (glyceraldehyde-3-
phosphate, glucose-6-phosphate, glucose-1-phosphate) accumulate. The build up 
of intracellular lactate and the other glycolytic intermediates contributes to 
osmotic load and results in cell swelling and sarcolemmal rupture upon 
reperfusion. 
 
1.10.3 Energy+metabolism+and+changes+in+the+nucleotide+pool+in+ischaemia+
Reserves of high-energy phosphate bonds (HEP) in the form of ATP and creatine 
phosphate (CP) are limited. The majority of HEP bonds stored within CP are 
consumed within the first 8-10 seconds following the onset of ischaemia.95 
 
ADP concentrations rise as ATP is utilised, this leads to an enhanced rate of 
salvage of HEP through the action of adenylate kinase; two molecules of ADP are 
used to create one molecule of ATP and one of AMP. 
 
AMP is metabolised by 5'-nucleotidase to adenosine (ADO) and inorganic 
phosphate (Pi). Adenosine is deaminated to inosine (INO) via adenosine 
deaminase.96 In contrast to the nucleotides, the nucleosides, adenosine and 
inosine, are highly diffusible and are able to leave the cell. Inosine is further 
catabolised to hypoxanthine and xanthine. 
 
The proportions of various catabolites of the adenine pool varies with duration of 
ischaemia.97 Initially ADP and AMP increase markedly. ADO, which is always 
found at a very low level, remains much the same whereas INO accumulates 
rapidly. After 40 minutes of severe ischaemia, AMP is the predominant nucleotide 
and INO the predominant nucleoside. After several hours of persistent ischaemia 
hypoxanthine becomes the principal catabolite. 
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1.10.4 Osmolar+load+
During ischaemia there is an accumulation of the waste products of cellular 
metabolism (e.g. Lactate, H+ and NH3, formed from the deamination of 
adenosine). This leads to an increase in the osmolar load of the cell that could 
result in substantial cell swelling if sufficient extracellular water was present. 
However, in total ischaemia the inability to replenish extracellular water limits the 
extent of cellular swelling. Furthermore in response to increasing osmotic load 
there is potassium flux out of the cell into the extracellular space. The increase in 
extra cellular potassium is likely to contribute to arrhythmogenesis and the typical 
ECG manifestations of cardiac ischaemia. 
 
1.10.5 Ultrastructural+changes+
Ultrastructural changes are relatively few in the early stages of ischaemic injury, 
glycogen depletion as a consequence of anaerobic glycolysis may be seen. 
However after 30-40 min of ischaemia the injury becomes irreversible. This 
transition is associated with a number of ultrastructural features: 
♦ diffuse mitochondrial swelling 
♦ the appearance of amorphous densities within the mitochondrial 
matrix 
♦ the virtual absence of glycogen 
♦ marked peripheral aggregation of nuclear chromatin 
♦ the appearance of gaps within the plasmalemma of the sarcolemma 
Scattered myocyte death is detectable after 20-25 min of low flow ischaemia. 
 
1.10.6 Microvascular+injury+
The capillary endothelium is relatively more resistant to ischaemia-reperfusion 
injury than cardiac myocytes,98 overt microvascular damage does not occur until 
irreversible myocyte damage is well advanced (after 60 min or more of 
ischaemia). Severe microvascular injury precludes reflow. 
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1.10.7 Reversible+and+Irreversible+injury+
The key event that marks the transition between reversible and irreversible injury 
is unknown. Irreversibly injured myocytes exhibit a number of metabolic and 
ultrastructural features: 
♦ very low levels of ATP (<10% of controls) 
♦ cessation of anaerobic glycolysis 
♦ high levels of H+, AMP, INO, lactate, alpha-glycerol phosphate and other 
glycolytic intermediates 
♦ increased osmolar load 
♦ mitochondrial swelling and formation of amorphous matrix densities 
♦ focal disruption of the sarcolemma 
 
The final event that appears to herald myocyte death and from which recovery is 
not possible is disruption of the sarcolemmal membrane. However, injury to the 
membrane is not observed unless there is concomitant mechanical stress. Thus, it 
appears that the damage to the sarcolemmal membrane has two components; 
weakening/ destabilisation of cytoskeletal elements supporting the membrane and 
mechanical stress which results in disruption of the membrane. 
 
1.11 Reperfusion/
Reperfusion therapies (pharmacological thrombolysis, primary PCI and other 
revascularisation strategies) are the mainstay of the modern management of AMI, 
optimal benefit is derived if reperfusion is achieved within the first 2-3 hours from 
the onset of ischaemia.99 Yet paradoxically reperfusion itself may be an injurious 
process. 
 
In broad terms Ischaemic injury may be thought of as predominantly the result of 
tissue necrosis and priming the cell for reperfusion injury, which consists of an 
early, predominantly necrotic, and later apoptotic phases. 
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Myocardial reperfusion injury may be considered to consist of four components: 
♦ Myocardial stunning - which describes the mechanical dysfunction that 
persists after reperfusion. It may take several days or weeks before normal 
contractile function is restored.  
♦ No-reflow - which refers to the failure of microvascular reperfusion of 
previously ischaemic tissue. 
♦ Reperfusion arrhythmias (possibly contributed to by increased extracellular 
[K+]) 
♦ Reperfusion injury - cell death induced by reperfusion 
 
1.11.1 Reperfusion+injury+
The existence of reperfusion injury as a cause of cardiomyocyte death has been 
the source of some contention.100 
 
The difficulty arises from the inability to visualise the evolution of myocardial 
infarction in vivo and in real-time. However, the ability of therapies introduced at 
the time of reperfusion to reduce myocardial infarct size, is regarded as surrogate 
evidence for the existence of reperfusion injury and may account for up to 50% of 
the final infarct size.101 A number of factors/ processes are thought to mediate 
reperfusion injury. 
 
1.11.2 The+oxygen+paradox+
The reoxygenation of previously ischaemic tissue is associated with oxidative 
stress, mediated by the release of significant quantities of reactive oxygen species 
(ROS), which leads to further cellular damage that exceeds that induced by the 
ischaemic insult alone. Moreover, ROS reduce the bioavailability of nitric oxide, 
an important cytoprotective signaling molecule, the effects of which include; 
inhibition of neutrophil accumulation and platelet aggregation, inactivation of 
superoxide radicals and the improvement of coronary blood flow. However, the 
administration of antioxidants at reperfusion has yielded conflicting results, as has 
treatment with the nitric oxide donor nicorandil.
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1.11.3 The+calcium+paradox+
Upon reperfusion, there is an abrupt increase in cytosolic [Ca2+], secondary to 
sarcolemmal membrane damage and oxidative stress–induced dysfunction of the 
sarcoplasmic reticulum (SR) resulting in intracellular and mitochondrial calcium 
overload leading to hypercontracture of the myofibrils and mitochondrial 
permeability transition pore (mPTP) opening.  
 
Attenuating intracellular Ca2+ overload with pharmacologic antagonists of the 
sarcolemmal Ca2+ ion channel, the mitochondrial Ca2+ uniporter, or the sodium–
hydrogen exchanger decreases myocardial infarct size by up to 50% in 
experimental studies.102,103 However, the results of the corresponding clinical 
studies have been negative.104,105 
 
Under ischaemic conditions, there is insufficient ATP to drive the Na/ K-ATPase 
resulting in loss of the trans-sarcolemmal Na gradient. As a consequence there is 
an intracellular accumulation of both Na+ and Ca2+. Upon reoxygenation, 
recovery of energy production rapidly reactivates two major cation pumps, the 
Ca2+ pump (Ca2+-ATPase) of the SR and the Na/ K-ATPase of the sarcolemma. 
Activation of the Ca2+ pump of the SR leads to a temporary sequestration of excess 
cytosolic Ca2+ within this intracellular storage organelle.106,107 As the capacity of 
the SR to take up the excess cytosolic calcium is exceeded, calcium efflux from 
the SR begins. Setting up spontaneous Ca2+ oscillations. These oscillations only 
cease once the cytosolic [Ca2+] returned to normal. Restitution of the cytosolic 
[Ca2+] is dependent upon the generation of a sufficiently large trans-sarcolemmal 
Na gradient to allow for the efficient expulsion by the Na/ Ca2+ exchanger of the 
sarcolemma operating in its ‘forward mode’.107  
 
The restoration of energy supply, in the form of ATP, in the context of high 
intracellular [Ca2+] leads to myofibrillar activation and the generation of excessive, 
uncontrolled, force resulting in damage to cytoskeletal elements and transmission 
of this excess force to the sarcoplasma causing focal disruptions in the membrane 
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and the sarcoplasmal membrane of adjacent cells. This process is termed 
hypercontracture and results in irreversible injury to the myocyte. 
 
This mechanism of reoxygenation-induced mechanical injury can be prevented if 
the contractile machinery is inhibited during the early stages of energy recovery, 
allowing time for the restitution of normal cytosolic [Ca2+]. Several studies have 
demonstrated that a direct blocker of the myofibrils, 2,3-butanedionemonoxime 
(BDM), can be used experimentally to inhibit the myofibrillar machinery during 
the early ‘vulnerable phase’ of reoxygenation, this strategy can reduce infarct size 
by as much as third.108 
1.11.4 The+pH+paradox+
The rapid restoration of physiological pH following reperfusion, as a result of 
washout and metabolism of lactic acid and the activation of sodium hydrogen 
exchanger (NaHE) is associated with lethal reperfusion injury. Lower intracellular 
pH is associated with an increased probability of mPTP opening. Indeed, the 
protective effect of post-conditioning may be in part due to delayed restoration of 
normal pH. Pharmacological inhibition of the NaHE has been shown to be as 
effective as ischaemic preconditioning in reducing infarct size.103 
 
1.11.5 Inflammation+
Ischaemia-reperfusion injury is a potent inflammatory stimulant. Chemoattractants 
released by damaged tissue draw neutrophils into the infarct zone within the first 
six hours of reperfusion. During the following 24 hours they migrate into the 
myocardial tissue. Neutrophil migration and infiltration may, as a result of 
microvascular plugging, the release of degradative enzymes and the generation of 
ROS, injure viable myocytes adjacent to necrotic areas.
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1.11.6 The+mitochondrial+transition+pore+(mPTP)+
The mPTP is a non-selective channel located in the inner mitochondrial 
membrane. Opening of the channel dissipates the mitochondrial membrane 
potential and un-couples oxidative phosphorylation resulting in ATP depletion 
and cell death. The mPTP remains closed during ischaemia, however, conditions 
present within the first few minutes after myocardial reperfusion such as:  
◆ Mitochondrial calcium overload 
◆ Oxidative stress 
◆ Restoration of physiological pH 
◆ ATP depletion 
favour opening of the mPTP, which is the critical effector of lethal reperfusion 
injury. 
1.11.7 Metabolic+and+ultrastructural+changes+associated+with+reperfusion+
Reperfusion injury is associated with significant release of ROS, a dramatic 
increase in intracellular calcium and the process of re-alkalinisation. These 
metabolic changes are associated with specific ultrastructural features including: 
the breakdown of mitochondrial structure and rupture. These ultrastructural 
changes become evident within a few minutes of reperfusion98,109 and culminate 
in the development of contraction–band necrosis.110 
 
Oxidative phosphorylation is restored within the first few minutes of reperfusion. 
However calcium overload and rising intracellular pH potentially target cells for 
apoptotic cell death. Changes in the cellular redox status can be seen as early as 
15 min following the onset of reperfusion. Which suggests that most of the injury 
associated with reperfusion is accrued early. 
 
1.11.8 Mechanisms+of+cell+death+during+ischaemiaXreperfusion+
Apoptosis is a genetically predetermined mechanism, often referred to as 
programmed cell death, which may be elicited by several molecular pathways, 
which are broadly grouped into the extrinsic and intrinsic pathways. 
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The extrinsic pathway, also known as the ‘death receptor pathway’, is triggered by 
ligand-induced activation of cell-surface ‘death receptors’. The best known of 
these is tumour necrosis factor receptor-1; other receptors include CD95/ Fas and 
TNF–related apoptosis inducing ligand (TRAIL) receptor-1 and -2. 
 
Of greater interest to researchers studying ischaemia reperfusion injury is the 
intrinsic pathway, also known as the ‘mitochondrial pathway’. Apoptosis results 
from the triggering of an intracellular cascade of events that culminate in 
mitochondrial membrane permeabilisation (MMP). 
 
Apoptosis was first described by Kerr et al in 1972.111 The morphological changes 
that define apoptosis are nuclear pyknosis (chromatin condensation) and 
karyorhexis (nuclear fragmentation). Apoptosis is understood to be fundamental to 
normal development and dysregulation of this process, a key component of many 
disease states. Ischaemia-reperfusion results in both necrotic and apoptotic cell 
death. In crude terms necrosis may be regarded as ATP independent cell death 
whereas apoptosis is ATP dependent and involves clear signaling pathways 
resulting in cytochrome C release from injured mitochondria, autacoid cell-
surface receptor activation (e.g. Fas-ligand) and the formation of other non-
selective pores in the outer mitochondrial membrane by the Bcl-2 family of pro-
apoptotic proteins such as Bax and resulting in what is known as mitochondrial 
transition or mitochondrial membrane permeabilisation (MMP). 
 
Necrosis is generally accompanied by the total depletion of intracellular ATP, is 
not genetically determined and typically occurs within a short period of time 
following the triggering insult (within 2 to 3 hours). The final phenotypic 
appearance of necrotic cells is highly dependent on the severity of injury. The 
principal feature of necrosis is a gain of cell volume (oncosis), which eventually 
results in rupture of the plasma membrane and the disorganised destruction of 
swollen organelles. Unlike the activation of caspases in apoptosis, necrosis lacks a 
specific biochemical marker. However, this traditional view of necrotic cell death 
has been challenged by the publication of experimental data indicating the 
contribution of both caspase activation and protein synthesis to the process of 
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cellular necrosis.112,113 These observations, in conjunction with recent knockout 
studies,114 suggest that the susceptibility to undergo necrosis is in part determined 
by the cell and subject to a degree of regulation. 
 
1.11.9 Mitochondria+and+cell+death+
It was not until the mid-1990s that the importance of the role played by 
mitochondria in the process of cell death began to be appreciated. 
 
The permeability of the outer mitochondrial membrane (OM) is tightly regulated 
both in life and death of the cell. During cell death the OM typically increases 
allowing for the release of soluble proteins usually contained within the 
mitochondrion or inter-membrane space (IMS). 
 
Activation of a specific family of proteases, the caspases (cysteine protease 
cleaving after aspartic acid), in particular the activation of a subset of caspases 
(caspase-3, -6 and-7)115 which are collectively known as the ‘executioner’ 
caspases, appears to be crucial in orchestrating and implementing cell death via 
both the extrinsic and intrinsic pathways. 
 
The majority of cell death in vertebrates proceeds via the intrinsic or 
mitochondrial pathway of apoptosis.116 Mitochondrial membrane permeabilisation 
(MMP), regarded as a key step in the intrinsic pathway, is thought to occur via two 
mechanisms. Firstly, permeabilisation of the outer mitochondrial membrane 
occurs as a result of translocation and integration of the pro-death members of the 
Bcl-2 family (e.g. Bax, Bak and Bid) into the outer mitochondrial membrane and 
results in the release of pro-apoptotic proteins normally resident in the inter-
membrane space. Most notably; cytochrome C, second mitochondria-derived 
activator of caspase/direct inhibitor of apoptosis binding protein (IAP) with a low 
pI (Smac/DIABLO), Omi stress-regulated endoprotease/ high temperature 
requirement protein A2 (Omi/HtrA2) and endonuclease-G (endoG). Cytochrome 
C, which normally resides only in the IMS where it functions as an electron 
shuttle in the respiratory chain, is the rate-limiting step in the formation of a 
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multimeric protein complex known as the "apoptosome" from the adapter 
molecule apoptosis protease activating factor-1 (APAF-1) in the presence of 
ATP/dATP.117 The apoptosome cleaves and activates the initiator caspase-9, which 
in turn activates the executioner caspases (caspase-3, -6 and-7). Thus, MMP is the 
critical event responsible for caspase activation in the intrinsic pathway. 
 
MMP can even commit a cell to die when caspases are not activated. This 
“caspase-independent death”112,118 can occur because of an irreversible loss of 
mitochondrial function as well as because of the mitochondrial release of 
caspase-independent death effectors including apoptosis-inducing factor (AIF),119 
endonuclease G (EndoG),120 and others.112,118 
 
1.12 Effectors/of/cell/death/
Mitochondrial permeability transition (mPT) describes a sudden increase in the 
inner mitochondrial membrane permeability to solutes with a molecular mass of 
up to 1.5 kDa and results from the opening of a large, voltage–dependent, high–
conductance channel located in the IM, known as the mitochondrial permeability 
transition pore (mPTP).  
 
Opening of the mPTP is not a binary phenomenon, it may exist in a range of 
opening states from a low conductance confirmation characterised by limited 
permeability, to a high conductance state which allows the free passage of solutes 
and molecules with molecular mass less than 1.5 kDa.121 
 
Caspase-3 cleavage, a key step in pro-apoptotic signaling, is noted during 
ischaemia,122 it is not until reperfusion that the characteristic DNA cleavage, 
identified by TUNEL-staining indicating apoptotic cell death is observed. 
 
Signaling pathways mediate apoptotic cell death, which offers the opportunity for 
therapeutic intervention.
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1.12.1 Therapeutic+strategies+to+prevent+cell+death+X+ischaemic+preconditioning+
Huge advances in our understanding of the mechanism of ischaemia–reperfusion 
injury have resulted from the study of the endogenous cardio-protective 
mechanisms. 
 
♦ Triggers - which bind to cell surface receptors 
♦ Mediators - signaling pathways 
♦ End-effectors 
 
Pre-conditioning must be initiated in advance of an ischaemic insult in order to 
achieve effective tissue protection. Moreover there is a requirement for a brief 
period of 'washout' reperfusion. 
 
The signal for ischaemic preconditioning is thought to comprise a variety of 
autocrine and paracrine factors which bind to cell surface receptors. Autacoids 
typically signal through G-protein coupled receptors (GPCRs), examples of which 
include adenosine receptors (A1
123and A3
124), bradykinin B2 receptors125 and δ-
opioid receptors.126 
 
Additionally, there appears to be an obligate roll for the tyrosine kinase receptors 
(TKRs), potentially through transact oration by GPCRs via sub-sarcolemmal 
signaling to intracellular domains of TKRs. 
 
1.12.1.1 Mediators 
Downstream of sarcolemmal receptors is a signaling cascade consisting of protein 
kinases that help propagate the preconditioning signal. This cascade involves a 
number of isoforms of protein kinase C (PKC),127 most notably PKCε,128 in turn 
there is activation of mitogen activated protein kinases which include 
extracellular signal regulated kinase (ERK) and p38 MAPK but also the proposed 
deleterious p54/JNK. 
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Furthermore, a major role is also played by endothelial nitric oxide synthase 
(eNOS) and phosphatidyl inositol-3 kinase (PI3K). 
 
Downstream of this pathway are kinases that are thought to directly impact on 
proposed end-effector mechanisms. In addition, there is also an important role for 
various transcription factors, such as nuclear factor kappa-B (NfKb). Whilst the 
signaling kinases play an important role in transducing the preconditioning signal, 
thus far none have been pinpointed as a method of conferring protection to the 
same degree seen with ischaemic preconditioning. 
 
1.12.1.2 Effectors 
The current paradigm holds that; apoptotic-mediated reperfusion injury is 
triggered by mitochondrial permeability transition resulting from the opening of a 
non-selective high-capacitance pore within the inner mitochondrial membrane 
(IM) known as the mitochrondrial permeability transition pore (mPTP). The mPTP 
is sensitive to alterations in the intracellular mileu, is a substrate for GSK-3β and 
also a target of various other apoptotic pathways. Opening of the mPTP is 
characterised by mitochondrial swelling, depolarisation and uncoupling of the 
electron transport chain. 
 
The precise composition of the mPTP remains controversial. Whilst the role of 
adenine nucleotide transcriptase appears essential in the formation and regulation 
of pore opening, doubt has arisen concerning the role of the voltage dependent 
anion channel. A High calcium concentration, oxidant stress, and a high 
intracellular pH (greater than 7.0) are associated with opening of the mPTP. 
Cyclosporine A, tri-fluroperazine and an acidotic pH (less than 7.0) significantly 
reduce the likelihood of the pore opening. 
  
The mPTP remains closed during ischaemia, opening upon reperfusion. It is likely 
that the acidotic milieu of ischaemia and the relatively normal intracellular 
calcium concentration during ischemia inhibit pore openning until these 
circumstances are reversed upon reperfusion.
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1.13 Improving/cardiovascular/outcomes/for/patients/with/CKD/
The modern management of acute myocardial infarction may be considered to 
involve a number of stages 
• Prevention - both primary and secondary 
• Early reperfusion 
• Remodelling 
1.13.1 Primary+prevention+through+risk+factor+modification+
The aim of primary prevention is to limit the risk of cardiovascular disease by 
making lifestyle changes or pharmacologically treating ‘modifiable’ risk factors. 
 
CKD, like diabetes mellitus, is considered to be a coronary heart disease risk 
equivalent.129 Thus an individual with CKD is considered to have the same risk of 
a future cardiovascular event as someone who has already suffered an acute 
coronary syndrome or has known coronary artery disease and therefore guidelines 
for secondary prevention of CVD should be followed. There is however, very little 
in the way of evidence base for these guidelines in patients with CKD. Indeed the 
few large randomised clinical trials (RCT) that have been conducted in patients 
with CKD have not been successful in establishing an evidence base for either 
modification of traditional34,35 or non-traditional risk factors. 
 
Table 3 summarises current advice for secondary prevention of cardiovascular 
disease from The National Institute of Clinical Excellence (NICE). 
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Table 3 - Summary of current NICE guidance for the secondary prevention of cardiovascular 
disease. 
 
1.13.2 The+effect+of+renal+allograft+transplantation+
The benefits of renal transplantation in terms of overall mortality have been well 
described.130,131 However, cause specific mortality and in particular cardiovascular 
mortality are unknown. Cardiovascular mortality remains high in recipients of 
renal allografts and considerably greater than that seen in the general population.
INTRODUCTION 
59 
1.13.3 Improving+outcomes+post+acute+myocardial+infarction+
The high rate of cardiovascular mortality in patients with CKD is driven by both; 
an increased event rate, which has proven difficult to reduce through risk factor 
modification and an increased case fatality rate. 
 
Following the seminal clinical trials of thrombolytic therapy and subsequently 
primary PCI, the sine qua non of contemporary management of acute myocardial 
ischaemia has become reperfusion therapy. Early reperfusion in accordance with 
the old adage that ‘minutes are muscle’, is vital in reducing infarct size and 
improving long-term prognosis.132 Additionally, pharmacological therapy has been 
proven to favorably alter the pathophysiologic post-infarct remodeling process.  
 
However, there is an additional phase which is at present largely neglected, and 
which may hold particular promise for improving outcomes in individuals with 
CKD, namely amelioration of reperfusion injury. Both ischaemic pre-conditioning 
(IPC) and remote ischaemic preconditioning (RIPC) have been shown to 
effectively attenuate reperfusion injury. 
 
1.13.3.1 Ischaemic conditioning 
Ischaemic conditioning may be used as an umbrella term to describe a variety of 
mechanical conditioning techniques, namely: 
♦ Ischaemic PRE-conditioning (IPC) 
♦ Remote ischaemic PRE-conditioning (RIPC) 
♦ Ischaemic PER-conditioning 
♦ Remote ischaemic PER-conditioning 
♦ Ischaemic POST-conditioning (iPost) 
♦ Remote ischaemic POST-conditioning (rPost) 
that confer resistance/ protection to the ‘conditioned’ tissue from ischaemia-
reperfusion (IR) injury.
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1.13.3.1.1 Ischaemic,Preconditioning,
In 1986 Charles Murray and his colleagues at Duke University Medical Centre, 
working with a canine model of myocardial infarction, made the seminal 
observation that repeated, brief episodes of ischaemia followed by reperfusion 
rendered the heart resistant to a subsequent more prolonged ischaemic insult.17 
Their discovery built on earlier observations made by the same group that 
repeated brief periods of ischaemia-reperfusion attenuated the rate of ATP 
consumption during subsequent episodes of ischaemia.133 
 
Murry et al performed a series of experiments employing 4 cycles of 5 minutes 
ischaemia followed by 5 minutes reperfusion prior to a sustained episode of 
ischaemia lasting 40 min. They found that in animals that had undergone 
repeated cycles of ischaemia-reperfusion the size of the infarct induced by 40 min 
of ischaemia was markedly reduced. They coined the term 'ischaemic 
preconditioning' to describe the myocardial protection afforded by exposure of 
the heart to repeated ‘sub-lethal’ (of insufficient duration to result in myonecrosis) 
episodes of ischaemia-reperfusion. 
 
However, when Murray and his colleagues repeated their experiment, using the 
same preconditioning protocol (4x 5 min cycles of ischaemia-reperfusion), but 
substituting a longer final ischaemic insult (3hrs instead of 40 min) there was no 
difference in infarct size between preconditioned and control animals, indicating 
that preconditioning must be complemented by timely reperfusion and that 
preconditioning delayed cell death rather than prevented it. 
 
Subsequently the phenomenon of preconditioning has been confirmed by 
numerous investigators around the world. 
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AIMS++
The aim of this work cannot be described better than by the following quote. 
 
“The development of rational therapeutic approaches to protect the ischaemic 
heart requires pre-clinical studies that examine cardioprotection specifically in 
relation to complicating disease states and risk factors.”134 
 
Cardiovascular disease is highly prevalent in patients with CKD and is the leading 
cause of death for patients with CKD. Both preclinical and clinical studies 
frequently fail to assess the effect of comorbidity on the efficacy of potential 
therapies. The broad aim of the investigations that constitute this thesis was to 
identify stratergies, both pharmacological and non-pharmacological, which 
provide myocardial protection against ischaemia-reperfusion injury (IRI). By 
attenuating IRI it is hoped that the case fatatlity rate for patients with CKD 
suffering an AMI could be reduced thereby leading to improvements in the 
prognosis for individuals with CKD. 
 
Specifically the aims of this work were to: 
♦ Develop a model of uraemic myocardial infarction. 
♦ Confirm the previously published findings of ‘reduced ischaemia 
tolerance’ in the sub-total nephrectomy model of chronic uraemia.135 
♦ Investigate the effect of more severe renal failure induced by adenine diet 
upon infarct size. 
♦ Investigate strategies to ameliorate infarct size in chronic uraemia, in 
particular to assess the efficacy of classical ischaemic preconditioning 
(IPC), remote ischaemic preconditioning and pharmacological 
preconditioning. Ultimately with the aim of providing preclinical data to 
justify clinical trials.  
♦ Examine the effect of acute renal dysfunction on myocardial infarct size.
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2 CHARACTERISATION+OF+THREE+MODELS+OF+CHRONIC+
URAEMIA
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2.1 Background/'/Animal/models/of/chronic/uraemia/
 
The kidneys serve a number of functions within the body: 
♦ The homeostatic regulation of body composition 
- fluid volume, osmolality, electrolyte concentration and acidity. 
♦ The excretion of end products of metabolism and xenobiotics. 
♦ Production and excretion of enzymes and hormones 
- Renin, erythropoietin and 1,25-dihydroxyvitamin D3 
The syndrome of uraemia comprises a number of features and conditions that are 
the direct and indirect consequence of the failure of the kidneys to fulfill these 
functions. It is characterised by anaemia, hypertension, LVH, disturbances in bone 
biochemistry, arterial remodeling (vascular calcification) and dyslipidaemia. 
 
Several animal models have been developed in order to investigate the complex 
interactions between reduced kidney function and the other organ systems. The 
most commonly employed are models of nephron mass reduction. 
 
2.1.1 Surgical+models+
A reduction in nephron mass may be achieved through two principal methods. 
 
2.1.1.1 Renal infarction model 
This is carried out as a two-stage procedure. Following a unilateral nephrectomy, 
arteries supplying the superior and inferior poles of the remaining kidney are 
ligated such that two thirds of the kidney is infarcted, the sub-totally infarcted 
kidney remains in situ.136 The advantage of this model is the reduced blood loss 
suffered by the animals, the disadvantages are; the large amount of necrotic tissue 
that is left behind which drives an inflammatory response and increased 
variability in the degree of renal dysfunction achieved, largely due to the 
increased technical difficulty of the model and anatomical variations in the 
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proportion of renal tissue supplied by each branch.137 The more commonly used 
nephron mass reduction model is that of 5/6tth or sub-total nephrectomy (SNx). 
 
2.1.1.2 Sub-total nephrectomy model 
First described by Chanutin and Ferris in 1932,138 subtotal nephrectomy (SNX) is 
usually carried out as a two-stage procedure. However, the first and second stages 
may be reversed and may be carried out either via a flank incision or a 
laparotomy. As practised in our laboratory, two thirds of one kidney is resected. 
Following a recovery period (typically 2 weeks), the contralateral kidney is 
removed leaving approximately one sixth of the original nephron mass remaining. 
Hence this model is also sometimes refered to as 5/6th nephrectomy. 
 
Some practitioners prefer to perform a unilateral nephrectomy as the first stage, 
weigh the excised kidney and following a recovery period resect two thirds of the 
weight of the nephrectomised kidney from the remaining kidney. 
 
Histological examination of the remnant kidney reveals hypercellular glomerular 
tufts, with expansion of the glomerular volume and tubular atrophy.139 In 
comparison to the infarction model, the sub-total nephrectomy results in a much 
less variability in serum creatinine and is technically easier. For this reason, the 
SNx model has become the most popular rodent model of chronic uraemia. 
 
2.1.1.3 Polar ligation model 
A further method of nephron mass reduction has been described by Perez-Ruiz et 
al,140 in which, following unilateral nephrectomy, the poles of the contralateral 
kidney are ligated. The authors claim that this technique maintains the advantage 
of avoiding excessive bleeding (as with the infarction model) whilst delivering the 
homogeneity, in terms of serum creatinine, seen with sub-total resection. 
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2.1.2 NonXsurgical+models+
2.1.2.1 Immune mediated CKD 
An alternative approach to the induction of experimental uraemia has been to 
mimic anti-glomerular basement membrane disease (anti-GBM) by injecting rats 
with purified rabbit anti-rat-GBM sera.141 This model results in progressive 
proteinuria, azotaemia and growth restriction. Histological lesions appear as early 
as day four with evidence of widespread segmental necrosis, followed by cellular 
crescents by day 11. At day 44 there is severe scarring with marked fibrosis but 
little in the way of active inflammation.141 Biochemical disturbances include a 
doubling of serum creatinine by day 30 with hypocalcaemia and 
hyperphosphataemia. However, substantial variation in the level of serum 
creatinine is still seen at three weeks. 
 
Despite the existence of commercially available rat-anti-GBM (Probetex, Inc. San 
Antonio, Texas, USA). This model has not been widely adopted for the induction 
of experimental uraemia. 
 
2.1.2.2 Adenine diet induced uraemia 
Yokazawa and colleagues first described the use of a diet supplemented with 
0.75% adenine to induce experimental uraemia in 1986.142 In recent years there 
has been a growth in the popularity of this model owing to the propensity the 
animals display for the development of vascular calcification. 
 
Adenine induced uraemia is predominantly the result of tubulointerstial disease, 
the histological features of which include; expansion of renal tubules, 
crystallisation of adenine within the tubules, stromal oedema with infiltration by 
inflammatory cells and the formation of giant cells leading to fibrosis, in the 
absence of glomerular changes.143 
 
Plasma biochemistry demonstrates creatinine values more than three fold greater 
than controls by the 30th day, rising to almost 5 times that of control animals by 
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the 50th day. The animals die between the 40th-65th days. Additionally, adenine 
fed rats were found to be hypoalbuminaemic, hyperlipidaemic, hypocalcaemic 
and hyperphosphataemic and to rapidly develop hyperparathyroidism and 
vascular calcification.144 
 
2.1.2.2.1 Advantages,of,adenine,induced,uraemia,over,other,models,
Adenine diet induced uraemia has a number of advantages over the more 
established nephron reduction models, in particular: 
♦ It is less time consuming to prepare the animals, 
♦ It does not require the acquisition of surgical skills, 
♦ Fewer animals are lost as a consequence of surgical or anaesthetic 
complications. 
♦ It induces more significant renal dysfunction, at least in terms higher 
levels of serum creatinine and urea, 
♦ With greater consistency, 
♦ In less time, and therefore associated with lower husbandry costs, 
♦ Moreover, the degree of renal dysfunction is, to an extent, titratable by 
varying the duration of feeding and/ or the introduction of a ‘wash-out’ 
period at the end of a course of diet. 
 
Myocardial ischaemia-reperfusion injury (IRI) has not previously been performed 
in this model. Therefore to determine the effects of uraemia induced through this 
method on myocardial infarct size would be novel. For these reasons the adenine 
diet model was chosen to produce uraemic animals for these experiments. 
 
2.1.2.2.2 The,mechanism,of,adenine,induced,uraemia,
In contrast to the other purine nucleotides (hypoxanthine and guanine), it is not 
possible to convert adenine directly to it’s nucleoside and therefore must first be 
converted to adenosine monophosphate (AMP) through the action of adenine 
phosphoribosyltransferase (APRT). AMP may then be metabolised via adenosine, 
inosine, hypoxanthine, xanthine and urate (in great apes) or finally excreted as 
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allantoin (in all other mammals).145 APRT displays saturable enzyme kinetics, 
under conditions of excessive dietary adenine intake the excess adenine is 
oxidised by xanthine oxidase (XO) first to 8-hydroxyadenine and then to 2,8-
dihydroxyadenine (2,8-DHA)146 (see Figure 3).  
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Figure 3 - Metabolic pathway of adenine. Xanthine oxidase (XO)/ Xanthine Dehydrogenase 
(XDH). 
 
2,8-dihydroxyadenine is relatively insoluble across the physiological pH range of 
urine and thus tends to precipitate causing a crystal nephropathy and the 
histological changes detailed earlier, ultimately leading to renal failure.
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2.1.2.2.3 Adenine,induced,uraemia,;,parallels,with,human,disease,
The human equivalent of the adenine diet induced uraemia is adenine 
phosphoribosyltransferase (APRT) deficiency, an autosomal recessive inborn error 
of metabolism with a homozygous frequency of between 1 in 50,000 to 1 in 
100,000.147 Whilst relatively rare in Caucasians it may affect up to 1.2% of 
Japanese.148 The condition is characterised by nephrolithiasis and may result in a 
progressive decline in renal function.  
 
APRT is a purine salvage enzyme which catalyses the formation of AMP and 
pyrophosphate from 5-phosphoribosyl-1-pyrophosphate. The APRT gene is 
located on chromosome 16q24.149 APRT deficiency has been categorised on the 
basis of enzyme activity. Complete loss of APRT activity is known as type I APRT 
deficiency whereas Type 2 APRT deficiency, which is seen more commonly in 
Japanese cohorts,148 results from a reduced affinity of APRT for adenine.  
 
2.1.2.2.3.1 Clinical+features+of+APRT+in+humans+
Individual differences in the ability to supersaturate the urine with 2,8-
dihydroxyadenine results in a disease spectrum from red/brown stains seen in 
children’s nappies to recurrent nephrolithiasis, urinary tract infections and 
progressive renal decline.150 A study by Bollée et al,146 of a French cohort of APRT 
deficient patients, reported that the mean age of diagnosis was 36.3 years, with 
34% of the cohort diagnosed in childhood. At diagnosis 32.5% of the cohort had 
evidence of renal failure (CKD 3-5), with 15% having reached ESRD by the time 
the diagnosis was made and in 11% the diagnosis was only made after the 
patients had been transplanted. Indeed recurrent disease post transplantation is a 
common pathway leading to diagnosis.146,151,152 
 
The diagnosis of APRT is made on analysis of the crystals, using morphologic 
examination by stereomicroscope and infrared spectroscopy or by measurement 
of APRT activity in erythrocytes. 2,8-dihydroxyadenine stones are radiolucent 
resulting in their frequent misidentification as urate stones. However, fortuitously 
the treatment of 2,8-dihydroxyadenine stones is the same as that of uric acid 
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stones, namely allopurinol and purine restriction. Kidney biopsy generally reveals 
multiple brown tubular and interstitial crystals, which may be mistaken for oxalate 
crystals.151 Additionally depending on duration of disease, there may be varying 
degrees of tubulointerstitial scarring.153  
 
Once APRT deficiency is diagnosed, family members should also be screened for 
the condition. Early diagnosis allows for treatment with allopurinol, which inhibits 
the conversion of adenine to 2,8-dihydroxyadenine, reducing the number of 
crystals seen in the urine by 94%; with 61% of affected individuals rendered 
crystal free.146  
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2.1.3 Comparison+between+Adenine+diet+and+SNx+models+
2.1.3.1 Death rate 
Death during the induction of uraemia with adenine is dependent upon the 
duration of the diet with 100% survival at two weeks, 80% at four weeks and just 
33% at six weeks.143 Similarly, loss of animals during the two stage sub-total 
nephrectomy is not uncommon. Terai et al154 reported 80% survival at four weeks 
in SNx animals compared in contrast they had 100% survival of AD rats. 
Interestingly they also reported 100% survival in SNx animals fed a low 
phosphate diet. However, the sample size was very small (4-5 animals in each 
group) and the authors did not subject the death rate to statistical analysis. 
 
2.1.3.2 Growth restriction 
Animals fed adenine diet (AD) display a marked reduction in food consumption154 
and over four weeks, the protein intake of rats fed AD has been reported to be as 
little as 65% of that of those fed standard chow.155 This reduction in food intake is 
accompanied by rapid weight loss. After just two weeks, rats fed AD have lost 
almost 20% of their body weight and by four weeks they have lost more than ¼ of 
their original body weight. Upon cessation of AD, weight is regained at a velocity 
similar to that of animals fed standard chow.143 Sub-totally nephrectomised 
animals also display growth restriction. It has been suggested that this is due to 
reduced food intake156 as pair fed sham-operated animals failed to gain weight 
compared to sham-operated animals allowed access to food ad libitium.  
 
2.1.3.3 Degree of uraemia 
The sub-total nephrectomy (SNx) procedure typically generates animals with a 
serum creatinine 2-3 fold higher than that of sham-operated controls.157-159 In 
contrast, adenine diet (AD) causes a much greater degree of uraemia with serum 
creatinine levels typically 3 and 10 times that of animals fed control diet.160-162 
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2.1.3.4 Time course of uraemia 
Uraemia is induced earlier with AD compared to SNx, significant derangement in 
renal function is seen within two weeks of the commencement of the Adenine 
diet.154 In the SNx model, four weeks is usually required after the second stage of 
the procedure before rats develop a significant degree of uraemia.163 
2.1.3.5 Reproducibility 
The subtotal nephrectomy model relies on the skill of the operator to achieve a 
similar reduction in nephron mass, this model takes time to learn and each animal 
requires several hours of labour during surgery and recovery. The Adenine diet 
model requires no surgical skill, and often generates a more consistent degree of 
uraemia when compared to the SNX model.154 
2.1.3.6 Calcium 
Serum calcium in SNx rats is similar to that of control rats,157,159,164,165 however four 
weeks of adenine diet causes a marked reduction (up to 40%) in serum calcium 
compared to animals fed control diet.161,166,167  
 
2.1.3.7 Phosphate 
Hyperphosphataemia occurs as early as two weeks following the commencement 
of AD compared to eight weeks following the second stage in SNx animals. 
Moreover, hyperphosphataemia is typically greater in AD animals than SNx 
animals.154 
 
2.1.3.8 Hyperparathyroidism 
Both sub-totally nephrectomised (SNx) and rats with adenine diet (AD) induced 
uraemia develop marked hyperparathyroidism. However, in keeping with the 
more pronounced derangements of divalent ion and phosphate metabolism, 
hyperparathyroidism in AD animals tends to be more severe with PTH levels 9-25 
fold greater than animals fed control diet.161 In comparison, SNx animals have 
PTH levels in the order of 3 to 17 times that of sham-operated controls.159 
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2.1.3.9 Vascular calcification 
In order to induce vascular calcification in the sub-total nephrectomy model, it is 
necessary to supplement the diet with additional phosphate or calcitriol168 or wait 
for up to 24 weeks.169Animals with adenine diet induced uraemia however, 
develop vascular calcification after just 4 weeks of adenine diet.4,5,170 Whether this 
is merely a function of the more severe renal dysfunction seen in this model or an 
idiosyncratic effect of adenine diet is unknown. 
 
2.1.3.10 Dyslipidaemia 
Both SNx163 and AD142 animals develop significant elevations in total cholesterol. 
Adenine treated animals do not develop hyper-triglyceridemia.142 There are 
conflicting reports of hypertriglyceridaemia in the SNx model with some authors 
finding no change in triglyceride levels154 and others reporting elevated levels.139 
 
2.1.3.11 Anaemia 
Subtotal nephrectomy (SNx) is associated with anaemia171 which is effected 
through intra-operative blood loss as well as relative deficiency of erythropoietin 
resulting from loss of functional nephron mass. Anaemia is seen in AD animals 
after four weeks of adenine diet.143 
2.1.3.12 Iron status 
Sub-totally nephrectomised rats display a trend towards an increased serum 
ferritin, reaching statistical significance by the 15th week post the 2nd stage 
procedure. This is mirrored by a fall in serum transferrin suggesting functional iron 
deficiency.139 In the AD model, despite marked anaemia, no difference in serum 
ferritin, iron or transferrin is seen after four weeks of adenine diet.172  
 
2.1.3.13 Urine abnormalities 
Both SNx rats173 and AD animals174 are proteinuric. Urinary abnormalities develop 
rapidly in rats with AD induced uraemia. After just one week of adenine diet, rats 
CHARACTERISATION OF THREE MODELS OF CHRONIC URAEMIA 
73 
develop polyuria (without polydipisa), naturia, calciuria and phosphaturia. 174 
Similar findings are reported in SNx animals.175 
 
2.1.3.14 Blood pressure 
Sub-totally nephrectomised rats develop marked hypertension, significantly 
greater than sham-operated control animals, just four weeks following the second 
stage procedure.176 There are conflicting reports regarding the development of 
hypertension in AD induced uraemia. Ataka et al177 reported no difference in 
blood pressure between animals fed for four weeks on adenine diet and those fed 
control diet, in spite of marked differences in renal function. However, six weeks 
after cessation of adenine diet, the uraemic animals began to develop significant 
hypertension. In contrast, Yokozawa et al178 found that AD animals developed 
hypertension after less than four weeks of adenine diet and became progressively 
more hypertensive the longer they remained on adenine diet. Additionally, they 
also reported a reduction in renal blood flow with, rising serum levels of 
angiotensin-II, angiotensin converting enzyme (ACE) and aldosterone and 
hypothesised that decreased renal blood flow led to hypertension mediated by 
activation of the renin-angiotensin-aldosterone axis.  
2.1.3.15 Left ventricular hypertrophy (LVH) 
Sub-totally nephrectomised animals develop LVH, as assessed by heart 
weight/body weight ratio163 and echocardiography. Moreover, echocardiography 
demonstrates eccentric LVH with septal thickening and increased left ventricular 
posterior wall dimensions.176 
 
2.1.3.16 Myocardial histology 
Histological examination of hearts from SNx rats demonstrates cardiomyocyte 
hypertrophy.176 In addition, 12 weeks following the second stage procedure, SNx 
animals are reported to develop myocardial fibrosis and reduced capillary 
density.163 
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2.1.3.17 Washout 
A principal advantage of the adenine model over other models of chronic uraemia 
is its reversibility. Even after seven weeks of adenine, cessation of AD results in 
almost complete recovery of renal function.179 Functional recovery is mirrored by 
a reduction in markers of apoptosis (Caspase activation and TUNEL positive 
nuclei) following 10 weeks of ‘washout’. 
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2.2 Aim/
A series of experiments were conducted in order to characterise the phenotype of 
each of the three models of chronic uraemia described in this thesis. 
2.3 Methods/
Three models of chronic uraemia were investigated and used to generate the 
experimental work contained within this thesis: 
♦ Sub-total of 5/6th nephrectomy 
♦ Adenine diet induced uraemia 
♦ Adenine washout 
Male Wistar rats were supplied (Charles River Laboratories UK, Margate, UK) at 
approximately 6 weeks of age and weighing ~250g for all three models. 
 
All experiments were approved by the ethics committee of the William Harvey 
Research Institute and performed under license (70/616 and 70/6923) granted by 
The Home Office (UK) in accordance with the Animals (Scientific Procedures) Act 
1986. 
 
Animals were housed in cages containing between 1-5 animals, with a 12-hour 
day night cycle with access to food and water ad libitium. Appropriate control 
groups were generated alongside the study groups for all models.
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2.3.1 SubXtotal+nephrectomy+model+
Sub-total nephrectomy was carried out in two stages in a manner similar to that 
previously described and published.90,180,181 
 
Operative procedures were carried out in accordance with the principles of 
asepsis, with surgical instruments sterilised by means of an autoclave. 
 
Following a one-week acclimatization period, the animals were anaethetised with 
isofluorane (Animalcare, York, UK) at a concentration that was varied between 1-
5%, with nitrous oxide and oxygen (BOC, UK) as carrying gases. Induction of 
anaesthesia occurred in an anaesthetic chamber following which the animals 
were transferred to the bench and maintenance anaesthesia was delivered by 
means of a nose cone. All animals received 0.04 mg/Kg buprenorphine (Reckitt 
Benckiser Healthcare Ltd, Hull, UK) for analgesia, administered prior to the 
commencement of surgery. 
2.3.1.1  First stage of sub-total nephrectomy 
The left flank was shaved and an incision was made approximately 1cm beneath 
the ribs. Blunt dissection was carried out in order to gain access to the 
retroperitoneal space. The left kidney was decapsulated and exteriorised. 
Following which, either the kidney was returned to the retroperitoneal cavity 
(sham procedure) or an arterial clamp applied to the renal pedicle and a portion, 
estimated to represent 2/3rd of the left kidney, resected from the superior pole, 
inferior pole and lateral surface. The weight of resected tissue was then weighed 
and further resection undertaken in order to achieve removal of the target amount 
of kidney. Haemostasis was achieved with direct compression. Once the bleeding 
had been controlled, the resected kidney was returned to the retroperitoneal 
space. To prevent dehydration during recovery from anaesthesia, 5 ml of saline 
was instilled into the peritoneal cavity before closure. 
 
The incision was closed in layers, an absorbable running suture (4/0 Vicryl) for the 
muscle layers and surgical clips (Precise Vista™, 3M, Bracknell, UK) to the skin. 
The latter were chosen to prevent the animals from re-opening their wounds. 
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2.3.1.2  Second stage of sub-total nephrectomy 
Following the first stage, the animals were allowed to recover for two weeks 
before undergoing the second stage of the procedure, either right total 
nephrectomy, or a sham procedure consisting of a right flank incision, 
decapsulation and exteriorisation of the right kidney. 
 
Total nephrectomy was performed through a right flank incision. The kidney was 
decapsulated and 2 silk ligatures tied around the renal vessels at the hilum. The 
kidney was then excised. The incision was closed in layers as before, 5 ml of 
saline were instilled into the peritoneal cavity and the animals recovered from 
anaesthesia. Using this method perioperative mortality was <10%. 
 
A minimum of four weeks was allowed for the animals to develop the uraemic 
phenotype before being utilised in myocardial IR experiments. 
 
2.3.1.3  Measures to improve reproducibility 
 
The most critical stage in the process of creating the SNx model is the partial 
nephrectomy (Stage 1). Removal of too much kidney can result in severe uraemia 
leading to death or the need to euthanase sick animals. A preliminary study was 
carried out in order to characterise the relationship between the weight of kidney 
removed during the first stage and the subsequent degree of uraemia, with the aim 
of improving reproducibility of the model. Some practitioners choose to perform 
the staged sub-total nephrectomy in reverse to the above description with total 
nephrectomy as the first stage. They then weigh the excised kidney and remove 
2/3 of the weight of the kidney from the contralateral kidney during the second 
stage. However, increased operative mortality may be experienced as a result of 
the development of more severe acute kidney injury. 
 
Following preliminary work, it was determined that it was desirable to remove an 
amount of kidney corresponding to between 0.3 to 0.325% of body weight in 
order to achieve a trebling of serum creatinine (see Figure 4). 
CHARACTERISATION OF THREE MODELS OF CHRONIC URAEMIA 
78 
Initially, I created the sub-totally nephrectomised animals. However, this process 
was time consuming and reduced the rate at which the other experiments could 
be carried out. Therefore, another member of the laboratory staff subsequently 
undertook the creation of sub-totally nephrectomised animals. The use of a single 
operator also helped to reduce variability in serum creatinine. 
 
Figure 4 – Amount of kidney removed vs. serum creatinine. 
To achieve a serum creatinine approximately 3 fold greater than sham-operated control animals it 
was necessary to remove an amount of kidney corresponding to between 0.3-0.325% of body 
weight. Correlation tested by two-tail Spearman’s rank. 
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2.3.2 Adenine+Diet+Induced+Uraemia+
Following a one week acclimatisation period, during which all animals received 
standard chow (Rat and mouse No.1 Maintenance diet: Special Diet Services UK 
(see Figure 49, for a break down of the constituents), the rats were randomly 
allocated to either continue to receive standard chow (ad libitium) or a diet 
containing 0.75% (by weight) adenine (Special Diet Services, Essex, UK) for a 
further four weeks. 
 
After four weeks the animals developed profound azotaemia and were ready to be 
utilised in other experiments. 
 
2.3.3 Adenine+diet+washXout+(WO)+model+
The adenine diet (AD) model was modified to include a two week ‘wash-out’ 
period during which time the animals, who were previously fed the diet 
containing 0.75% adenine for four weeks, were returned to standard chow. The 
rats were then used for experiments during the third week following cessation of 
adenine diet. The control group continued on standard chow throughout.
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2.3.4 Methods+X+Characterization+of+the+models+
Four weeks following the second stage nephrectomy (SNx model), after four 
weeks of adenine diet (Ad model) or two weeks following the cessation of 
adenine diet (WO model), study and control animals were housed overnight (18 
hours) in metabolic cages (Harvard Apparatus, Kent, UK) with free access to a 
known quantity of food and water, enabling the amount of food eaten and volume 
of water drunk to be calculated. 
 
Urine was collected and the volume produced recorded. The urine was 
subsequently spun in a 50 ml Falcon tube at 500G for 5 min in order to remove 
any contaminating debris. The urine was then aliquoted into 2 ml Eppendorf and 
stored at -80oC before being subsequently sent for analysis. 
 
Following removal from the metabolic cages, the animals were anaesthetised (for 
full details of anaesthesia see page 104) and underwent morphometric assessment 
(consisting of weight, body length, tail length and tibial length). The rats then 
underwent venous and arterial cannulation and a tracheostomy was performed 
(for full details of basic surgery protocol see basic surgery section page 105). 
Mean arterial pressure and heart rate were recorded (for full details of the 
measurement and recording of cardiovascular parameters see page 106).  
 
One ml of blood was withdrawn from the arterial line in a heparinised syringe; 
approximately 200 µl was used for arterial blood gas analysis using an ABL 77 
blood gas analyser (Radiometer Ltd, Copenhagen, Denmark). The remaining 
blood was transferred into a 1.5 ml Eppendorf and spun at 6000G for 3 min at 
20oC. The plasma was aspirated into a new Eppendorf tube and stored at -80oC for 
later analysis. 
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Plasma (P) and urine (U) samples were sent to a commercial laboratory (IDEXX 
laboratories, UK) for measurement of creatinine (P+U), urea (P), albumin (P), 
sodium (P+U), potassium (P+U), calcium (P), phosphate (P), cholesterol (P) and 
total protein levels (U). 
 
2.3.5 Assessment+of+left+ventricular+hypertrophy+
Left ventricular hypertrophy (LVH) is a key feature of ‘uraemic cardiomyopathy’ in 
humans. The extent of left ventricular hypertrophy in the rodent experimental 
models was assessed in two ways. Firstly, whole heart weight was expressed as a 
ratio of the body weight, an indirect measurement of LVH. Secondly, a 
histological technique was employed to directly measure the area of the left 
ventricle. This was carried out for the SNx model only. 
 
Hearts were harvested from SNx animals and Sham SNx animals under deep 
anaesthesia and placed in 10% formalin for 10 days. The hearts were processed 
by the Pathology group, Blizard Institute of Cell and Molecular Science, Queen 
Mary University of London. The samples were embedded in paraffin, cut in 
transverse section at the widest point of the heart into 5 µm thick slices using a 
microtome before staining with haematoxylin and eosin. The cross sectional area 
of the left ventricle (LV) was calculated by subtracting the LV cavity area from the 
total area of the left ventricle using Image-J software (National Institutes for 
Health, http://rsbweb.nih.gov/ij). The observers were blinded to the status of the 
animals (uraemic versus non-uraemic).
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2.3.6 Statistical+analysis+
Statistical analysis of all data was carried out using Microsoft Excel and GraphPad 
Prism software (San Diego, Ca, USA). Data was tested for normality using 
Kolmogorov-Smirnov, D’Agostino and Pearson, and Shapiro-Wilk tests. If all three 
tests were satisfied, parametric tests were employed. Normally distributed data is 
presented as mean ± standard deviation (SD). Non-parametric data is presented as 
median with interquartile range (IQR). An unpaired two-tail t-test, Mann-Whitney, 
Kruzkal-Wallis with Dunn’s post-test and two way ANOVA with Bonferroni post 
test were used to assess significance. All values are quoted to three significant 
figures 
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2.4 Results/'/Phenotypic/characterisation/
2.4.1 Characterisation+of+subtotal+nephrectomy+model+(SNx)+
Compared to a sham operated controls, sub-total nephrectomy produced animals 
which were mildly growth restricted with a 7% difference in mean weights 
(p=0.05), but without other significant differences in body morphometry (body 
length, tail length, tibial length). 
 
Uraemic (SNx) animals were polyuric (p<0.0001) and polydiptic (p=0.001). 
However, no difference in food consumption was seen (see Table 4). 
 
SNx Model Sham SNx p 
Weight (g) 408 (29.5) 378 (33.4) 0.05 
Water intake (ml/hr) 1.87 (0.40) 3.34 (0.40) <0.0001 
Urine output (ml/hr) 0.73 (0.21) 1.87 (0.47 <0.0001 
Food intake (g/hr) 1.52 (0.20) 1.45 (0.29) 0.78 
    
Tail length (cm) 19.4 (0.88) 18.8 (1.02) 0.18 
Body length (cm) 25.2 (0.85) 24.4 (1.21) 0.08 
Tibial length (cm) 5.89 (0.25) 5.87 (0.33) 0.89 
Blood pressure (mm/Hg) 137 (26) 157 (19.6) 0.01 
Pulse (BPM) 392 (51.6) 387 (44.7) 0.75 
Heart weight (g) 1.14 (0.11) 1.31 (0.20) 0.04 
Heart weight index 2.85 (0.25) 3.44 (0.46) 0.003 
Haematocrit (%) 37.8 (4.51) 27.1 (5.06) < 0.0001 
Serum albumin (g/l) 27.6 (2.24) 27.5 (1.90) 0.94 
Serum Urea (mmol/l) 6.2 (1.34) 17.4 (4.61) <0.0001 
Serum creatinine (μmol/l) 42.1 (5.41)  99.9 (30.1) <0.0001 
Serum cholesterol  1.85 (0.37) 2.72 (0.50) 0.003 
Serum triglycerides (mmol/l) 0.83 (0.50)   
Serum sodium (mmol/l) 141 (1.73) 1.43 (1.76) 0.53 
Serum potassium (mmol/l) 3.88 (0.54) 4.16 (0.41) 0.27 
Serum phosphate (mmol/l) 2.50 (0.29) 2.29 (0.29) 0.11 
Serum calcium (mmol/l) 2.52 (0.12) 2.75 (0.18) 0.003 
Urine protein creatinine ratio 1.4 (0.24) 4.25 (2.62) 0.0003 
Urine sodium (mmol/l) 87.6 (27.3) 44.1 (11.0) 0.002 
Fractional excretion of sodium (%) 0.36 (0.10) 1.16 (0.58) 0.001 
Urine sodium excretion (mmol/h/g) 0.15 (0.04) 0.21 (0.04) 0.003 
Table 4 – Characteristics of animals rendered uraemic by means of Sub-total nephrectomy (SNx). 
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2.4.1.1 Plasma biochemistry 
The SNx animals had a mean plasma creatinine nearly 2.5 times that of sham-
operated animals with a similar elevation in plasma urea concentration 
(p<0.0001).  
 
Surprisingly, SNx rats were hypercalcaemic (p=0.003) compared with sham-
operated control animals, chronic uraemia being more commonly associated with 
hypocalcaemia. In addition they were hypercholesterolaemic (p=0.003) but not 
acidotic, hypoalbuminaemia, hypertriglyceridaemia, hyperkalaemia or 
hyperphosphataemia. 
 
2.4.1.2 Urine biochemistry 
SNx animals had significant proteinuria (p=0.0003) as evidenced by an elevated 
urine protein/ creatinine ratio (uPCR) and natriuresis as evidenced by increased 
fractional excretion of sodium (FENa, p=0.001) and increased urine sodium 
excretion (p=0.003). 
2.4.1.3 Cardiovascular findings 
The uraemic (SNx) animals were hypertensive (p=0.01), anaemic (p<0.0001) with 
increased heart weight (p=0.04) and a greater heart weight to body weight ratio 
(p=0.0003), which is frequently used as a marker of cardiac hypertrophy and 
LVH.182 
 
2.4.1.3.1 Left,ventricular,hypertrophy,
(See Table 5 and Figure 5) 
Total heart weight: body weight ratios were significantly greater for uraemic 
animals in all models (see Table 5). Analysis by 2 way ANOVA with Bonferroni 
post test demonstrated an interaction between model and uraemia (p=0.0008) 
indicating that although uraemia appeared to have a consistent effect on heart 
weight: body weight ratio the effect was of differing magnitude in the various 
models. 
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Visual inspection revealed obvious differences in LV wall thickness for some of 
the specimens; this was confirmed by statistical analysis of LV area measurements 
made with Image-J software. 
Sham SNx (n=5) SNx (n=9) p
LV area (mm2)
LV area (mm2/Kg)
37.8 [34-41.4] 45.1 [41.7-60.7] 0.01
92.7 [83.3-101.4] 19.3 [110.3-160.6] 0.003
Model Non-uraemic Uraemic p
Adenine (AD)
Adenine wash-out (AD-WO)
Subtotal nephrectomy (SNx)
0.265 [0.254 - 0.276] 0.3456 [0.335 - 0.358] < 0.0001
0.2931 [0.278 - 0.329] 0.4335 [0.427 - 0.459] 0.0022
0.2783 [0.267 - 0.306] 0.3299 [0.274 - 0.347] 0.0305
(a)
(b)
(c) AD - Con AD WO - Con Sham AD AD WO SNx
AD - Con
AD WO - Con
Sham
AD
AD WO
SNx
ns ns < 0.0001
0.0022
ns 0.0305
< 0.0001 P < 0.0001 ns
0.0022 P < 0.0001 P < 0.0001
0.0305 P < 0.0001
 
Table 5 – Assessment of left ventricular hypertrophy. 
(a) Table of results using histomorphometric method to determine LVH. (b) Heart weight as a 
percentage of body weight for all three models, significance tested with Mann-Whitney U-test (two 
tailed). (c) Table of results for 2-way ANOVA with Bonferroni post test comparison indicating that 
the model with the greatest degree of LVH was the adenine wash-out (WO). 
 
 86 
 
Figure 5 – Assessment of left ventricular hypertrophy. 
(a) Heart weight as a % of body weight for all models. All uraemic animals had significantly greater heart weight/ body weight ratio compared to non-uraemic animals. 
Adenine wash-out animals (uraemic) had significantly greater heart weight/ body weight ratio compared to either of the other uraemic groups (§), tested with 2 way 
ANOVA and Bonferroni post test. (b) Graph demonstrating significantly greater LVH as assessed by crossectional LV area. (c) Section through non-uraemic heart 
demonstrating normal LV wall thickness and cavity size (d) Hypertrophied heart with obliterated LV cavity from a uraemic animal.  
CHARACTERISATION OF THREE MODELS OF CHRONIC URAEMIA 
87 
2.4.2 Results*–*Characterisation*of*adenine*diet*model*(AD)*
After four weeks on the adenine diet, there was a marked disparity with respect to 
all morphometric parameters assessed (see Table 6). After 4 weeks of adenine 
diet, the AD animals were 31% lighter than the control group (fed standard chow, 
p<0.0001).  
 
The adenine treated animals were polyuric (p<0.001) but not polydiptic and per 
Kg body weight, ate less than a third of the amount of food eaten by the control 
rats. 
 
2.4.2.1 Cardiovascular findings 
Unlike SNx animals, AD rats were not hypertensive, but were significantly more 
bradycardic than controls (p<0.0001). In spite of the absence of hypertension, 
heart weight (as percentage of body weight), a surrogate marker for LVH, was 
significantly greater in uraemic (AD) rats compared with controls (p<0.0001). This 
is consistent with observations from patients with CKD and was probably, at least 
in part, as a consequence of profound anaemia (p<0.0001) that occurred in 
association with adenine induced uraemia. 
 
2.4.2.2 Plasma biochemistry 
Adenine treatment resulted in significant uraemia with plasma creatinine and urea 
concentrations 8 fold higher than the control groups with a similar elevation in 
urea concentrations (p<0.0001). In addition AD animals were hypercalcaemic, as 
seen in the SNx model (p<0.002) and hyperkalaemia (p<0.0001). However, they 
were not acidotic, hypoalbuminaemia, hypertriglyceridaemia, or 
hyperphosphataemia and unlike the SNx model they were not 
hypercholesterolaemic 
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2.4.2.3 Urine biochemistry 
Analysis of the urine obtained revealed that the AD animals had significant 
proteinuria (p<0.0001) and a natriuresis as evidenced by increased fractional 
excretion of sodium (p=0.0001) and elevated urine sodium excretion (p=0.006) 
suggestive of a defective concentrating ability. 
  
Adenine model Control Adenine p 
Water intake (ml/hr) 2.66 (0.79) 2.63 (0.51) 0.91 
Urine output (ml/hr) 0.8 (0.39) 1.59 (0.4) <0.001 
Food intake (g/hr) 1.50 (0.17) 0.82 (0.25) < 0.0001 
    
Morphometry    
Weight (g) 434 (25.6) 221(32.8) <0.0001 
Tail length (cm) 20 (0.64) 17.5 (0.65) < 0.0001 
Body length (cm) 24.8 (0.75)  21.4 (0.98) < 0.0001 
Tibial length (cm) 5.91 (0.29) 4.99 (0.22) < 0.0001 
Blood pressure (mm/Hg) 137 (8.3) 129 (19.5) 0.19 
Pulse (BPM) 397 (37.2) 296 (65.3) < 0.0001 
Heart weight (g) 1.15 (0.08) 0.78 (0.13) < 0.0001 
Heart weight/ body weight ratio (%) 0.265 (0.024) 0.353 (0.042) < 0.0001 
    
    
Haematocrit (%) 42.3 (3.54) 27.3 (5.46) < 0.0001 
  
Plasma biochemistry  
Serum albumin (g/l) 26.9 (2.23) 27.9 (2.30) 0.37 
Urea (mmol/l) 5.87 (0.91) 59.34 (17.7) < 0.0001 
Creatinine (μmol/l) 33.5 (2.70) 266 (71.5) < 0.0001 
Cholesterol  1.86 (0.37) 2.01 (0.16) 0.28 
Triglycerides (mmol/l) 1.30 (0.86) 0.81 (0.71) 0.19 
Sodium (mmol/l) 145 (2.36)  145 (1.93)  0.95 
Potassium (mmol/l) 4.18 (0.57) 5.36 (0.88) 0.02 
Phosphate (mmol/l) 2.86 (0.48) 2.66 (0.72) 0.47 
Calcium (mmol/l) 2.22 (0.91) 2.57 (0.26) 0.02 
    
Urine biochemistry  
Urine protein/ creatinine ratio 
(mg/mmol) 
1.71 (0.33) 4.57 (1.33) < 0.0001 
Urine sodium (mmol/l) 76.9 (30.6) 35.7 (6.0) 0.006 
Fractional excretion of sodium (%) 0.32 (0.07) 5.90 (1.69) < 0.0001 
Urine sodium excretion (mmol/h/g) 0.139 (0.042) 0.254 (0.073) 0.007 
 
Table 6 - Characteristics of animals rendered uraemic by adenine diet (AD). 
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2.4.3 Results*–*Characterisation*of*the*adenine*washout*model*(WO)*
The animals were similar in weight at baseline (Control median 244g [235-250g] 
vs. WO 240g [218.8-248.8g], p=0.550, see Table 7). The WO animals remained 
significantly lighter (p<0.0001) at the end of two weeks eating standard chow 
compared to control animals fed standard chow for 6 weeks (see Figure 6). After 4 
weeks the control animals had almost doubled their weight (445g [408-446g], 
p=<0.0001), a 78% increase in weight. A 13% increase in weight was seen in the 
control animals over the subsequent two weeks compared with the washout 
group who experienced on average, just 5% (9.5g) weight gain in the first four 
weeks (on adenine diet, 249.5g [232-254]), with some rats actually losing weight. 
This compared to a 40% increase in weight during the washout period whilst fed 
on standard chow (97.7g ±19.2g compared with just 57.7g ±13.0g, p=0.014). 
Thus growth velocity was 48 g/wk for the control group over the first 4 weeks 
compared with just 3 g/wk for the WO animals over the same time period and 29 
g/wk during the washout period for the control group and 49 g/wk for the WO 
rats once switched to standard chow (Fisher’s Exact test, p<0.0001). 
 
In addition to being significantly lighter, WO animals displayed a growth-
restricted phenotype as evidenced by other morphometric measurements - a 
shorter tail, (p<0.0001), body (p<0.0001) and tibia (p<0.0001, see Table 7). 
 
Adenine treated animals remained polyuric (p=0.001) and polydiptic (p=0.002) at 
the end of the washout period and gram for gram, consumed almost 60% 
(p=0.002) more food per hour compared to the control group, consistent with 
their increased growth velocity (see Table 7). 
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Figure 6 – Growth velocity in the adenine washout model (error bars indicate SD) 
 
2.4.3.1  Cardiovascular findings 
As with the AD rats, the WO animals were not hypertensive and as with the AD 
animals, heart weight/ body weight ratio was significantly greater than the control 
group (p<0.0001). However, the pronounced bradycardia seen with adenine 
treatment (in the AD model) had resolved by the end of the washout period with 
WO infact displaying a significantly faster heart rate than controls (see Table 7). 
 
2.4.3.2  Haematological and biochemical findings 
The adenine washout model resulted in moderate uraemia with plasma creatinine 
and urea concentrations around three times that of the control group (P<0.0001). 
Additionally, WO animals were significantly more anaemic (p<0.0001), 
hyperkalaemic (p<0.0001) and hypercholesterolaemic (p=0.009) than control 
animals (see Table 7). 
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Unlike the other two models, the WO animals were hyperphosphataemic, which 
was just statistically significant (p=0.05) and in contrast to the other models, were 
not hypercalcaemic, nor were they acidotic or hypoalbuminaemic (see Table 7). 
2.4.3.3  Urine biochemistry 
As with the other models, WO animals had significant proteinuria as 
demonstrated by an elevated uPCR (p=0.04) and a natriuresis as evidenced by an 
increased fractional excretion of sodium (p=0.002) and urine sodium (p=0.02, see 
Table 7). 
 
Adenine Wash-out (WO) model Control Ad wash-out p 
Sample size (n) 5 11  
Weight (g) 477 (35.2) 348 (22.99) <0.0001 
Water intake (ml/hr/kg) 3.94 (2.30) 11.9 (1.92) 0.002 
Urine output (ml/hr/kg) 1.86 (0.474) 7.35 (1.32) 0.001 
Food intake (g/hr/kg) 3.41 (0.201) 5.33 (0.783) 0.002 
Tail length (cm) 20.2 (0.76) 17.9 (0.44) < 0.0001 
Body length (cm) 24.9 (0.74) 22.7 (0.54) < 0.0001 
Tibial length (cm) 5.42 (0.40) 4.79 (0.21) 0.005 
    
Blood pressure (mm/Hg) 144 (31.1) 152 (26.6) 0.73 
Pulse (BPM) 404 (12.0) 442 (33.6) 0.02 
Heart weight (g) 1.43 (0.08) 1.43 (0.12) 0.95 
Heart weight (%body weight) 0.302 (0.032) 0.436 (0.026) 0.0022 
    
Haematocrit (%) 41.6 (1.82) 20.4 (5.19) < 0.0001 
Plasma bicarbonate (mmol/l) 31.6 (2.36) 28.9 (3.70) 0.23 
Plasma base excess (mEq/L) 6.24 (1.36) 4.16 (3.05) 0.09 
Serum albumin (g/l) 28.7 (1.00) 27.0(1.98) 0.11 
Serum urea (mmol/l) 6.06 (0.69) 22.1 (11.1) < 0.0001 
Serum creatinine (μmol/l) 38.4 (3.01) 112 (54.4) < 0.0001 
Serum cholesterol (mmol/l) 2.18 (0.38) 3.13 (0.66) 0.009 
Serum sodium (mmol/l) 142 (1.37) 144 (2.25) 0.08 
Serum potassium (mmol/l) 4.02 (0.24) 5.44 (0.58) < 0.0001 
Serum phosphate (mmol/l) 2.34 (0.12) 2.65 (0.34) 0.05 
Serum calcium (mmol/l) 2.51 (0.11) 2.58 (0.22) 0.43 
    
Urine protein creatinine ratio 1.86 (0.2) 11.7 (13.3) 0.04 
Urine sodium (mmol/l) 0.44 (0.07) 3.23 (1.59) <0.0001 
Fractional excretion of sodium (%) 0.44 (0.07) 3.23 (1.59) 0.002 
Urine sodium excretion (mmol/h/g) 0.20 (0.04) 0.31 (0.08) 0.02 
Table 7 – Summary of characteristics for adenine washout (WO) model. 
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2.4.4 Comparison*of*the*three*uraemic*models*
For this analysis, 2-way ANOVA with Bonferroni post-test comparison was 
employed. This test gives three significance statistics for; row effect (uraemia), 
column effect (model) and interaction between row and column in determining 
the dependent variable (interaction). Bonferroni post-test comparison this test 
compares like with like, either the non-uraemic groups for each of the models or 
the uraemic groups for each model. 
 
2.4.4.1 Weight 
2-way ANOVA returned p values <0.0001 for uraemia, model and interaction. 
AD animals were significantly lighter than WO animals (p<0.0001), which were 
significantly lighter than SNx animals (p<0.01). Of the control animals, the WO 
control group was the heaviest, and significantly more than sham-SNx (p<0.001, 
see Figure 7a). 
 
2.4.4.2 Heart weight/ body weight ratio 
As for weight, renal function (p<0.0001) and model (p<0.0001) were observed to 
have a significant effect on heart weight/ body weight ratio with evidence of an 
interaction (p=0.0008, see Figure 7b). WO animals had the most severe left 
ventricular hypertrophy in comparison to both AD and SNx animals (p<0.0001 for 
both). There was no difference between SNx and AD animals and no difference 
between any of the control groups.  
 
2.4.4.3 Morphometry 
A direct comparison of morphometric parameters between the three models is 
complicated by the differing time taken to create the various models. The AD 
animals being approximately 11-12 weeks old whilst the WO and SNx rats are 
13-14 weeks old. 
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2.4.4.3.1 Tibial+length+
An interaction was observed between renal function and model (p< 0.0001). The 
adenine washout control animals were found to have a significantly shorter tibial 
length than both the adenine control (p<0.01) and the sham animals (p<0.05). 
There was no difference in tibial length between the AD and the WO animals 
suggesting that; despite the accelerated weight gain once returned to normal 
chow, other measures of growth were not significantly altered by two weeks of 
normal diet (see Figure 6 and Figure 7c). 
 
2.4.4.3.2 Tail+length+
As with the majority of these measurements, an interaction between model and 
renal function was observed. There was no significant difference in tail length 
between the control groups of the various models. The SNx animals had 
significantly longer tails compared with the AD animals but there was no 
difference between SNx and as WO rats and no difference between AD and WO 
animals which mirrors the results for tibial length (see Figure 7d). 
 
2.4.4.3.3 Body+length+
An interaction was observed between model and renal function (p=0.0002). 
Comparing the Adenine and Adenine washout groups; body length of the 
Adenine washout group was significantly greater for both uraemic (WO, p< 
0.0001) and non-uraemic (Control-WO, p<0.0001) animals (see Figure 7e). There 
was no significant difference in body length between the Adenine-Control and 
SNx-Sham animals. However, Control-WO animals, which were the largest 
animals, had a significantly longer body length compared to SNx-Sham animals. 
For the uraemic animals, WO > SNx > AD (p<0.0001, p<0.001 respectively). 
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2.4.4.4 Food and water 
The amount of chow (g) eaten per Kg body weight per hour was calculated. A 
significant (p<0.0001) interaction between model and renal function was seen, 
i.e. the various models ate different amounts of food depending on the presence 
of uraemia (see Figure 7). Significantly less food was eaten by the uraemic animals 
being fed the adenine diet compared with either the adenine diet wash-out (WO) 
animals (uraemic) and the SNx animals (uraemic, p<0.0001 for both 
comparisons), there was no difference in the amount of food eaten by the 
respective control groups (Control, Control-WO and Sham) and no difference 
between the WO and SNx animals (uraemic). 
 
The amount of water consumed was calculated (ml water/ Kg body weight/ hour). 
An interaction was also observed between renal function, model and the amount 
of water drunk. In general uraemic animals consumed more water than their 
respective controls. However, animals eating the adenine diet (AD) drank less 
water. Strangely the AD control animals also appeared to drink more water than 
either the Control-WO or Sham animals. This may be due to leakage from the 
water bottle, especially as two of these animals also had the highest urine volume, 
causing contamination of the urine collection. This pattern was reversed in the 
uraemic groups. 
 
Urine output varies between the models and again an interaction was observed 
between renal function and model (p=0.0011). There is no significant difference 
between the control groups (i.e. control, control washout, Sham). However, the 
adenine animals had significantly less urine output when compared to either the 
adenine washout uraemic animals or the SNx rats. There was no significant 
difference between Adenine washout and SNx.
CHARACTERISATION OF THREE MODELS OF CHRONIC URAEMIA 
95 
 
Adenine Adenine WO SNx
0
200
400
600
W
ei
gh
t (
g)
Non-uraemic
Uraemic
Adenine Adenine washout SNx
0
2
4
6
8
Ti
bi
al
 le
ng
th
 (c
m
)
Non-uraemic
Uraemic
Adenine Adenine washout SNx
0
10
20
30
Bo
dy
 le
ng
th
 (c
m
)
Non-uraemic
Uraemic
Adenine Adenine washout SNx
0.0
0.1
0.2
0.3
0.4
0.5
H
ea
rt 
w
ei
gh
t (
%
bo
dy
 w
ei
gh
t)
Non-uraemic
Uraemic
Adenine Adenine washout SNx
0
5
10
15
20
25
Ta
il 
le
ng
th
 (c
m
)
Non-uraemic
Uraemic
Adenine Adenine washout SNx
0.0
0.2
0.4
0.6
0.8
1.0
C
ho
w
 (g
)/ 
Kg
 b
od
y 
w
ei
gh
t/ 
H
ou
r
Non-uraemic
Uraemic
(a) (b)
(c) (d)
(e) (f)
*
*
*
*
*
 
Figure 7 – Comparison of morphometry between the three models. 
(a) AD animals were lighter than WO animals (p<0.0001), which were lighter than SNx animals 
(p<0.01). Of the control animals, WO were significantly heavier compared to sham-SNx 
(p<0.001). (b) WO animals had the most severe LVH, as evidenced by an increased heart/ weight 
body weight ratio (p<0.001 for both). There was no significant difference between SNx and AD 
animals or any of the control groups. (c) Tibial length was significantly longer in SNx animals 
compared to both WO and AD rats (p<0.0001). WO control animals had a shorter tibial length 
compared to either AD control (p<0.01) or sham-SNx (p<0.05). (d) SNx animals had longer tails 
than AD animals (p<0.001). There was no significant difference between either SNx rats and WO 
animals, WO and AD animals or any of the control groups. (e) WO had a longer body length 
compared to SNx animals (p<0.0001) which had a longer body length compared to AD rats 
(p<0.0001). Control WO animals had a longer body length compared to sham-SNx. (f) AD 
animals consumed considerably less food than either WO (p<0.0001) or SNx (p<0.0001). There 
was no difference between WO and SNx animals or any of he control groups. 
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2.4.4.5 Blood biochemistry 
As expected, a significant interaction, row (uraemia) and column (model) effect 
was seen (all p<0.0001) for both plasma creatinine and urea. There were no 
significant differences between the non-uraemic animals belonging to any of the 
models. Adenine (AD) animals were significantly more uraemic, as evidenced by 
greater plasma creatinine (p<0.0001) and urea (p<0.0001), than either WO or 
SNx animals. There was no significant difference between the WO or SNx 
animals (see 8a & b). 
 
A significant effect of both model and renal function was seen on plasma calcium 
levels but no evidence of interaction. There were no significant differences in 
plasma calcium between the uraemic animals of the three models. 
 
Surprisingly uraemia appeared to have no significant effect on serum phosphate 
levels. Overall, model did appear to affect serum phosphate (p=0.032) but no 
significant differences were seen between the models. 
 
No differences in plasma sodium were observed, however a marked difference in 
the fractional excretion of sodium (FENa) was seen between both the models and 
uraemic animals with evidence of an interaction (all p<0.0001). AD animals had 
the highest FENa (p<0.0001), with WO animals continuing to have significantly 
greater FENa compared to SNx animals (p<0.001). 
 
Renal function was significantly (p=0.0035) associated with an increased urinary 
protein/ creatinine ratio (uPCR). WO animals had the greatest uPCR but this was 
only significantly greater than SNx animals, no difference between SNx and AD 
rats was observed. 
 
Once more a statistically significant row effect (uraemia, p<0.0001), column 
effect (model, p=0.0002) and interaction (p=0.017) was observed for plasma 
cholesterol. WO rats had significantly greater (p<0.0001) cholesterol levels 
compared to AD animals, as did SNx rats (p<0.01), there was no significant 
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difference between WO and SNx rats. 
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Figure 8 – Comparison of blood and urine biochemistry between the 3 models.  
(a) AD animals had the most severe renal dysfunction as measured by Cr (p<0.0001) or (b) Ur 
(p<0.0001), there was no difference between WO and SNx animals in terms of plasma Cr or Ur. 
No statistically significant differences were seen in plasma calcium (c), phosphate (d) or sodium 
(e). Ad animals had the greatest FENa (p<0.0001). 
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3 INFARCT*SIZE*IN*URAEMIC*RATS:*
REDUCED*ISCHAEMIA*TOLERANCE?
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3.1 Background.
As described in the introduction to this thesis, patients with CKD have an adverse 
prognosis following acute myocardial infarction. It has previously been reported 
that rats with experimental uraemia sustain larger myocardial infarcts than sham-
operated control animals.135 The factors that may contribute to increased infarct 
size in uraemic animals have been discussed earlier (pg 22 to pg 41). In seeking to 
replicate and validate this earlier report, a number of factors were taken into 
consideration when designing the following experiments. 
 
3.1.1 Determinants*of*infarct*size*
Various factors have been reported to influence infarct size, these include; The 
size of the area at risk, the extent of collateral blood supply and the residual flow 
through the infarct related artery, the duration of ischaemia, myocardial 
temperature and heart rate. 
 
3.1.2 Duration*of*ischaemia*
Myocardial ischaemia-reperfusion is usually performed by occluding the LAD for 
30 minutes,183,184 longer durations of ischaemia are sometimes employed (60-90 
min). Increasing the duration of LAD occlusion typically results in larger infarct 
sizes and substantially increased mortality.185 
 
Current technology does not permit us to visualise the evolution of a myocardial 
infarct in real time. However, if we able to do so, we might expect that a 
sustained period of ischaemia (without reperfusion) would give rise to a graph 
such as Figure 9a. The organ or tissue is initially able to resist the effects of 
ischaemia at the expense of little to no injury, the ‘tolerant phase’. With 
increasing duration of ischaemia a point is eventually reached when the organ 
can no longer resist the effects of sustained oxygen and nutrient deprivation and 
there then begins a phase where injury is accrued rapidly (‘injury phase’). Oxygen 
tension is not uniform throughout the ischaemic zone. Even in a ‘non-
collateralised’ animal such as a rat, up to 5% of normal myocardial blood flow 
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may be derived from non-coronary sources.186 This results in a slowing in the 
velocity of growth of the infarct as it nears completion. Thus it might be predicted 
that a plot of infarct size against time would be a sigmoid curve. 
 
Comorbidities might be expected to shift the curve to the left (analogous to the 
oxygen dissociation curve) resulting in reduced ischaemia tolerance similarly an 
organ might be ‘conditioned’ to increase its ability to tolerate periods of 
ischaemia, shifting the curve to the right (see Figure 9). Of course the gradient of 
the ‘injury phase’ may not remain constant, some interventions may affect infarct 
size by reducing the gradient of the injury phase, this might be the case in 
circumstances of reduced metabolic demand (e.g. beta-blockade). Conversely, 
rather than altering the inflection point, a co-morbidity might increase the rate of 
growth of an infarct decreasing the window of opportunity to intervene with 
reperfusion therapies. This might have important implications for patients with 
comorbidity such as diabetes and CKD. 
 
This hypothesis of the dynamics of myocardial infarction influenced the 
experimental design in a number of ways but none more so than in choosing the 
duration of both ischaemia and reperfusion. 
 
The ability to detect a difference between two groups is dependent upon three key 
factors: 
♦ The difference between the mean/ medians of the groups 
♦ The degree of intra-group variation 
♦ The sensitivity of the technique/s used to detect the differences 
Thus the optimal conditions under which to conduct an experiment would be 
those that result in the greatest difference between the test and control groups 
whilst at the same time minimising the variation between individual results.  
 
Most experiments using models of acute myocardial infarction aim to reduce the 
infarct size with an intervention, in contrast it was expected that an increase in 
infarct size would be observed having rendered an animal uraemic. In order to 
demonstrate the ‘reduced ischaemia tolerance’ of uraemic animals it was felt it 
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would be desirable to have the control animals near to the inflection point 
(beginning of the injury phase) with the test group high on the injury portion of 
the curve but before the infarct nears completion thus maximising the difference 
between the two groups. 
 
A series of preliminary investigations were conducted, in non-uraemic control 
animals, with the aim of defining the median infarct size after 15 min ischaemia 
and 120 minutes reperfusion this was compared to 25 min ischaemia and 120 
min reperfusion. We went on to reduce the length of reperfusion to 60 min.
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Figure 9 – Evolution of an infarct. 
(a) The evolution of an infarct might be hypothesized to be a sigmoid curve. (b) Interventions or 
comorbidities may act to decrease or increase the duration of the ‘tolerant phase’. (c) 
Alternatively, they may affect the rate at which injury develops during the ‘injury phase’, to 
increase or decrease the slope of the linear portion of the sigmoid curve.
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3.2 Aim.
 
The purpose of this first series of experiments was: 
♦ To replicate the previously published findings of increased infarct size in 
the SNx model. 
♦ To investigate infarct size in the more severe model of chronic uraemia 
induced by adenine diet. 
♦ Thereby establishing a model of AMI in the context of chronic uraemia 
in which to test strategies to ameliorate myocardial IRI and reduce 
infarct size.
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3.3 Methods.8.Infarct.size.in.uraemic.rats.
 
Male Wistar rats were rendered uraemic as described earlier (pg 76 and pg 79) 
and together with an appropriate control group underwent myocardial ischaemia-
reperfusion. 
 
3.3.1 Reversible* Coronary* artery* (LAD)* ligation* model* of* acute* myocardial*
Infarction*
  
Myocardial ischaemia reperfusion injury was carried out as previously 
described183 and performed as a terminal procedure. 
 
Animals were weighed and anaethetised with an intra-peritoneal (IP) injection of 
sodium thiopental (LINK Pharmaceuticals, Horsham, UK). 
 
3.3.1.1  Anaesthetic dosing: 
Anaesthetic dosing was optimised for each model in order to minimise the risk of 
respiratory arrest following the induction of anaesthesia. 
 
Animals with adenine-induced uraemia were given (58 mg/Kg; 16 mg/ml), sub-
totally nephrectomised (SNx) animals received (73 mg/Kg; 20 mg/ml) as did 
adenine wash-out animals and control or sham operated animals received (88 
mg/Kg; 24 ml/Kg). 
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The volume of anaesthetic was kept constant for two reasons; 
♦ The volume of anaesthetic determines the amount of peritoneal surface 
area recruited affecting the rate of absorption. 
♦ To ensure that the animals received comparable levels of volume 
expansion prior to surgery. 
 
3.3.1.2  Basic surgery 
The animals were placed on a homeostatic blanket (Harvard Apparatus) and their 
core temperature monitored, by means of a digital rectal thermometer and 
maintained within the range of 37oC ±1.0oC. (see Figure 12). 
 
The fur and skin was removed from the ventral surface of the neck and the 
cervical musculature divided along the tissue planes. 
 
3.3.1.2.1 +Tracheostomy+
A tracheostomy was performed in order to protect the airway and facilitate 
mechanical ventilation. An incision was made between the cartilaginous rings 
and a piece of PP90 tubing (Smiths Medical, Watford, UK; internal diameter (ID) 
of 1.67mm) beveled at one end, was inserted into the trachea and secured with 
two braided silk ligatures. 
 
3.3.1.2.2 +Arterial+access+
Arterial access was obtained to facilitate measurement of the animal’s blood 
pressure and heart rate and to take blood samples. The right carotid artery was 
identified and dissected away from the supporting fascia. Care was taken not to 
damage the vagus nerve and dissect it away from the carotid in its entirety. Two 
silk ligatures were placed around the artery. The caudal ligature was tightened so 
as to occlude the carotid artery. A micro-vessel clip was applied beneath the 
rostural ligature. A small incision was made in the carotid artery, between the clip 
and caudal ligature, through which a piece of PP50 (ID 0.58mm) tubing (Smiths 
Medical, Watford, UK), beveled at one end and attached to a 2ml syringe 
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containing heparinised saline (15 U/ml), was inserted. Correct positioning of the 
line was confirmed by the presence of pulsatile blood flow in the line following 
release of the micro-vessel clip. The line was secured with silk ligatures and 
attached to 2 ‘three way’ taps in series and a pressure transducer (BP domes MLA 
844, AD instruments). Real-time, continuous recordings of mean arterial pressure 
(MAP) and heart rate (HR) were made (Quad Bio Amp, AD instruments and Chart 
for windows software running on a Dell PC). 
 
3.3.1.2.3 +Venous+access+
Venous access was obtained to give fluid replacement during the course of the 
experiment, administer drugs and to inject Evans Blue dye at the end of the 
experiment to delineate the ‘area at risk’. 
 
The supporting fascia was carefully dissected away from the jugular vein, typically 
the right. Two silk ligatures were placed around the vein. The ligatures were not 
used to occlude the jugular, but facilitated mobilisation of the vein and were used 
to secure the line once inserted. A small incision was made in the Jugular through 
which a piece of beveled PP25 (ID 0.4mm) tubing attached to a 2ml syringe and 
primed with normal (0.9%) saline was inserted. Again the line was secured in 
place with the ligatures and correct position confirmed by freely aspirating blood. 
 
3.3.1.3  Recording of heart rate (HR) and mean arterial blood pressure 
(MAP) 
The arterial line was connected to a pressure transducer (BP domes MLA 844 AD 
instruments) by means of a three-way tap and a broken blue needle. The output 
from the transducer was run through a Powerlab/85p system via bridge amplifiers 
(all supplied by ADI instruments). The setup was calibrated at the start of each 
experiment by means of a mercury sphygmomanometer attached to the BP domes 
and inflated to pressures of 90 and 150 mm/Hg. The arterial pressure wave was 
displayed on a computer monitor using Lab Chart software. MAP and HR were 
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recorded at regular intervals throughout the experiment, the precise timings varied 
depending on the experimental protocol. 
 
Following basic surgery, the animals were left undisturbed for at least 5 min in 
order to establish baseline BP. 
 
3.3.1.4  Ventilation 
The animals were mechanically ventilated using small animal ventilators (Harvard 
Apparatus UK, Kent, UK). 
 
Positive pressure ventilation was critical to the experimental protocol as following 
thoracotomy, the normal physiological function of the rib cage and intercostal 
muscles was lost and death would result rapidly without mechanical ventilation. 
A rat requires a minute volume in the order of 575 cm3/min/Kg (range 460 - 900 
cm3/min/Kg).187 Therefore, a 300g rat requires a minute volume of 172.5 cm3, 
when breathing at a rate of 70 BPM this equates to a tidal volume (Vt) of 2.46 
cm3. 
 
Initial ventilator settings were judged according to the weight of the animal. 
3.3.1.4.1 +Ventilator+calibration+
To ensure accuracy in the delivered minute volume the ventilators were 
calibrated. This was done using a 1L measuring cylinder inverted in a basin of 
water so as to create an underwater seal (see Figure 10). The ventilators were set 
to 70 BPM and the minute volume measured for three different Vt (2.0 cm3, 3.0 
cm3 and 4.0 cm3). The volume of water displaced in 60 s was equivalent to the 
minute volume, dividing by 70 yielded the delivered Vt. A marked disparity was 
observed between the target or set Vt and the delivered Vt for almost all the 
ventilators pronounced differences were also seen between the ventilators with 
one ventilator delivering a volume that was on average 50% less than the set Vt. 
The calibration procedure was repeated at different respiratory rates, however this 
did not appear to alter the Vt to any great degree. 
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This data was used to create normagrams for each ventilator (see Figure 10) in 
order to deliver the desired Vt. Using this data together with infrequent arterial 
blood gas analysis it was possible to maintain physiological pH and PCO2 and 
avoid hypoxaemia. 
 
Connected

 to ventilator

Water bath

 
Figure 10 – Diagram of ventilator calibration. 
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Figure 11 – Variation in desired and delivered tidal volume. 
(a) Graph of set and delivered tidal volume (Vt), illustrating the considerable variation both 
between the desired Vt and between ventilators. (b) mean delivered Vt in comparison to ideal. 
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3.3.1.4.2 +Arterial+Blood+Gas+Analysis+(ABG)+
Supplemental oxygen was delivered to the rats. Oxygen (O2) and nitrogen (N2), 
from cylinders, were mixed by means of two flow meters, to deliver the desired 
fraction of inspired oxygen (FiO2) though the ventilators. The FiO2 was monitored 
using an oxygen sensor (TED 200T7 Teledyne industries) and adjusted during the 
course of the experiments by varying the relative flow of O2 and N2 so as to 
maintain a pO2 of 10-14 kPa, as measured on ABG. 
 
Following basic surgery, the rats were left on the ventilator for 15 min to stabilise, 
after which time 1 ml of blood was drawn from the arterial line, 200µl of this 
blood was used for arterial blood gas analysis (ABL77, Radiometer Ltd. Crawley, 
Sussex, UK)  
 
Hypercapnic acidosis has been shown to precondition the rabbit myocardium188 
against ischaemia-reperfusion injury. Blood gas analysis permitted the titration of 
ventilatory parameters in order to maintain physiological pH and CO2 tension. In 
addition it afforded the ability to monitor the arterial partial pressure of oxygen 
and finally, use of the blood gas machine also provided an accurate measurement 
of haematocrit. 
 
Blood gas analysis, was performed at three time points during the course of the 
experiments 
♦ 10-15 minutes after being placed on the ventilator - this provided a 
baseline haematocrit before more extensive surgery had taken place, 
♦ pre-occlusion of the LAD, 
♦ and at the end of reperfusion, just prior to the termination of the 
experiment. 
Selection of these time points was made on both economic and practical grounds. 
In addition, blood would be drawn for an ABG if the rat displayed signs of 
haemodynamic instability. Further samples would also be taken if the previous 
sample had demonstrated an abnormality requiring adjustment of the ventilator 
settings.
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Figure 12 – Illustration of the experimental ‘set-up’.  
(1) Oxygen tank, (2) Nitrogen tank, (3) twin flow meters to create gas mixtures with various [O2], (4) Oxygen sensor, (5) Ventilator (Harvard Apparatus) (6) homeostatic 
blanket, (7) Venous catheter, (8) Dome pressure transducer, (9) Quad amp (AD instruments) (10) PC, (11) Monitor. 
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3.3.1.5  Thoracotomy 
The fraction of inspired oxygen (FiO2) was increased prior to commencing the 
thoracotomy. 
 
Animals were checked for the depth of anaesthesia (response to peripheral painful 
stimuli) supplemental sodium thiopentone (in 0.2 ml boluses) was given 
intravenously as required. Once sufficiently anaesthetised the animals were 
restrained on a metal conductive plate attached to an electrosurgery system 
(PromhoVet, Barcelona, Spain). The skin and fur were removed from the anterior 
chest wall to reveal the underlying musculature. A left parasternal incision was 
performed using electrocautery (PromhoVet, Barcelona, Spain) set to 40 watts 
(cut/coagulate). The ribs and thymus were retracted to reveal the heart and the 
pericardium was gently resected (see Image 1). A 6/0 silk suture with a curved, 
cutting needle was inserted into the myocardium in the area of the ventricular 
groove (approximately 2mm inferior to the left atrium) with the intention of under-
sewing the LAD (see Image 2). Following which a ‘snare occluder’ made from a 
short piece of polythene tubing (Portex™, Smiths Medical, Watford, UK), flared at 
one end, was placed over the free ends of the suture to form a snare. The animals 
were then taken off the diathermy plate and allowed to recover for a minimum 10 
minutes and not until the pre-occlusion MAP was >90 mmHg. 
3.3.1.6  Left Anterior Descending (LAD) artery occlusion 
Once the animals had recovered from the thoracotomy a further ABG sample 
(pre-occlusion sample) was taken this was used to confirm oxygenation, 
normocapnia and physiological pH. Following this the Snare was tightened so as 
to occlude the LAD. Pallor/ blanching of the dependent vascular territory, which 
if the LAD has been occluded should include the apex of the heart, was used to 
confirm LAD occlusion (see Image 3). In addition occlusion was further confirmed 
by the development of arrhythmias characteristically ~5 min after occlusion. 
 
The snare was held in place with a clamp. The LAD was occluded for 25-35 
minutes depending on the experimental protocol (see results chapters). At the end 
of the ischaemic phase the snare was loosened to allow reperfusion, which was 
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confirmed visually by the dependent vascular territory becoming hyperaemic (see 
Image 4) and by the development of early reperfusion arrhythmias, these typically 
occurred within one minute of reperfusion. The myocardium was reperfused for 2 
hours before terminating the experiment and assessing infarct size. 
 
 
Image 1 - Post thoracotomy, pericardial membrane resected and thyroid retracted. 
 
 
Image 2 - The LAD is undersewn with a 6/0 silk suture. 
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Image 3 - Occlusion of the LAD with pallor of the dependent vascular territory indicating 
ischaemia. 
 
 
Image 4 - Reactive hyperaemia indicating reperfusion of the myocardium.
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3.3.2 Assessment*of*infarct*size*
3.3.2.1 Histochemical determination of infarct size 
A number of methods to determine infarct size were tried. 
 
3.3.2.1.1 Nitro*blue*tetrazolium*(NBT)*myocardial*weight*ratio*
This formed the principal means of determining myocardial infarct size and was 
carried out as previously described by Wayman et.al.183 
 
Immediately prior to the end of reperfusion a 1ml blood sample was taken in a 
heparinised syringe for arterial blood gas analysis and Troponin I level. At the end 
of the reperfusion period the LAD was re-occluded and 2.5 ml of (2% w/v) of 
Evans blue dye (Sigma-Aldrich Company Ltd. Dorset, England) injected via the 
internal jugular vein. The heart and all other perfused tissue stained blue, whilst 
the dependent vascular territory remained unstained. The heart was excised with 
the LAD still occluded and cardioplegia achieved by rapid emersion of the heart 
in ice-cold normal saline. 
 
The heart was then sliced into 2 mm sections using a rat heart matrix 
(HSMS001.1, Zivic, instruments, PA, USA) from the apex to the level of the suture. 
The right ventricle was identified and resected leaving the left ventricle. The 
unstained portion of the left ventricle was separated from the blue stained portion 
of the left ventricle. The two quantities of tissue were weighed. The ratio of these 
aliquots was expressed as the left ventricular area at risk or area at risk (AAR). 
The unstained potion of the left ventricle, being that potion which had been 
subjected to ischaemia, was then cut into small ~0.5 mm3 pieces and then 
incubated in 5 ml of NBT solution (0.5 mg/ml) for 30 minutes at 37oC. 
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3.3.2.1.1.1 The(tetrazolium(reaction(
The ability of living biological tissue to reduce tetrazolium salts to coloured, 
insoluble formazans was first described by Khun and Jerchel in 1941. The 
reaction has been widely used since that time as a marker of cellular viability and 
metabolic activity. The reaction forms the basis of the MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H 
tetrazolium) assay of cellular viability. NBT is reduced to insoluble diformazan, 
which is a deep purple colour. This may occur either enzymatically by various 
dehydrogenases and reductases or directly by the pyridine dinucleotides (NADH 
and NADPH). Thus formation of the purple diformazan suggests both the 
presence of intact cellular membranes and a functioning electron transport chain. 
Loss of NADH/ NADPH has been proposed as the watershed for reversible versus 
irreversible ischaemic tissue injury.189 The pieces of tissue are then separated 
according to the presence (viable tissue) or absence of staining by diformazan 
(infarcted tissue). The two aliquots are weighed and the ratio of the weights 
provides an index of the size of infarct, which may be conveniently expressed as a 
percentage of the area at risk.
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3.3.2.1.2 Planimetry*
In the majority of the published literature, the preferred means of determining 
infarct size is by planimetry. Planimetry is the measurement of the area of a planar 
(flat) shape. This is applied to the task of measuring infarct size by slicing the heart 
in transverse sections (typically around 2mm thick) from the apex having, first 
occluded the LAD and injected a dye, usually Evans Blue, to delineate the area at 
risk. The slices of heart are then incubated in a solution of 2,3,5-
triphenyltetrazolium chloride (TTC), which similar to NBT, is reduced to an 
insoluble (rust red) azole. Infarcted tissue, by virtue of the lack of metabolic 
activity, does not stain and appears white. The slices of heart are then 
photographed.  
 
In the present day digital images are imported into image analysis software but 
prior to the advent of digital photography the same technique would be carried 
out with transparencies and graph paper. The area of infarcted (white tissue is 
measured for both sides of each slice of heart. The ratio of the area of infarct 
relative to the area at risk (total non-blue area) for each slice of heart is added 
together giving an assessment of the infarct size. 
 
The advantages this technique offers over the weight ratio method are: 
♦ In terms of research governance, there is a permanent record of the raw 
result of the experiment, such that should one’s data be challenged, the 
original images maybe produced and analysed independently. 
♦ It is easy to rename the image files thus making blinding, and assessment 
of intra-observer variability easier and more robust. 
♦ The duration of the experiment is curtailed. 
I reviewed the published methods of a number of papers and visited another 
laboratory, with extensive experience using the technique, and experimented with 
the following method: 
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3.3.2.1.2.1 Method(6(Planimetry(
Myocardial IR was carried out as previously described. The LAD was re-occluded 
at the end of the experiment. Following which 2% Evans Blue dye was injected 
via the right jugular vein. The heart was excised and immersed in ice-cold saline 
to induce cardioplegia and wash off excess Evans Blue. The heart was sectioned 
in 2 mm slices, using a steel rat heart matrix. The slices of heart were then 
incubated in 2,3,5-triphenyltetrazolium chloride (TTC) (concentration) for 30 min 
at 37oC for 30 minutes, at the end of which the slices of heart were dried, placed 
between two microscope slides and placed on a flat bed scanner. 
The images were scanned at high resolution in 64-bit colour. Image analysis was 
carried out using ‘Image J’ software (http://rsbweb.nih.gov/ij/). 
 
3.3.2.1.2.2 Results(6(Planimetry(
The initial results were disappointing; the TTC staining overpowered the Evans 
Blue, rendering the non-ischaemic area a muddy brown colour that was virtually 
indistinguishable form the area at risk. It was decided to perfuse the heart with 
Evans Blue ex-vivo. However, whilst this enhanced the contrast between the 
ischaemic and non-ischaemic area it failed to resolve the problem. 
 
Under pressure to complete the project, it was decided to persist with the weight 
ratio technique and abandon further attempts to develop a planimetric method of 
measuring infarct size. 
 
3.3.2.1.3 Observer*bias*and*variability*in*the*measurement*of*infarct*size*
Infarct size measurement using NBT is dependent upon a subjective judgement 
made by the assessor. Staining of the pieces of tissue is not a binary phenomenon 
in that some of the sectioned tissue would be viable and thus stain dark purple 
and some would be non-viable retaining the natural hue of the myocardium 
(pinkish red) giving rise to a heterogenous staining pattern. The assessor is then 
forced to make a judgement as to whether a piece of tissue is more purple or 
more pink/ red and thus introducing the potential for bias. To an extent this 
problem may be overcome by cutting the heart into smaller sections to begin 
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with. However, it is possible that processing the heart in this manner may cause 
further damage. 
 
Alternatively, a piece of heart may be further sectioned, post staining, to divide 
viable from non-viable tissue. However, not infrequently the tissue sections would 
be neither dark purple nor pink, but somewhere in-between. 
 
Planimetry using image analysis software is also dependent upon a subjective 
assessment to determine the threshold for viable versus non-viable tissue. 
However, the great advantage with this method is the relative ease in which the 
assessor can be blinded to treatment allocation. Blinding was particularly 
problematic for some of the experiments as uraemic animals were considerably 
smaller than their non-uraemic counterparts and although they had LVH the 
absolute size of the heart was smaller and this was reflected in the quantity of 
heart that was sectioned and incubated in NBT. In addition, in the case of 
mechanical conditioning strategies, due to the nature of the intervention, it was 
difficult to blind the assessor to the treatment allocation. To address this 
weakness; throughout the course of the entire research project animals were 
selected at random and an additional assessment of infarct size was carried out by 
a blinded second researcher to ensure that there was no bias between the groups. 
Several samples were also reassessed by the same observer in order to determine 
the extent of intra-observer variability. 
 
After the pieces of heart were counted and weighed, the sections were 
resuspended in saline and recounted; 7 results were recounted. The intra-observer 
variability in these experiments was small with a median absolute variability of 
0.57% [IQR 0.3-1.1%] and a median relative variability of 1.7% [IQR: 1.5-5.2]. 
 
The inter-observer variability was determined from 165 results. Firstly, the 
potential for variation in measurement of the area at risk was considered. The area 
at risk was determined by briefly drying and weighing the non-perfused tissue 
(red) and the remainder of the left ventricle (stained with Evan’s blue). The Area at 
risk was given by the ratio of the red weight to the sum of the weights of both the 
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red and blue stained tissue. When the pieces of heart were dried before weighing, 
more vigorous drying could alter the weight and hence the AAR. The average 
absolute difference in weight between the observers was 0.024g (SD 0.03g); the 
relative difference between the observers was 10.7% (SD 15.2%). There was no 
tendency for one observer to dry out the hearts more than the other as on 73/165 
occasions one observer made the heart tissue heavier and 85/165 the other 
observer made the heart heavier, with 7 occasions when both observers got 
exactly the same result. 
 
Measurement of infarct size involved two stages where variability might be 
introduced: 
♦ Firstly, the judgement of viable versus non-viable tissue, based on a 
subjective assessment of the predominant colour of the pieces of tissue. 
♦ Secondly, similar to the area at risk, there is the potential for one 
observer to dry out the tissue aliquots more aggressively than the other. 
 
No significant difference was seen in the measurement of infarct size determined 
by the two observers. The mean absolute inter-observer variability in infarct size 
estimation was 6.8% (SD 7.5%), the mean relative inter-observer variability was 
13.4% (SD 20.1%). No consistent trend in observer bias was seen; observer 1 
judged the infarct size greater than observer 2 in 52% of the sample, while 
observer 2 judged the infarct size greater in 47% of the sample with both 
observers agreeing, to 2 decimal places, in 1% of estimates. 
 
To examine the extent to which interobserver variability was determined by the 
degree of injury; inter-observer variability was plotted against mean infarct size 
(see Figure 13b). Absolute variability was greatest when the infarct size was 
approximately 50% and agreement was closest at the extremes of infarct size. This 
effect is not surprising, when the infarct size approaches 50%, more sections of 
heart are likely to contain a mixture of viable and non-viable tissue making the 
allocation of that section more subjective. If the infarct is very large or very small 
fewer pieces of tissue contain a mixture of viable and non-viable tissue, which 
explains why the absolute variability is reduced at extremes of infarct sizes. 
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Plotting relative inter-observer variability (Figure 13a) against mean infarct size, 
variability decreased as infarct size increases. This is an example of a numerator 
effect, with a small infarct, a single discrepancy may cause a large difference in 
infarct size estimation. 
 
One might expect that with time and increasing experience, the variation in 
infarct size estimation between the two observers might diminish. However, when 
both the relative and absolute variability were plotted (see Figure 13c & d) no 
increase in agreement was seen with time. 
 
These results suggest that the lowest absolute difference in infarct size detectable 
with the NBT method is in the order of 6%. There did not appear to be a 
significant bias between the observers. However, this does not mean that the 
results were not biased just that the observers shared the same degree of bias. 
Furthermore it is possible that when double assessment of infarct size was 
undertaken, both observers may have taken more care to avoid biasing their 
measurement.  
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Figure 13 –Inter-observer and intra-observer variability 
(a) Absolute inter-observer variability. (b) Graphs of relative and absolute inter-observer variability 
with time.
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3.4 Results*–*Infarct*size*in*uraemic*rats*
3.4.1 Preliminary*study,*varying*duration*of*myocardial*ischaemia*
Shortening the duration of ischaemia or reperfusion made no significant 
difference to infarct size, with the median infarct size being virtually identical for 
both 15 min and 25 min ischaemia (46% [IQR 4.4-58%] and 45.5% [41.9-81%]). 
Median infarct size was smaller for 60 min reperfusion (37.8% [30.5-56.1%]) than 
120 min reperfusion 48.9% [38.9-60%]) but not statistically so (p=0.501). 
However, alterations in the duration of both phases did appear to increase the 
standard deviation (30% 15min vs. 22% 25min Ischaemia and 20.9% for 60 min 
vs. 13.9% for 120 min reperfusion), despite a greater degree of variation in the 
area at risk of the animals exposed to 120 min reperfusion. 
3.4.1.1 Conclusion 
Although these experiments were performed in non-uraemic animals, it was 
hypothesized that the addition of another variable, namely the degree of uraemia/ 
renal dysfunction, which was expected to influence infarct size, would further 
contribute to variability in infarct size. As a result of these preliminary studies it 
was decided to perform 25 min ischaemia and 120 min reperfusion. The infarct 
size in control animals appeared sufficiently low that we might still expect to see 
an increase and therefore be able to detect a difference between uraemic and 
non-uraemic animals.
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3.4.2 Infarct*size*in*sub?totally*nephrectomised*rats*
Higher blood pressure and HR did result in a statistically significant (p=0.02) 
increase in pressure rate product (PRP) (see Figure 16). 
 
In keeping with previous work (see Table 4) utilising the SNx model, the rats used 
in this experiment displayed a growth-restricted phenotype as evidenced by 
reduced weight (p=0.02). In addition they were significantly more anaemic than 
sham-operated controls (p=0.0003). Plasma creatinine was more than 2.5 fold 
greater than sham-operated animals (p<0.0001, see Figure 15). 
 
Following 25 minutes of LAD ligation and 2 hours reperfusion the Sham operated 
group had a mean infarct size of 47.2% and the SNx group had a significantly 
higher mean infarct size of 62.3%, a relative increase of 32% (p=0.03). The area 
at risk for both groups was similar. 
 
 Sham  (n=12) SNx (n=20) p  
Weight (g) 430 [391-450] 380 [370-410] 0.02 
Haematocrit (%) 39 [36.3-41] 27 [24-31] 0.0003 
Creatinine (µmol/l) 34.4 [33.4-35.7] 91.0 [83.7-116.3] <0.0001 
Area at risk (%) 50.9 [43.5-56.2] 44.8 [42.2-51.4] ns 
Infarct size (%) 47.2 [39.8-63.7] 62.3 [53.54-69.51] 0.033 
 
Table 8 – Table of results for ‘reduced ischaemia tolerance in sub-total nephrectomy model’ 
(median values with [interquartile range]}. 
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Figure 14 – Results of arterial blood gas analysis for ischaemia tolerance in sub-total 
nephrectomy model. 
(a) SNx rats had a significantly lower haematocrit, which persisted throughout the experiment. (b) 
pH, (c) pO2, (d) pCO2, (e) bicarbonate and (f) base excess were similar for both groups.  
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Figure 15 – Reduced ischaemia tolerance in the sub-total nephrectomy model.  
(a) SNx rats had a relative increase in infarct size of 32% (p=0.03,*). (b) Area at risk was similar for both groups (p=0.235). (c) SNx animals were significantly lighter than 
sham-operated controls (p=0.021,*). (d) SNx animals had a median creatinine approximately 2.5 fold greater than sham animals (p=<0.0001,***).
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Figure 16 - Physiological recordings made during myocardial ischaemia-reperfusion in SNx 
animals. 
(a) SNx animals tended to have a higher mean arterial blood pressure (MAP) throughout the 
experiment, but this was not statistically significant. (b) There was no difference in heart rate but 
(c) pressure rate product was significantly higher in SNx animals (p=0.02).
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3.4.3 Infarct+size+in+adenine+induced+uraemia+
 
A large number of animals were used for this experiment, a total of 26 animals in 
the control group and 22 animals in the adenine group (uraemic). No difference 
in mean infarct size was seen between the two groups, with the mean infarct size 
and standard deviation being almost identical for both groups (Control 50.2% 
±16.2% vs. Adenine 49.3% ±15.3%, p=0.847, see Table 9 and Figure 18a). The 
area at risk was comparable for both groups (Control 47.1% ± 7.30% vs. Adenine 
42.2% ± 9.1%, p=0.100, see Figure 18b). 
 
Mean serum creatinine in animals with adenine induced renal failure was 6 times 
that of control animals (39.6 µmol/L ±4.86 µmol/L vs. Adenine 240 µmol/l ±37.6 
µmol/L, p=0.0002, Figure 18d). Animals with adenine induced uraemia were 
markedly more anaemic (mean HCT 42.2% SD ±3.31% vs. 29.0% SD ±5.42%, 
p=0.0002) and after four weeks of adenine diet displayed marked growth 
restriction as evidenced by considerably lower body weight (mean weight Control 
408 ± 30.9g vs. Adenine 211g ± 16.4g, p<0.0001, Figure 18c). 
 
 Control  (n=26) Adenine (n=22) p  
Weight (g) 410 [390-434] 220 [200-224] <0.0001 
Haematocrit (%) 43.0 [41.0-44.0] 29.0 [24.0-34.0] 0.0002 
Creatinine (µmol/l) 40.4 [38.3-41.6] 250 [206-270] 0.0002 
Area at risk (%) 48.0 [43.5-50.8] 42.1 [33.3-50.8] 0.1 
Infarct size (%) 45.2 [40.9-64.1] 50.6 [36.4-60.9] 0.847 
 
Table 9 – Results of infarct size in adenine-induced uraemia (median with [IQR]). 
 
Both initial blood pressure and BP throughout the duration of the experiment, was 
comparable between the two groups (see Figure 17a). However, There was a 
marked reduction in heart rate both initially and at all subsequent time points, this 
difference was statistically significant (t-test at all time points), as indicated by the 
non-overlapping confidence intervals, and resulted in a statistically significant 
difference in the pressure rate product (see Figure 17b & c). 
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(a)
(b)
(c)
 
Figure 17 – Physiological recordings made during myocardial ischaemia-reperfusion in adenine 
induced uraemia. 
(a) Mean arterial blood pressure (MAP). (b) Animals with adenine-induced uraemia displayed a 
relative bradycardia (c.f. control animals) which persisted through out the duration of the 
experiment. (c) This resulted in a significantly reduced pressure rate product (a surrogate marker 
for myocardial oxygen demand). 
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Figure 18 – Infarct size in adenine diet (AD) induced uraemia model.  
(a) No difference in infarct size was seen between adenine (uraemic) and the control group (p=0.926). (b) Area at risk was similar for both groups (p=0.100). (c) Control 
animals were significantly heavier than those with AD induced uraemia (p<0.0001, ****). (d) Median plasma creatinine was more than 6 fold greater in the AD animals 
than the controls (p=0.0002, ***). 
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3.5 Discussion+,+Infarct+Size+in+Chronic+Uraemia+
In keeping with previously published reports,135 SNx animals sustained larger 
infarcts than their sham operated counterparts. SNx animals were anaemic and, as 
a result of a trend towards higher blood pressure and a slightly faster heart rate, 
had an elevated PRP, a surrogate for of myocardial oxygen demand. In addition, 
we know from the prior characterisation of the cardiac phenotype of the sub-total 
nephrectomy model, SNx animals have left ventricular hypertrophy. All of these 
factors may contribute to an increased vulnerability to ischaemia of the uraemic 
myocardium. 
 
Despite having significantly greater renal dysfunction than that seen in sub-totally 
nephrectomised animals, no increase in infarct size was observed in animals with 
adenine induced uraemia. There are a number of possible explanations for this; 
Firstly, given the size of the experiment, a total of 48 animals, and the relatively 
small standard deviation it is unlikely that a type II error has occurred. 
Nonetheless, a Type II error, failure to reject the null hypothesis when it is in fact 
false, may have occurred. 
 
Secondly, Dikow and colleagues135 used a different experimental protocol with a 
much longer period of ischaemia (60 min) then that employed in this experiment. 
As discussed in the introduction the ischaemic phase of ischaemia-reperfusion 
injury can be broadly thought of as resulting in necrotic cell death. If uraemia 
results in a loss of ischaemia tolerance, then restricting the length of the ischaemic 
period to 25 min should amplify the differences between the groups. 
 
Perhaps the most likely explanation is that physiological and metabolic factors 
associated with adenine-induced uraemia were in some way cardioprotective. In 
particular, heart rate (HR) and consequently pressure-rate product (PRP), a 
surrogate marker of myocardial oxygen consumption,190 was considerably lower 
in the AD animals. 
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Two possible explanations were considered for the marked bradycardia seen in 
the AD animals: 
 
Firstly, AD animals displayed marked growth restriction, and ate significantly less 
of the adenine diet (see results of phenotypic characterisation pg 87) compared to 
the amount of standard chow consumed by the control animals (0.181 +/-0.068 
g/hr/Kg body weight vs. 0.639 +/-0.010 g/hr/Kg body weight, p<0.0001). Thus the 
bradycardia of the AD animals may have resulted from a starvation state. 
 
Alternatively, when developing a new experimental model, particularly one 
involving a xenobiotic, it is essential to consider the possibility of ‘off-target’ 
effects of the agent being used. Given the necessity to saturate adenine 
phosphoribosyl transferase (APRT) before renal failure will be induced by the 
intratubular precipitation and obstruction by, crystals of 2,8-dihydroxyadenine, it 
was possible that the intracellular adenine nucleotide pool had been expanded 
resulting in increased stores of high energy phosphate which in theory might 
induce a state of ischaemia tolerance. The bradycardia might therefore be the 
consequence of increased extracellular adenosine. This lead to a series of 
experiments designed to investigate the bioenergetics of the two principle models, 
sub-total nephrectomy and adenine diet induced uraemia. 
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3.6 Assessment+of+bioenergetics+
3.6.1 Background/
Adenosine induces bradycardia, this property is used frequently in clinical 
practice to both treat and determine the cause of a narrow complex supra-
ventricular tachycardia. Moreover, the cardioprotective effects of administration 
of exogenous adenosine are well documented.191 
 
Adenosine has a very short half-life in the circulation and is rapidly degraded 
making it difficult to measure directly. 
3.6.2 Aim/
An experiment was conducted in order to establish the levels of adenine, and 
other purine nucleotides in the hearts of animals with both adenine diet induced 
uraemia (AD) and subtotal nephrectomy (SNx). 
 
3.6.3 Methods/
The models (Subtotal nephrectomy and Adenine diet) were created as previously 
described (see pg 76 & pg 79). Four weeks following the second stage of the 
subtotal nephrectomy or after 4 weeks of adenine diet; the animals were 
anaethetised with IP sodium thiopentone, the thorax was opened rapidly, the 
heart excised with a single cut and completely immersed in liquid nitrogen. The 
snap frozen hearts were then transferred to cryotubes and stored at −80oC until 
processing. 
 
3.6.3.1  Sample preparation 
The hearts were triturated under liquid nitrogen in a pestle and mortar; the 
powder was then aliquoted into pre-chilled 15 ml polythene tubes, the liquid 
nitrogen evaporated and the remaining powder swiftly weighed to avoid thawing. 
Perchloric acid (9%) was added to the powdered tissue (1ml/ 100mg tissue). The 
samples were then sonicated and incubated on ice for 5 minutes. The samples 
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were then centrifuged at 3000 rcf for 10 min. The resulting supernatant was 
aspirated and divided into 500 µl aliquots in 1.5 ml Eppendorfs. The supernatant 
was neutralised by adding 100 µl (1:5 ratio) of 5M potassium carbonate solution, 
this reliably gave rise to a solution with a pH of 7.5-8. The resultant chemical 
reaction liberated CO2 and yielded a precipitate of perchlorate. The aliquots were 
centrifuged for 10 min at 12000 rpm the supernatant was aspirated and stored at 
−80oC until analysis. 
 
Prior to analysis the samples were thawed and underwent further centrifugation in 
order to ensure all particulate matter had been removed to avoid damaging the  
HPLC. 
 
3.6.3.2  Measurement of nucleotide pool by high-performance liquid 
chromatography (HPLC) 
Nucleotide, phosphocreatine and creatine concentrations were determined by 
high-performance liquid chromatography (HPLC). HPLC apparatus comprised of a 
PU-2089 Quaternary Low Pressure Gradient Pump and MD-2010 Photometric 
Diode Array UV/ Vis Detector (195-650nm) from Jasco Instruments (UK) Ltd. The 
pump was connected to an AS-2055 autosampler and separations were performed 
on a reversed phase AceTM C18 column (4.6 mm x 15 cm, 5 µm particle size) from 
Hichrom Ltd. (Theale, Reading, UK). Peak area was calculated by EZChrome Elite 
software and concentrations determined against reference material standard 
curves. 
 
For ion-pair reversed-phased HPLC determination, the method described by 
Perrett et al192 for the assay of nucleotides was used but slightly modified. Briefly, 
the mobile phase consisted of 2 % methanol, 98 % buffer (83.3 mmol/L 
orthophosphoric acid H3PO4 titrated to pH 5.8 with triethylamine). 10 µL of 
sample was injected onto the column with a flow rate of 0.6 mL/min and a cycle 
time of 20 min. The column was cleaned at the end of each working day with 100 
% methanol for 30 min and the autosampler injector was cleared with distilled 
water. Values were quantified against known standard concentrations of xanthine 
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monophosphate (XMP). Each sample was processed twice and a CV of less than 
10% was accepted. The identification of each target molecule was confirmed by 
adding exogenous standard material (all from Sigma Aldrich Chemical Company) 
to samples.  
 
3.6.4 Results/
There was a marked disparity between the two models in the absolute 
concentrations of adenine nucleotides. As this disparity applied to all the 
nucleotides assayed and was maintained between both the control groups (‘Sham’ 
operated and ‘Control’ diet fed) it is likely that these differences reflect either 
superior recovery or increased degradation of adenine nucleotides in the samples 
obtained from the two different models (SNx and AD). Processing and 
measurement of the samples from the two models took place at different times. 
Because of these differences, it is difficult to make a direct comparison between 
the models. The ratios of the nucleotides and other molecules appear to be 
maintained therefore comparison is made for pCr/ ATP, whilst other variables are 
considered with respect to the control group (Control diet or Sham operated). 
 
3.6.4.1  Results of nucleotide analysis and bioenergetics 
Total cardiac levels of adenine differed significantly between the SNx and AD 
models (Figure 19a, p<0.0001), However, compared to their respective control 
groups, uraemia either induced by sub-total nephrectomy or more importantly by 
adenine diet, did not affect total cardiac adenine levels (analysed with two way 
ANOVA and confirmed by post test Mann-Whitney U-test performed separately 
for the two models). SNx model; sham 3.16 µM [2.65 − 3.88], SNx 2.83 µM [2.28 
− 3.87], p=0.31, adenine model; control 21.3 µM [17.2 − 25.4], AD 18.3 µM 
[15.9 − 27.1], p=0.89. 
 
Similar findings were observed with respect to the total adenine nucleotide pool, 
with a significant difference observed between the two models (p=0.01), but no 
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significant difference between sham and SNx animals (p=0.31) or between 
Control and AD animals (p=0.48, see Figure 19b). 
 
Hypoxanthine levels were found to be higher in animals fed the adenine diet. 
However, the difference was not statistically significant (control 4.74 µM [3.70 − 
5.82] vs. AD 6.04 µM [4.55 - 7.00], p=0.093 and sham 1.14 [0.910 − 1.67] vs. 
SNx 0.983 [0.843 − 1.22], p=0.47, see Figure 19d). 
 
The ATP/ ADP ratio, a measure of the free energy available to drive energy 
consuming processes, varied between models and groups and on two-way 
ANOVA an interaction between model and uraemia in determining the ATP/ADP 
ratio was identified (p=0.046, see Figure 20a), indicating that renal failure did not 
have the same effect upon ATP/ ADP ratios in the two models. In SNx animals it 
was reduced compared to the sham animals, but the difference was not 
statistically significant. In the adenine model, the AD animals had an increased 
ATP/ ADP ratio but again the difference was not statistically significant (tested by 
two-tailed Mann-Whitney U-test). No significant differences in the absolute 
concentrations of ATP between the groups were identified. 
 
The phospho-creatinine/ ATP ratio was increased in both the SNx (uraemic) and 
AD (uraemic) animals. Two-way ANOVA returned a significant effect of both 
model and renal function upon pCr/ ATP but no evidence of an interaction. 
However, analysing the models individually using a Mann-Whitney U-test 
revealed no difference between the respective groups (i.e. Sham vs. SNx and 
Control vs. Adenine), although there difference in the median pCr/ ATP ratio 
approached significance (p=0.063, see Figure 20b).
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Sub-total nephrectomy model (SNx) Sham (n=7) SNx (n=10) p
Adenine (μM)
pCr/ ATP (AU)
Total Adenine Nucleotide Pool (mM)
ATP/ ADP (AU)
Adenylate charge
pCr/ Total Cr (AU)
Hypoxanthine (μM)
3.16 (2.64-3.88) 2.83 (2.23-3.87) 0.89
2.35 (1.64-2.67) 2.39 (2.19-2.58) 0.74
3.16 (2.65-3.88) 2.83 (2.28-3.87) 0.89
2.49 (2.32-2.65) 2.74 (2.36-3.39) 0.16
0.813 (0.806-0.817) 0.825 (0.797-0.849) 0.36
0.43 (0.31-0.49) 0.48 ( 0.45-0.51) 0.19
1.14 (0.91-1.67) 0.98 (0.84-1.22) 0.47
Adenine diet model (AD) Control (n=9) Adenine (n=9) p
Adenine (μM)
pCr/ ATP (AU)
Total Adenine Nucleotide Pool (mM)
ATP/ ADP (AU)
Adenylate charge
pCr/ Total Cr (AU)
Hypoxanthine (μM)
21.3 (17.2-25.4 18.3 (15.9-27.1) 0.54
2.71 (1.67-3.81) 4.66 (2.68-7.73) 0.06
21.3 (17.2-25.4) 18.3 (15.9-27.1) 0.54
3.65 (2.90-3.99) 2.12 (1.35-3.34) 0.16
0.817 (0.789-0.826) 0.709 (0.562-0.805) 0.063
0.69 (0.60-0.82) 0.69 (0.67-0.73) 1
4.74 (3.70-5.82) 6.04 (4.55-7.0) 0.09
 
Figure 19 – Results of bioenergetic assessment of SNx model and AD models.  
(a) Total Adenine, a marked and highly significant difference in the amount of adenine recovered 
from the two models was observed, however intra-group comparison revealed no difference 
between uraemic and non-uraemic animals. (b) No difference in the total nucleotide pool was 
seen. (c) Adenylate charge was lower in the adenine animals, this was of borderline statistical 
significance (p=0.063). (d) Hypoxanthine was elevated in AD animals. 
INFARCT SIZE IN URAEMIC RATS: REDUCED ISCHAEMIA TOLLERANCE? 
138 
 
SNx Model Adenine Model
0
1
2
3
4
AT
P/
 A
D
P 
(A
U
)
Non-uraemic
Uraemic
SNx Model Adenine Model
0
2
4
6
8
pC
r/ 
AT
P 
(A
U
)
Non-uraemic
Uraemic
SNx Model Adenine Model
0.0
0.2
0.4
0.6
0.8
pC
r/ 
To
ta
l C
r
Non-uraemic
Uraemic
(a)
(b)
(c)
 
Figure 20 – Bioenergetic assessment of SNx and AD models. 
(a) ATP/ADP ratio, interaction p=0.046. (b) Phospho-creatinine/ ATP ratio. (c) Phospho-creatinine/ 
total creatinine ratio.
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3.6.5 Discussion/
Adenosine has an extremely short half-life, making it difficult to accurately 
quantify, being metabolized rapidly to hypoxanthine via inosine. Thus an excess 
of extracellular adenosine may manifest as an increased concentration of 
hypoxanthine. Such an increase, although not statistically significant (p=0.09), 
was seen in the AD animals. 
 
Taken together these results do not explain either the increased infarct size in SNx 
animals or why despite a greater degree of renal dysfunction, a comparable 
increase in infarct size was not observed in AD rats.
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4.1 Background+
Modern management of acute myocardial ischaemia encompasses early 
reperfusion together with strategies to favourably alter post-infarct cardiac 
remodeling (e.g. ACE inhibitors and aldosterone antagonists). However, there is 
an additional aspect of the pathophysiology of acute coronary syndromes, which 
if successfully modulated, presents an opportunity to improve outcomes still 
further, namely amelioration of lethal reperfusion injury. 
 
There is a pressing need to improve outcomes post AMI for patients with CKD. As 
previously discussed, it has been suggested that the extent of myocardial 
infarction for the majority of patients suffering an AMI will be maximally limited 
through the use of timely reperfusion alone. However, approximately one quarter 
of patients experiencing an AMI will still have a myocardial infarcts of >75% of the 
area at risk.193 
 
IPC is the most powerful technique after reperfusion, for limiting the damage from 
acute myocardial ischaemia.194  
 
4.2 Ischaemic+Preconditioning+
 
Short sub-lethal episode/s of ischaemia-reperfusion, render a tissue or organ 
resistant to a subsequent sustained ischaemic insult. This phenomenon was first 
observed by Charles Murry17 and his colleagues at Duke University in 1986. They 
coined the term ‘Ischaemic preconditioning’, sometimes referred to as ‘classical’ 
or ‘early’ preconditioning, to describe this effect. The discovery of ischaemic 
preconditioning built on their earlier observations of changes in ATP and total 
adenine nucleotide levels in response to brief periods of ischaemia and 
reperfusion.133 In a canine model of myocardial infarction they observed that after 
a single 10 minute episode of ischaemia, ATP levels were depleted by 61% and 
total adenine nucleotides (TAN) by 41%, but after 2 episodes of ischaemia ATP 
levels were reduced to 54% (TAN 38%) and after four episodes, ATP levels were 
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51% (TAN 39%) Thus repeated episodes of short, ischaemia interspersed by 
reperfusion, did not lead to a cumulative loss of ATP or total adenine nucleotides. 
Moreover, lactate levels improved following repeated episodes of ischaemia (5.6 
fold increase after a single 10 min episode of ischaemia, 4.4 fold after two 
episodes and 3.5 fold after 4 episodes of ischaemia). These observations would 
suggest that metabolic adaptations occur at a cellular level in response to 
ischaemia to reduce the cellular energy demands and thus preventing the total 
exhaustion of high energy phosphate (HEP) bonds which would inevitably lead to 
cell death. This led Murry and his colleagues to hypothesise that exposure to a 
brief period of ischaemia and reperfusion may reduce the injury caused by a 
subsequent sustained ischaemic episode. 
 
Since this seminal observation was made, numerous investigators around the 
globe have confirmed Murray et al’s findings in various organs other than the 
heart and in numerous different animal species; the reproducibility of the 
therapeutic effect of ischaemic preconditioning is extraordinary. 
 
The protective effect of ischaemic pre-conditioning is transient. Van Winkle et 
al195 demonstrated that if the interval between the preconditioning stimulus and 
the period of test ischaemia was extended to beyond 60 min the protective effect 
of IPC was lost. However, it was subsequently shown that there is a 
recrudescence of protection after approximately 24 hours and lasting up to 72 h. 
This is termed the ‘second window of protection’. It would seem that ischaemic 
preconditioning is a highly conserved adaptive response to the deprivation of 
metabolic substrates necessary to sustain life.
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4.2.1 Mechanism/of/ischaemic/preconditioning/
 
The mechanism of early ischaemic preconditioning may be thought of as 
comprised of a number of stages: 
♦ Triggers - A substance which is released in response to ischaemia and 
which is capable of activating signaling pathways which ultimately lead 
to cellular resistance to ischaemia-reperfusion injury. 
♦ Mediators - the mechanism through which the preconditioning trigger/ 
stimulus is transduced. 
♦ Effectors - the final target of preconditioning, modulation of which is 
responsible for manifesting the protective effect of ischaemic 
preconditioning. 
 
4.2.1.1  Triggers of ischaemic preconditioning: 
The characteristics of a ‘trigger’ include: 
◆ An increase in concentration with ischaemia 
◆ Exogenous administration of a putative trigger would induce a state of 
‘pharmacological’ preconditioning and confer tissue protection against 
IRI. 
◆ Administration of an inhibitor would abolish the effect of 
pharmacological preconditioning. 
◆ Moreover, administration of an inhibitor would also abolish the effect 
of ischaemic preconditioning. 
A number of molecules have been felt to fulfill these criteria, perhaps the most 
widely acknowledged and best characterised is adenosine (others include; 
endogenous opioids and bradykinin). 
 
4.2.1.1.1 %Adenosine%
Adenosine is an endogenous purine nucleoside of adenine, it is formed from 
adenine mono-phosphate through the action of 5'-nucleotidase. The intracellular 
concentration of adenosine rises rapidly in response to ischaemia196 and then 
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diffuses freely down a concentration gradient into the extracellular space where it 
is available to activate specific cell surface G-protein coupled receptors (GPCR). It 
has been shown under experimental conditions that both adenosine and A1 
agonists are capable of inducing pharmacological preconditioning.197,198 
Furthermore the protective effect of adenosine is abolished by pharmacological 
blockade of the A1 receptor 8-(p-sulfophenyl) theophyline (SPT).191,197 Finally the 
protective effect of ischaemic preconditioning could also be nullified by pre-
administration of SPT.197 
 
It is suggested that, adenosine acts in parallel with endogenous opioids and 
bradykinin, to excite the preconditioned phenotype through the activation of their 
respective G-protein coupled receptors. Inhibition of any one of these three 
triggers prevents preconditioning. However, amplification of the preconditioning 
stimulus, by increasing the number of cycles of ischaemia-reperfusion has been 
shown to overcome inhibition of a single trigger125,199 indicating that the three 
triggers have an additive or synergistic effect in stimulating preconditioning. 
 
4.2.1.2  Mediators 
All three triggers converge to activate protein kinase C (PKC), inhibition of PKC 
has been demonstrated to abrogate the protection induced by exogenous 
opioid,199 bradykinin125 or adenosine administration.200 Several other pro-survival 
kinases have been identified which play a role in transducing the IPC stimulus. 
 
PKC activation is widely regarded as the hub of the IPC signal transduction 
pathway. However, IPC is capable of achieving substantial myocardial protection 
in aged rabbits despite inhibition of PKC.201 
 
Several other ligands of G-protein coupled receptors, known to be capable of 
activating PKC, have also been shown to induce preconditioning, these include; 
catecholamines,202 angiotensin II203 and endothelin.204 However, in contrast to 
adenosine, endogenous opioids and bradykinin, pharmacological inhibition of 
ISCHAEMIC PRECONDITIONING IN URAEMIC RATS 
145 
these receptors does not abolish ischaemic preconditioning, indicating that they 
are not essential triggers of the preconditioning survival pathways. 
 
4.2.1.2.1 %The%Reperfusion%Injury%Salvage%Kinase%(RISK)%pathway%
 A number of signaling molecules upstream of PKC have been implicated in 
mediating the cytoprotective effect of IPC. These have been loosely grouped 
together and somewhat misleadingly termed the ‘reperfusion injury salvage 
kinase’ (RISK) pathway. This term was first coined by Derek Yellon’s group in a 
report of infarct size limitation by urocortin.205 The administration of urocortin 
3min before reperfusion, in an in vivo model of myocardial infarction, was found 
to up-regulate extracellular regulated kinase 1/2 (ERK 1/2 also known as p42/44) 
and it’s myocardial protective effect was inhibited by the concomitant 
administration of the inhibitor PD-98059. The first of these survival kinases to be 
ascribed a role in mediating ischaemic preconditioning was phosphatidylinositol 
3-kinase (PI3-kinase).206 Pretreatment with the PI3 kinase inhibitors wortmanin 
and LY 294002 attenuated the cardioprotective effects (recovery of contractile 
function and infarct size) of ischaemic preconditioning.207 However application of 
1,2,-dioctanoyl-sn-glycerol (DOG), an activator of PKC was shown to afford 
similar degrees of protection as ischaemic preconditioning and was shown to be 
independent from the activation of PI3K. 
 
4.2.1.2.1.1 %ERK%1/2%
ERK 1/2 displays a transient increase in phosphorylation in response to ischaemia 
and reperfusion. Inhibition of ERK 1/2 in vitro results in enhanced apoptosis in 
cardiomyocytes and in vivo delays functional recovery of isolated rat hearts. 
Interestingly the co-administration of SB203580 (an inhibitor of p38 and JNK) was 
able to abrogate the effects ERK 1/2 inhibition, suggesting that a dynamic balance 
in the activation state of the various mitogen activated protein kinases (MAPK) is 
critical in determining outcome.208 
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4.2.1.2.1.2 %Akt%
The binding of all GPCR to their ligands appears to result in phosphorylation of 
Akt, mediated via PI3 kinase, with the exception of adenosine, which has been 
shown to activate Akt in a PI3K independent manner.209 It is thought that the 
activation of the adenosine (A1) receptor results in direct activation of 
phospholipase-C (PLC) and phospholipase-D (PLD) which in turn phosphorylate 
PKC.209 
 
Additional kinases implicated in the IPC signal transduction pathway include: 
♦ p38-mitogen activated protein kinase (MAPK) 
♦ Receptor tyrosine kinases of the src family 
♦ JAK/ STAT  
♦ Glycogen synthase kinase - beta 
 
4.2.1.2.1.3 %The%Survivor%Activating%Factor%Enhancement%(SAFE)%Pathway%
Recently Lecour and colleagues have proposed a further signaling pathway, 
which operates independently of the RISK pathway to mediate cardioprotection 
induced by IPC. Evidence for this pathway has predominantly been derived from 
studies of pharmacological preconditioning using TNF-alpha, which has been 
shown to provide cardioprotection independently of Akt and ERK 1/2 
activation.210 Both TNF-alpha and classical IPC result in phosphorylation of signal 
transduction and activator of transcription-3 (STAT-3) and inhibition of STAT-3 
with AG490 abolishes the protection afforded by both IPC and TNF-alpha.210 
Moreover, in pigs, ischaemic post-conditioning results in phosphorylation of the 
RISK pathway kinases (Akt, ERK and P70S6K) but inhibition of the same kinases 
does not abrogate the infarct size limiting effects of post-conditioning211 
suggesting the presence of an alternative pathway mediating post-conditioning 
induced cardioprotection. 
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4.2.1.2.1.4 %Reactive%oxygen%species%(ROS)%in%preconditioning%
With the exception of adenosine, most other triggers of IPC appear to result in the 
opening of ATP-dependent voltage gated ion channels in the mitochondrial 
membrane. Through a mechanism that remains incompletely understood, opening 
of mitochondrial potassium ATP (mKATP) channels results in potassium influx into 
the mitochondria, which subsequently leads to the production of ROS.212 In the 
absence of ischaemia, the protective effect of IPC may be mimicked by exposure 
to ROS and abolished by the antioxidant N-acetylcysteine,213 but appears to be 
contingent upon the activation of PKC.214 Drugs, such as diazoxide and 
nicorandil, which purportedly induce the opening of the mKATP channel, have 
been shown to afford protection against ischaemia-reperfusion injury, comparable 
to that achieved by ischaemic preconditioning. However, the tissue protective 
effect of diazoxide may be abolished by glibenclamide,215 which inhibits opening 
of the mKATP channel, and ROS scavengers. 213 
 
4.2.1.2.2 Effectors%
The mitochondrial permeability transition pore (mPTP) 
Inhibition of the mitochondrial permeability transition pore is thought to be the 
end result of ischaemic preconditioning and as a result of which reperfusion 
injury is attenuated.216 The mitochondrial transition pore is a large non-specific 
conductance channel that forms within the inner mitochondrial membrane. Its 
composition remains to be fully identified, however it is thought that the binding 
of cyclophylin-D (CyPD), to one or more of the pore components, modifies the 
sensitivity of the mPTP to calcium triggered opening.217 Opening of the pore 
results in: 
♦ The release of mitochondrial cytochrome C and the triggering of 
apoptosis. 
♦ The dissipation of the mitochondrial membrane potential, leading to the 
uncoupling of oxidative phosphorylation resulting in ATP depletion and 
subsequent necrotic cell death. 
The probability of opening of the transition pore is increased by the same 
conditions that prevail at the end of ischaemia/ onset of reperfusion namely; high 
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mitochondrial calcium and inorganic phosphate load, oxidative stress, ATP 
depletion. The probability of pore opening is reduced by low intracellular pH and 
adenine nucleotides. Pharmacological inhibition of mPTP opening with 
ciclosporin A (CyA) is associated with a cytoprotective effect.218 
 
It was previously thought that ischaemic preconditioning exerted its protective 
effect by inducing a state of resistance to ischaemia, largely mediated by an 
attenuation in the rate of ATP consumption during an ischaemic episode.219 
However subsequent experiments demonstrated that IPC induced protection 
could be abrogated by the administration, at reperfusion, of inhibitors of a number 
of the prosurvival kinases, suggesting that at least a proportion of the 
cytoprotective effect of IPC is mediated through the activation of the RISK 
pathway at reperfusion.220 At the end of a period of lethal ischaemia cells might 
be considered to be in one of three states; irreversibly injured and undergoing 
necrotic death, critically injured such that reperfusion will result in the opening of 
the mPTP and trigger apoptosis, or sub-lethally injured, destined to survive. It 
seems unlikely that the well described effects of IPC on cellular bioenergetics are 
of no consequence. In addition, it is likely that IPC also reduces the proportion of 
cells in both the irreversibly and critically injured groups. The ability to decrease 
the populations of both these groups rather than simply alter the fate of a 
proportion of the critically injured cells is perhaps why IPC has a more potent 
cytoprotective effect than iPost.
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4.2.2 Evidence/for/preconditioning/in/Humans/
For obvious reasons it has been difficult to unequivocally prove the existence of 
preconditioning in humans. However, a number of phenomena and empirically 
derived data are taken as surrogate evidence that preconditioning is relevant in 
human health and disease. 
 
Firstly, both pain and ST elevation have been shown to be diminished following a 
second balloon inflation during PTCA.221 Moreover, in the same study, cardiac 
lactate production and mean pulmonary artery pressure were also shown to be 
reduced following the second inflation independent of coronary flow. Tomai et 
al222 and Taggart et al also reported similar findings. 
 
Secondly, there is the ‘warm-up phenomenon’, which describes the situation 
when a patient is forced to stop exercising by the onset of angina but upon 
recovery is able to resume the same level of exercise with-out experiencing 
further angina. The ‘walk-through phenomenon’, describes how anginal pain 
lessens despite continued exercise. Both phenomena have been objectively 
assessed in a number of small studies which have demonstrated reduced ST 
depression during subsequent periods of exercise despite a higher pressure rate 
product.223  
 
In a post-hoc analysis of the Thrombolysis in myocardial infarction-4 (TIMI-4) 
cohort,224 patients who experienced an anginal episode within 48 hrs of their 
presentation with AMI, were found to have a non-statistically significant trend 
toward a reduced risk of in-hospital death (3% versus 6%; P=0.09), a lower 
incidence of severe congestive heart failure (CHF) or shock (1% versus 6% 
P=0.008), a lower combined end point of death, CHF, or shock (3% versus 10%; 
P=0.006), reduced infarct size as evidenced by a smaller rise in serum creatinine 
kinase (115 versus 151 CK units; P=0.03) and a trend toward fewer Q-wave 
infarcts, in spite of a greater delay between onset of chest pain and presentation 
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for those patients with prior angina. In addition, there was no difference in the 
extent of collateral blood supply. It has been suggested that the reduction in 
infarct size associated with pre-infarct angina may be a clinical correlate of 
ischaemic preconditioning. However, pre-infarct angina has not been consistently 
associated with improved prognosis and several other observational studies have 
reported contrary results.225,226 Several studies have shown that patients who 
experience transient ischaemic attacks (TIA) prior to a stroke affecting the same 
vascular territory, sustain smaller infarcts227 and less severe symptoms with 
improved functional recovery.228 
 
Empirically derived in vitro evidence of a preconditioning effect, has been 
provided by Ikonomidis229 and colleagues, who demonstrated using primary 
cultures of human cardiomyocytes, obtained at the time of cardiac surgery, 
improved survival and attenuation of injury induced by exposure to 90 min of 
anoxia in cells which had previously been exposed to a brief (20 min) period of 
anoxia. Evidence of improved functional recovery in superfused human atrial 
trabeculae has also been obtained following preconditioning with a combination 
of rapid pacing and hypoxia.230  
 
However the most compelling evidence that the human heart can be 
preconditioned comes from in vivo studies. Preconditioning is associated with 
characteristic alterations in the metabolic profile of ischaemic tissue, in particular 
ATP levels are depleted and the total adenine pool is diminished. Additionally 
lactate levels are elevated and cellular [H+] is also increased. Preconditioning 
attenuates these metabolic manifestations of ischaemia. Derek Yellon and 
colleagues were the first to demonstrate an in vivo effect of preconditioning in 
samples obtained from patients undergoing cardiac bypass surgery231 by showing 
that ATP levels were not reduced in patients who had experienced intermittent 
cross clamping prior to a sustained 10 min episode of ischaemia. In contrast 
patients that did not undergo cross-clamping had a three fold reduction in the 
cellular ATP levels to approximately half the level of the cross-clamped 
(preconditioned group). 
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Ischaemic preconditioning is associated with improved endothelial function in 
animals.232 Kharbanda et al demonstrated superior endothelial function in the 
forearms of subjects who received preconditioning, by means of a blood pressure 
cuff inflated to supra-systolic blood pressure, before an ischaemic insult of 20 
min.233 
 
4.2.3 Effect/ of/ aging/ and/ comorbidity/ on/ the/ efficacy/ of/ ischaemic/
preconditioning/
Senescence has been shown to blunt the efficacy of ischaemic preconditioning.234-
236 Moreover a number of important metabolic and physiologic conditions such 
as; diabetes mellitus,236-238 dyslipidaemia,239 left ventricular hypertrophy235 and the 
metabolic syndrome, all of which are frequently seen as co-morbidities in patients 
with CVD and CKD, have also be shown to attenuate the tissue protection 
afforded by ischaemic preconditioning. 
 
It has been suggested that disturbances in PI3-Akt signaling underpin the 
increased threshold for induction of protection by preconditioning seen in 
diabetic animals. Lower basal levels of phosphorylated Akt are observed in 
diabetic myocardium from both experimental and human samples.237,238 
 
Additionally, the signal transduction mechanism for IPC may vary under different 
physiological conditions (e.g. with increasing age201). It is also possible that the 
relative importance of the various signaling pathways implicated in mediating IPC 
are also altered by co-morbid conditions. The effect of uraemia on the efficacy of 
preconditioning is unknown.
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4.3 Aims+
 
To determine the efficacy of early ischaemic (classical) preconditioning in 
ameliorating myocardial ischaemia-reperfusion injury in rats rendered 
‘chronically uraemic’ by sub-total nephrectomy and adenine diet. The two 
principle questions were: 
♦ Can uraemic rats be preconditioned? 
And if so, 
♦ Is the threshold for eliciting protection increased? 
A series of four experiments were conceived and undertaken. 
 
1) Experiment A: two groups of SNx animals, one group preconditioned 
with (3 cycles of 5min ischaemia 5 min reperfusion) prior to 25 min of 
ischaemia and 2 hrs reperfusion and a non-preconditioned control 
group. 
2) Experiment B: two groups of animals with adenine induced uraemia, 
same experimental protocol as experiment A. 
3) Experiment C: ‘Threshold’ experiment, two groups of animals SNx and 
sham operated animals, both groups preconditioned prior to 35 min 
LAD occlusion, 2 hrs reperfusion. 
4) Experiment D: second ‘Threshold’ experiment; a 2x2 factorial design 
consisting of animals fed adenine diet for 4 weeks followed by a two 
week wash-out and a control group fed normal diet for six weeks. 
Animals from both groups were selected at random to receive one 
cycle of preconditioning (5 min ischaemia, 5 min reperfusion) prior to 
25 min of LAD occlusion. Infarct size was determined after 2 hours 
reperfusion.
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4.4 Methods+,+ischaemic+preconditioning+
Male Wistar rats supplied by Charles River Laboratories UK (Margate, Kent) were 
rendered uraemic by way of sub-total nephrectomy, 4 weeks of adenine diet or 4 
weeks adenine diet and 2 weeks of “washout”. 
Four weeks following the second stage (right total nephrectomy) or during the 5th 
week of adenine diet or 3rd week of washout, the animals underwent myocardial 
ischaemia-reperfusion (as described on pg 112). 
Following basic surgery, the animals were randomly assigned to receive either 
one cycle (5min LAD occlusion, 5min reperfusion) of preconditioning, in the 
‘threshold’ experiment or three cycles of preconditioning (IPCx3) in the ‘initial’ 
experiment. At the end of the final reperfusion period of he preconditioning cycle 
the animals underwent sustained LAD occlusion either for 25 min (as per previous 
work pg 112) in the initial experiment or 35min for SNx animals in the threshold 
experiment. 
The duration of ischaemia was increased, from 25min to 35min, for the SNx 
threshold experiment as preliminary results indicated that a single cycle of 
preconditioning in SNx animals may be sufficient to maximally limit the size of 
infarct induced by 25 min of LAD occlusion. Out of three SNx animals; one had 
an infarct of 25% another had an infarct of just 1.49% and a third had no 
detectable infarction despite a clear area at risk and characteristic arrhythmias. 
 
4.4.1 ‘Threshold’/for/IPC/in/adenine/induced/uraemia/
This experiment had a 2x2 factorial design. Initial work with the adenine model 
had demonstrated that animals with AD induced uraemia had significantly slower 
heart rates and therefore a reduced pressure rate product (an index of myocardial 
oxygen consumption). Although this relative bradycardia did not seem to be the 
result of excess adenosine the slower heart rate and therefore reduced myocardial 
oxygen demand might afford cardio-protection and offset the reduced ischaemia 
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tolerance seen in the SNx model. It was decided to allow the AD animals a 
washout period. It was therefore imperative to establish the infarct size in a 
control group of animals with adenine diet induced uraemia therefore a 2x2 
factorial design was chosen. After completing 4 weeks of adenine diet the animals 
were switched to normal chow for a further two weeks before being used for 
experiments in the 7th week (3rd week of normal chow). The remainder of the 
experiment was conducted in the same manner as previously described. In 
contrast to the ‘threshold’ experiment in SNx animals, only 25 min of ischaemia 
was employed in this experiment. 
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Figure 21 – Diagrammatic representation of protocols used in experiments A, B and C 
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Figure 22 – Diagrammatic representation of protocol for Experiment D – Threshold for 
preconditioning in WO animals.
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4.4.2 Immunoblotting/and/Protein/extraction/
Hearts from sham operated or uremic animals, subjected to the IPC protocol 
detailed above were excised, washed once in ice-cold PBS, snap frozen in liquid 
N2 and stored at -80
oC until further use. Tissues for western blot were triturated 
with a mortar and pestle under liquid N2 and subsequently polytron-homogenised 
(3x 30sec bursts with 1min intervals on ice) in a mammalian protein extraction 
buffer (GE healthcare; 10:1 v/w) supplemented with the following inhibitors: 1mM 
EDTA, 0.5mM DTT, 1% v/v protease inhibitor cocktail (Sigma), 1mM NaF, 5µM 
fenvalerate (Calbiochem), 1mM Na3VO4 and 1% v/v phosphatase inhibitor 
cocktails I and III (Sigma). The tissue homogenate was incubated for 10 minutes 
on ice and then centrifuged at 5,000g for 10 minutes at 4oC. The supernatant was 
aliquoted and stored at -80oC until further use. Protein concentrations were 
determined using the Bicinchoninic Acid assay (BCA, Pierce), with bovine serum 
albumin (BSA, Sigma) as the protein standard. 
 
Lysates (40µg of protein) were subjected to SDS-polyacrylamide gel 
electrophoresis using the NuPAGE electrophoresis system (Invitrogen) under 
reducing conditions as previously described.240 The ECLplus chemiluminescence 
detection kit (Amersham Pharmacia) was used to visualise protein bands. The 
following antibodies (supplied by Cell Signalling) were used: rabbit anti-phspho-
p44/p42 MAPK (Thr202/Tyr204), rabbit anti-p44/p42 (total ERK), mouse anti-
phospho-AKT (Ser473), rabbit anti-AKT (total AKT), mouse anti-phospho-STAT-3 
(Tyr705), rabbit anti-STAT-3 (total STAT-3) and peroxidase-conjugated secondary 
antibodies.
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4.5 Results+–+Ischaemic+preconditioning+
4.5.1 Experiment/A:/Ischaemic/preconditioning/(IPC)/of/uraemic/(SNx)/animals/
Employing a pre-conditioning protocol consisting of 3 cycles of 5 min ischaemia/ 
5 min reperfusion it was possible to achieve significant myocardial protection 
with an absolute reduction in infarct size of more than 50% (relative reduction of 
86% p=<0.0001, see Figure 23a). The area at risk (AAR) was similar for the two 
groups (p=0.305, Figure 23b). 
 
4.5.1.1 Haematological, biochemical and physiological variables 
Weight: there was no significant difference in the mean weight of the animals 
between the two groups (p=0.110, see table in Figure 23), however the variation 
in weight was considerably greater in the preconditioned group. This is probably 
because the animals making up the preconditioned group were drawn from two 
different batches of animals created at different time points. The heart weight 
(expressed as % body weight) was similar for both the control and preconditioned 
groups (control 0.334% [0.305 − 0.364%] vs. IPCx3 0.343% [0.325 − 0.384%], 
p=0.694). 
 
Animals receiving IPCx3 had higher baseline HCT (p=0.026, see Figure 23e). 
However, crucially pre-occlusion there was no significant difference between the 
SNx-Control and SNx-IPCx3 animals (25.0% [24.0-28.0%] vs. 28.0% [26.0-
32.0%], p= 0.1764) or at the end of reperfusion (23.5% [21.3-28.8%] vs. 25.0% 
[21.0-31.0%], p= 0.9135). 
 
4.5.1.2 Renal function  
There was no difference in median creatinine (p=0.182, see table in Figure 23 and 
Figure 24e) or median urea (control 17.2 [16.3-17.8] mmol/L vs. IPCx3 17.4 
[15.9-22.0] mmol/L, p=0.201, Figure 24f) between the control and 
preconditioned groups.  
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4.5.1.3 Arterial blood gas analysis 
Blood pH, pCO2, haematocrit and base excess were similar for the both groups at 
all time points (see Figure 23c, d, e, f). However a highly significant difference in 
the arterial partial pressure of oxygen was observed (median pO2 Control 53.6 kPa 
[24.3 − 60.8 kPa] vs. IPCx3 13.7 kPa [12.9 − 15.7 kPa], p=0.0003).
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Figure 23 – Results of Experiment A.  
(a) Three cycles of IPC resulted in a substantial reduction in infarct size in SNx animals (p=0.002,***), graph shows median with IQR). (b) Area at risk (AAR) was 
comparable for both groups (graph shows median with IQR). (c) pH, (d) pCO2, (e) Haematocrit, (f) bases excess did not differ significantly over the course of the 
experiment (graphs show means with 95% CI). 
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Figure 24 – Biochemical and physiological results for Experiment A.  
(a) Mean arterial blood pressure (MAP), (b) heart rate, (c) pressure rate product, (d) weight, (e) plasma creatinine, (f) plasma urea. I1 refers to the first cycle of ischaemia, 
R1 the first cycle of reperfusion, thereafter numbers refer to minutes after onset of ischaemia or onset of reperfusion. 
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4.5.2 Experiment. B:. Ischaemic. preconditioning. (IPC). in. the. Adenine. diet.
induced.uraemia.
The ability of three cycles of IPC (IPCx3) to provide cardioprotection, in the 
context of experimental uraemia induced by adenine diet, was tested in a further 
series of experiments. Utilising the same preconditioning protocol employed for 
the SNx animals. IPCx3 resulted in a 42% relative reduction in infarct size 
(p=0.014, see Figure 25a). The area at risk (AAR) was similar for the two groups 
(p=0.397, see Figure 25b). 
 
4.5.2.1 Haematological, biochemical and physiological variables 
The animals receiving IPC were slightly heavier (p=0.05, see Figure 25 – table). 
However, blood pressure (MAP), heart rate (HR), and pressure rate product (PRP) 
were similar throughout the duration of the experiment. The animals receiving IPC 
were more anaemic (median HCT 22% vs. AD-Con 24%) however the difference 
in haematocrit was not significantly different at baseline (p=0.07), or over the 
course of the experiment. 
 
Both the AD-Control and AD-IPCx3 groups had a similar degree of renal 
dysfunction. No significant differences were observed in arterial blood gas 
parameters between the control and preconditioned animals. 
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Figure 25 – Ischaemic preconditioning (IPCx3) in AD animals. 
(a) IPCx3 resulted in a 42% relative reduction in infarct size (p<0.05,*). (b) Area at risk was similar for both groups. (c) pH, (d) pCO2, (e) Haematocrit, (f) bases excess 
did not differ significantly over the course of the experiment (graphs show means with 95% CI).
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Figure 26 – Cardiovascular measurements and plasma biochemistry for Experiment B – preconditioning (IPCx3) of AD animals. 
No differences in MAP (a), HR (b) or PRP (c) were seen throughout the course of the experiment (graphs show median with IQR). There was no difference in weight (d), 
plasma creatinine (e) or urea between animals receiving IPCx3. 
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4.5.3 Experiment.C:.‘Threshold’.for.preconditioning.in.sub>total.nephrectomy.
model.
Having established convincingly that uraemic animals (both SNx and adenine-
induced) could be preconditioned, investigations were undertaken to determine if 
there was an increase in the threshold for eliciting cytoprotection in uraemic 
animals with IPC. As near maximal protection was seen in SNx with one cycle of 
IPC and 25 min of sustained ischaemia (n=3, median infarct 1.49% [0.0-25.1%], 
AAR 39.9% [29.9-49.0]), for the second series of experiments the period of 
sustained ischaemia was increased to 35 min. 
 
In uraemic (SNx) animals receiving one cycle of IPC, a significant reduction in 
infarct size was demonstrated compared to non-uraemic (sham) animals, 
preconditioned with a single cycle of IPC (p<0.01, see Figure 27a). The area at 
risk was similar for sham (non-uraemic) and SNx animals (p=0.299, Figure 27b). 
 
4.5.3.1.1 Haematological,1biochemical1and1physiological1variables1
The SNx animals were generally lighter, but not significantly so (370g [333−389g] 
vs. 338g [316−353g], p=0.13). The sub-totally nephrectomised animals had 
significantly higher serum creatinine (Median creatinine sham animals 37.9 
µmol/L [32.3 − 42.7], SNx animals 93.2 µmol/L [89.6 − 118], p=0.0003) and urea 
(6.45 mmol/L [6.00−7.18] vs. 17.4 mmol/L [16.8−19.7], p=0.002). 
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Figure 27 – Results of Experiment C: ‘Threshold’ for preconditioning in SNx animals. 
(a) A single cycle of preconditioning (5 min ischaemia 5 min reperfusion) was more effective in reducing infarct size in SNx animals than Shams (RR 43.6%, p=<0.01). 
(b) Area at risk was comparable for both groups. No significant differences in pH (c), pCO2 (d), HCT (e) or BE (f) was observed (Graphs show median with IQR). 
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Figure 28 - Cardiovascular measurements and plasma biochemistry for Experiment C. 
No significant differences in MAP (a), HR (b), or PRP (c) were seen throughout the course of the experiment (graphs show median with IQR). SNx animals were lighter 
but not significantly so (p=0.13) (d), plasma creatinine was significantly greater in the SNx animals (p=0.0003) (e) as was urea (p=0.002)
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4.5.4 Experiment- D:- ‘Threshold’- for- preconditioning- in- adenine- induced-
uraemia-
The efficacy of a single cycle of preconditioning was also assessed in the adenine 
diet model of chronic uraemia. 
 
4.5.4.1 Infarct size 
Both groups, adenine washout (WO) and control animals, experienced a 
substantial reduction in infarct size with a single cycle of preconditioning (RR 
48.7% for control animals vs. 30.6% for WO animals, p<0.0001). Although the 
magnitude of the protection appeared marginally greater in control animals than 
WO animals, testing with 2-way ANOVA failed to demonstrate evidence of an 
interaction. Indicating that IPC had the same degree of effect in reducing infarct 
size reduction in animals with adenine induced uraemia as control animals. This 
result was corroborated by Mann-Whitney test. The area at risk for the four groups 
was similar. 
 
4.5.4.2 Haematological, biochemical and physiological variables 
The adenine washout animals were significantly more anaemic than control 
animals. There was no difference, in either uraemic or non-uraemic animals, in 
the degree of anaemia between those animals that received IPC and those that did 
not. Plasma creatinine was around 3 fold higher in WO animals compared to 
controls. There was no difference in serum creatinine between the preconditioned 
and control animals. 
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Figure 29 – The effect of IPC in adenine wash out model. 
(a) Infarct size was significantly reduced by a single cycle of preconditioning (p=0.002). (b) 
Area at risk was similar between the four groups. (c) WO animals were significantly lighter. 
(d) In keeping with their uraemic phenotype, WO animals had left ventricular hypertrophy 
as evidenced by an increased Heart weight/ body weight ratio (p<0.0001). (e) Plasma 
creatinine was approximately 3 fold higher in WO animals compared to controls 
(p=0.0006). 
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Figure 30 – Arterial blood gas measurements for IPC in adenine washout model. 
(a) No significant difference was seen in pH, (b) pCO2 or (d) base excess throughout the duration 
of the experiment. (c) Haematocrit was significantly lower for uraemic animals (WO). 
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4.5.4.3 Results – Immunoblotting: IPC in uraemia 
A limited study of the signaling pathways believed to be important in the 
intracellular transduction of the IPC stimulus was conducted. Immunoblots 
demonstrated an early and robust phosphorylation of both ERK 1/2 and STAT-3 
following three cycles of IPC (5 min ischaemia, 5 min reperfusion) that was 
similar in magnitude in both SNx (uraemic) and sham operated control animals. It 
was not possible to demonstrate a consistent response with respect to the 
phosphorylation state of Akt. 
 
This study indicates that preconditioning in the context of chronic uraemia is 
associated with the same changes in phosphorylation state of ERK and STAT3 as 
those seen in non-uraemic animals and therefore indicates the likelihood that 
these same pro-survival kinases are responsible for IPC signal transduction in 
uraemic animals.
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Figure 31 – Immunoblots prepared from hearts of both SNx (uraemic) and sham-operated control animals, 
A robust increase in pStat3 and p-ERK ½ were observed an appeared similar in magnitude for both uraemic (SNx) and non-uraemic (Sham) animals each column 
represents a separate animal.
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4.5.5 Discussion+–+Ischaemic+preconditioning+
The results of these experiments provide robust evidence that animals with 
experimental uraemia, induced by both adenine diet and subtotal nephrectomy 
can achieve substantial myocardial protection through ischaemic preconditioning. 
Furthermore, unlike senescence, diabetes mellitus and dyslipidaemia, uraemia 
does not attenuate the efficacy of ischaemic preconditioning. The consistency of 
the results obtained from these different models of chronic uraemia is mutually 
supportive. 
 
In contrast to non-uraemic (sham) animals, a single cycle (5 min ischaemia, 5 min 
reperfusion) of preconditioning was more effective in reducing infarct size in SNx 
animals. It is unclear why preconditioning should be more effective in uraemic 
versus non-uraemic animals. However, it is possible that the lower haematocrit 
seen in the uraemic group resulted in less extensive micro-thrombosis and thus 
less ‘no-reflow’ and superior reperfusion. The experimental groups were broadly 
similar with respect to their baseline characteristics, except for those related to the 
degree of renal dysfunction. However the same increased potency of IPC was not 
seen in the adenine washout animals, which, although not statistically significant, 
in fact experienced a smaller reduction in infarct size (RR 48.7% for Control-WO 
animals vs. 30.6% for WO animals) 
 
It is important to note that these experiments were carried out in juvenile animals, 
no more than 13 to 14 weeks old. There is data to suggest that the mechanism 
through which ischaemic preconditioning is mediated may vary with the age. 
Activation of PKC, which is regarded as a fundamental component of the signal 
transduction mechanism for ischaemic preconditioning and a target on which 
many survival pathways converge, may not be required to induce protection 
induced by IPC, as pharmacological inhibition of PKC in aged rabbits did not 
abrogate cardio-protection afforded by IPC.201 Variation in the relative importance 
of transduction pathways with age and possibly the presence of co-morbid 
conditions raises the possibility that uraemic animals may lose the ability to be 
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preconditioned at an earlier age than their sham counterparts. Such a possibility 
remains to be investigated. 
Although the relative reduction in infarct size was somewhat larger in the control 
animals than the uraemic (adenine wash-out) animals, this did not reach statistical 
significance, thus we concluded that there is no attenuation of the effectiveness of 
ischaemic preconditioning in animals rendered chronically uraemic through 
adenine diet. However, we should be cognisant of the possibility that either a 
larger sample size, or extending the duration of the index ischaemia, may have 
altered the results such that a relatively subtle loss of efficacy might have been 
detected. 
 
Employing a washout period harmonised the baseline haemodynamic 
characteristics and brought the weights of the groups closer together. However, 
the changes to the protocol made in this experiment preclude a direct comparison 
with the results obtained from Experiment B. 
 
The consistency of the results obtained from this series of four experiments, 
conducted in two different models of chronic uraemia, provides compelling 
evidence that in young animals, with a relatively short duration of uraemia, IPC 
provides robust and reproducible protection from myocardial ischaemia-
reperfusion injury. 
 
It is hoped that this work would provide the justification for further clinical 
research with the aim of providing the evidence base to incorporate ischaemic 
preconditioning into part of everyday practice.
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4.6 Arrhythmia,suppression,by,ischaemic,pre5conditioning,
In addition to its cytoprotective effect, ischaemic preconditioning has also been 
widely reported to have a pronounced anti-arrhythmic effect.241,242 The 
mechanism through which preconditioning inhibits arrhythmias is unclear, but it 
appears to be independent of the tissue protective effect and specifically 
independent of PI3K/ Akt. Matejikova et al243 demonstrated abolition of the 
cardioprotective effect of IPC but not the anti-arrhythmic effect following the 
administration of a PI3K/Akt inhibitor. Similarly, it has also been shown that 
pharmacological inhibition of bradykinin, prostaglandin or adenosine fail to 
suppress the anti-arrhythmic effects of IPC.242 However, Driamov et al244 reported 
that bradykinin antagonists abolished the anti-arrhythmic effects of IPC, that 
infusion of bradykinin mimicked the anti-arrhythmic effect of IPC and that both 
these effects could be abrogated by a sarcolemmal specific KATP inhibitor. The 
fundamental difficulty with identifying a specific mechanism for the anti-
arrhythmic effects of IPC is that interventions which may lead to increased 
ischaemia tolerance may indirectly lead to a reduction in reperfusion arrhythmias 
by virtue of the fact that there is less tissue damage. 
 
The single most common cause of cardiovascular mortality for patients with CKD 
is sudden cardiac death.3 Additionally, patients on dialysis have more than twice 
the risk of unexpected cardiac arrest post-AMI.14 It is hypothesised that: fluid and 
electrolyte shifts during dialysis, combined with coronary vascular disease, LVH, 
myocardial fibrosis and heart failure, contribute to the increased risk of arrhythmic 
death.46 The effect of comorbidity on the anti-arrhythmic effect of IPC has not 
previously been investigated. 
ISCHAEMIC PRECONDITIONING IN URAEMIC RATS 
176 
4.6.1 Methods+–+Suppression+of+arrhythmias+by+IPC+
During all experiments, a continuous recording of pulse and blood pressure 
(MAP) was made using a Powerlab/85p system (AD Instruments Ltd. Oxford, UK). 
This was displayed in real time using LabChart software (AD Instruments Ltd. 
Oxford, UK). The timing of each intervention during the experiment was recorded 
on the LabChart software for later off-line analysis (see Figure 32). 
 
Blood pressure and heart rate measurements were made following completion of 
the experiment. The pulse trace could be analysed for evidence of arrhythmias. 
For the purposes of analysis, an arrhythmia was defined as a change in the 
character of the pulse trace lasting greater than 2 seconds. The time frame of 2 s 
was selected so as to exclude ventricular ectopics, which would be unlikely to be 
clinically significant. Cardiac arrest was defined as absent pulse trace or MAP <20 
mmHg for more than 2 s. 
 
Arrhythmias occurring within the first 30 s following LAD occlusion were 
excluded, as it was not uncommon to observe brief episodes of rhythm 
disturbance as a consequence of manipulating the heart whilst tightening the 
snare to occlude the LAD. 
 
The duration of arrhythmias (including cardiac arrest) occurring during 
preconditioning, reperfusion or during the index ischaemia were recorded. In 
addition the time taken from when the LAD was occluded at the beginning of the 
index episode of ischaemia until the first arrhythmia was recorded for each 
animal.
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Figure 32 – BP and HR recorded using LabChart software used to determine time to and duration of arrhythmias. 
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4.6.2 Results+–+Suppression+of+arrhythmias+by+IPC+
In the SNx model, 3 cycles of IPC resulted in a reduction in the duration of 
arrhythmias occurring during the 25-minute index ischaemia (i25), which 
approached statistical significance (p=0.06, see Figure 33a). IPC reduced the 
duration of reperfusion arrhythmias from a median of 20 s to 9.5 s (p=0.03, Figure 
33b). IPC did not alter the time to the first episode of ischaemia induced 
arrhythmia, the duration of cardiac arrest, the time from onset of reperfusion to 
the first episode of arrhythmia or the total duration of all arrhythmias. 
 
Experiment - A SNx SNx IPCx3 p
Duration of preconditioning arrhythmias (secs)
Time to develop first arrhythmias during i25 (secs)
Duration of i25 arrhythmias (secs)
Duration of cardiac arrest during i25 (secs)
Time to develop first reperfusion arrhythmias after i25 (secs)
Duration of reperfusion arrhythmias (secs)
Total duration of all arrhythmias (secs)
na 53 (24.5-79)
325 (250-360) 380 (60-700) 1
58 (22.25-112.5) 0 (0-50) 0.06
0 (0-6) 0 (0-1.5) 0.38
21 (14.75-24) 22.5 (20-25) 0.68
9 (7.25-17) 0 (0-7) 0.03
20 (8-48) 9.5 (4-47) 0.43
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Figure 33 - The impact of 3 cycles of IPC in SNx animals on the duration of arrhythmias during 
reversible LAD occlusion.  
Results presented as median (IQR). P values are expressed as results of Mann-Whitney test using 
GraphPad software. 
 
In the AD model, 3 cycles of IPC (IPCx3) led to a reduction in the duration of 
arrhythmias during i25 (p=0.05, Figure 34a) and a trend towards reduced duration 
of reperfusion arrhythmias (p=0.06, Figure 34b). Again IPC had no effect on the 
time to the first ischaemic or reperfusion arrhythmia, nor did it have any effect on 
the duration of cardiac arrest or the total duration of arrhythmias (see Figure 34c).  
 
Finally the anti-arrhythmic effect of IPC was examined in the adenine washout 
model (WO, experiment D) with comparison to non-uraemic controls (see Figure 
34g-i). Following a single cycle of IPC (5 min ischaemia, 5 min reperfusion), the 
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WO animals had significantly fewer arrhythmias than the non-uraemic control 
animals (p=0.01). Furthermore, no adenine washout animals experienced cardiac 
arrest during ischaemia (p<0.0001). In addition, IPC reduced the duration of 
cardiac arrest in the control group (p<0.005). Neither uraemia nor IPC appeared 
to alter the time between onset of ischaemia and the first ischaemic arrhythmia. 
 
The duration of ischaemic, reperfusion and combined arrhythmias were 
compared using 2-way ANOVA. IPC reduced the duration of i25 arrhythmias in 
both uraemic and non-uraemic animals (p=0.04). No interaction was observed 
between IPC and uraemia. Uraemic animals had a shorter duration of ischaemic 
arrhythmias when IPC was accounted for; this result approached significance 
(p=0.08). Similar results were seen with reperfusion arrhythmias. IPC reduced the 
duration of reperfusion arrhythmias in both uraemic and non-uraemic animals 
(p=0.04) and there was no interaction between IPC and uraemia. Uraemic 
animals had a shorter duration of reperfusion arrhythmias after IPC was accounted 
for (p= 0.02). Finally when all arrhythmias were considered together, IPC did not 
alter the duration of these arrhythmias (p=0.7). When IPC was accounted for 
uraemia was still associated with a reduction in total duration of arrhythmias 
when compared to control fed animals (p=0.003). 
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Experiment - C Sham IPCx1 SNx IPCx1 p
Duration of preconditioning arrhythmias (secs)
Time to develop first arrhythmias during i25 (secs)
Duration of i25 arrhythmias (secs)
Duration of cardiac arrest during i25 (secs)
Total duration of all arrhythmias (secs)
97 (38.5-160) 42 (29-99) 0.46
390 (300-480) 280 (195-365) 0.53
5 (0-38.5) 12 (3-27.5) 0.71
0 0
17.5 (9.5-48.5) 26.5 (12-36.25) 0.78
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Experiment - B Ad Ad IPCx3 p
Duration of preconditioning arrhythmias (secs)
Time to develop first arrhythmias during i25 (secs)
Duration of i25 arrhythmias (secs)
Duration of cardiac arrest during i25 (secs)
Time to develop first reperfusion arrhythmias after i25 (secs)
Duration of reperfusion arrhythmias (secs)
Total duration of all arrhythmias (secs)
na 30.25 (7-50)
362 (150-442.5) 150 (150-720) 0.94
12 (4.5-40.5) 0 (0-9.5) 0.05
0 (0-13) 0 (0-0.25) 0.43
27 (2-30.5) 25 (5-26) 0.61
3 (0-16) 0 (0-2) 0.06
 15 (9-29) 14 (6.5-22.5) 0.62
(d) (e) (f)
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Experiment - D Control Control IPCx1 Adenine Adenine IPCx1 p
Duration of preconditioning arrhythmias (secs)
Time to develop first arrhythmias during i25 (secs)
Duration of i25 arrhythmias (secs)
Duration of Asystole during i25 (secs)
Time to develop first reperfusion arrhythmias after i25 (secs)
Duration of reperfusion arrhythmias (secs)
Total duration of all arrhythmias (secs)
na 132 (103-305) na 15 (7-60) 0.001
260 (180-312) 234 (39.8-372) 380 (312.5-435) 109 (20-198) 0.01
87 (47-128) 3 (0-7) 16 (4-53) 0 (0-4) 0.0007
18 (13-147) 0 (0-1) 0 (0-0) 0 (0-0) 0.0001
25 (10-32) 27 (10-34.5) 21 (19-21) 15 (7-21) 0.5
15 (9-22) 9 (0-17) 5 (0-15) 0 (0-7) 0.02
37 (13-101) 15 (4-83) 15 (7-26.5) 8 96-34.75) 0.03
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Figure 34 – Arrhythmia suppression in AD model (experiment B), comparison of the effects of 
IPC between sham operated control and SNx animals (experiment C), and arrhythmia 
suppression in the WO model (experiment D). 
(a) Box and whisker plot indicating a reduction in the duration of ischaemic arrhythmias occurring 
during the index ischaemic episode (i25). (b) The duration of reperfusion arrhythmias was reduced 
following IPC, the reduction was of borderline statistical significance (p=0.06). (c) The total 
duration of arrhythmias was similar for both IPC and control groups. (d) Arrhythmias induced by 
the preconditioning protocol were similar for both groups. (e) Total duration of arrhythmias 
occurring during the 35 min index ischaemic episode was similar for both groups (f). 
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5.1 Background.
Ischaemic preconditioning is of limited clinical utility as access to the target 
vascular territory is required. Clinical scenarios in which this is possible are 
relatively few. More importantly the timing of the ischaemic event for which 
protection is desired must be known in advance. Therefore, as a strategy to 
prevent or attenuate injury resulting from ischaemia-reperfusion ischaemic, 
ischaemic preconditioning is only useful in the setting of elective surgical (e.g. 
coronary artery bypass grafting) or interventional radiological/ cardiological 
procedures (e.g. percutaneous coronary intervention). 
 
Following Murray and colleagues discovery of ischaemic preconditioning, 
Przyklenk et.al,245 again using a canine model of myocardial ischaemia-
reperfusion injury (IRI), discovered that vascular beds adjacent to the 
preconditioned territory, that had not experienced ischaemia-reperfusion, so 
called ‘virgin’ myocardium, were also rendered resistant to IRI. 245 Repeated brief 
occlusions of the circumflex artery resulted in a reduction in the size of 
myocardial infarct induced by subsequent LAD occlusion. Originally described as 
regional ischaemic preconditioning, it was later determined that myocardial 
protection could be induced as a result of the exposure of distant organs (e.g. the 
kidneys) and vascular beds (mesenteric)246 to brief episodes of ischaemia thus this 
alternative form of ischaemic conditioning was subsequently termed remote 
ischaemic preconditioning (RIPC). Later it was shown, in the rabbit hind limb, that 
a combination of partial occlusion of the femoral artery and pacing of the 
gastrocnemius muscle of the same leg could be used as a strategy to induce 
remote ischaemic preconditioning.247 Partial occlusion or pacing alone did not 
reduce infarct size, possibly because the supply-demand balance was not 
sufficiently altered to induce RIPC. However, this observation paved the way for 
further experiments, which demonstrated that total limb ischaemia, achieved by 
the application of a tourniquet, could reduce the severity of reperfusion 
arrhythmias through the induction of RIPC. Finally Kharbanda et al showed in 
humans that an ordinary blood pressure cuff, inflated to supra-systolic pressure, 
improved the response to acetylcholine in the contra-lateral arm following 15 min 
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of ischaemia.248 This method of inducing RIPC promises to be highly practicable 
in a variety of clinical settings. 
 
5.1.1 Mechanism+of+RIPC+I+humoral+triggers+
The requirement for a period of reperfusion of the remote organ or vascular bed 
prior to the episode of test ischaemia has suggested the need to ‘wash-out’ a 
factor from the ischaemic tissue which is then transported in the systemic 
circulation and renders all other organs and tissue resistant to subsequent 
ischaemic insults.246 Further evidence for a humoral factor has been supplied by a 
number of elegant experiments. Firstly, blood249 and coronary effluent250 taken 
from preconditioned animals or isolated perfused hearts (respectively) is capable 
of inducing a preconditioned phenotype when administered to non-
preconditioned animals or hearts, suggesting the transfer of a factor or factors in 
both the blood and coronary effluent.249-251 Interestingly, there was no difference 
in the concentration of either norepinephrine or adenosine in the coronary 
effluent from preconditioned hearts compared with control hearts,250 suggesting 
that neither of these two molecules is responsible for triggering RIPC. Secondly, 
isolated perfused hearts from animals that have undergone RIPC in vivo have 
smaller infarcts than controls. Although these observations may be explained by 
induction of the preconditioned phenotype via a neuronal mechanism before the 
hearts were excised. Konstantinov et al252 demonstrated in a porcine model that 
remote limb preconditioning was capable of reducing myocardial infarct size in 
pigs with denervated donor hearts. However, this data does not exclude the 
possibility of an afferent neural signal mediating the release of a second 
messenger into the systemic circulation. Despite extensive investigation, the 
identity of the putative humoral factor/s remains elusive. Using a proteomic 
method, Lang et al253 identified 3 peptides which were up regulated and one 
peptide which was down regulated in animals which either received 3 cycles of 
cardiac preconditioning (5 min ischaemia, 5 min reperfusion) or a single cycle (10 
min ischaemia, 20 min reperfusion) of renal remote ischaemic preconditioning. 
The 3 up-regulated peptides were identified as fragments of albumin and the 
down regulated peptide as liver regeneration-related protein (LRRG03). Thus the 
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authors concluded that if a humoral trigger of RIPC does exist, its molecular 
weight must be <8kDa. In a similar study, Serejo et al254 identified temperature 
sensitive hydrophobic substances, >3.5 kDa, in the coronary effluent from 
preconditioned rat hearts that conferred myocardial protection through the 
activation of protein kinase C. 
 
A number of other studies have investigated the possibility that endogenous 
substances such as adenosine,255 bradykinin,256 opioids,257 calcitonin gene related 
peptide (CGRP)258and endocannabinoids259 might trigger remote ischaemic 
preconditioning either as a result of entry into the systemic circulation or via the 
stimulation of an afferent neural pathway. 
 
5.1.1.1 Opioids 
Naloxone, a non-specific opioid receptor antagonist, has been shown to abolish 
the protective effects of RIPC induced by intestinal ischaemia. Similarly, Dickson 
et al251 found that the bowel could be protected from ischaemia reperfusion injury 
through the application of a concentrate derived from the coronary effluent of 
preconditioned rabbit hearts, but this too was abrogated by naloxone. There are 
conflicting reports regarding which opioid receptor is responsible for trigerring the 
protective effect of RIPC, some investigators have suggested the δ1 receptor,
260 
whilst others have implicated the kappa receptor.261 
 
5.1.1.2 Endocannabinoids 
As with IPC, endocannabinoids acting via cannabinoid receptor 2 (CB2) receptor 
have been implicated in trigerring the response to remote ischaemic 
preconditioning. Pre-treatment with a CB2 antagonist (AM630), prior to a single 
cycle of preconditioning to the mesentery was seen to eliminate the cardio-
protective effects of mesenteric RIPC.259 
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5.1.1.3 Bradykinin 
The specific bradykinin B2 antagonist, HOE140 has been shown to prevent RIPC 
(induced by mesenteric ischaemia) of the heart. Additionally, administration of 
bradykinin into the mesenteric circulation was shown to confer cardio-protection 
in a hexamethonium sensitive manner.256 Wolfrum and colleagues262 
demonstrated that an RIPC protocol of the mesentery was associated with a 
reduction in the cardiac protein kinase C-epsilon (PKCε) cytosolic/particulate ratio 
(indicative of activation of PKCε). Infusion of bradykinin was associated with a 
similar degree of activation of PKCε and that activation of PKCε by RIPC could be 
abolished by the application of both HOE140 and hexamethonium. Taken 
together this data suggests that PKCε activation may be positioned down stream of 
both bradykinin and the neural pathway. 
5.1.1.4 Calcitonin gene-related peptide (CGRP) 
Another potential trigger of RIPC is the neurotransmitter calcitonin gene-related 
peptide (CGRP). CGRP is released from capsaicin sensitive nerve fibres in 
response to nitric oxide (NO) and has been implicated in both IPC and RIPC. 
Mesenteric RIPC is associated with a detectable rise in blood levels of CRGP. 
Pretreatment of rabbits with capsaicin, 4 days before undergoing a single cycle of 
mesenteric RIPC attenuated infarct size reduction and prevented an increase in 
blood CGRP levels associated with RIPC alone.258 Moreover capsaicin 
pretreatment was found to have a similar effect on the late phase of RIPC.263 
 
5.1.2 Evidence+for+a+systemic+antiIinflammatory+response.+
A number of studies, both in humans and animal models, have demonstrated a 
favourable impact of RIPC on a number of gene products involved in cytokine 
synthesis, leukocyte chemotaxis, adhesion and migration, exocytosis, innate 
immunity, signalling pathways and apoptosis.264,265 However, whilst this effect of 
RIPC is probably important in the second window of protection (SWOP) induced 
by RIPC, its relevance to the early preconditioning response is at present unclear. 
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5.1.3 Neural+pathway+
The first study to demonstrate inter-organ protection with RIPC was also the first 
to propose a neuronal mechanism in conveying the RIPC stimulus. Observing that 
the cardio-protective effect of RIPC of the mesentery could be abolished by the 
ganglion blocker hexamethonium.246 It was later reported that resection of the 
renal nerve prevented conditioning of the kidney from attenuating cardiac 
ischaemia-reperfusion injury.266 Similarly Dong et al267 demonstrated that 
resection of the femoral nerve also resulted in the failure of RIPC of the rat hind 
limb to reduce myocardial infarct size.  
 
The neural pathway hypothesis has been further elaborated by the proposal that 
endogenous compounds released from the ischaemic organ or tissue might 
stimulate afferent nerve fibres which convey the RIPC signal to the target organ by 
way of efferent nerve fibres. Evidence to support this hypothesis came from 
studies examining the role of adenosine in RIPC. Firstly, administration of the 
non-selective adenosine receptor antagonist 8-sulphophenyltheophylline (8-SPT) 
prior to an RIPC protocol could prevent the reduction in myocardial infarct size 
seen with RIPC.255 Subsequently it was shown that administration of 8-SPT after 
the RIPC protocol also eliminated cardioprotection,268 suggesting that stimulation 
of cardiac adenosine receptors was also required in order to manifest the 
cytoprotective effects of RIPC. The authors used their finding of elevated blood 
adenosine levels in blood samples from the carotid artery of rabbits that received 
RIPC compared to IPC as supporting evidence for this hypothesis. 
 
As suggested by Goto et al in relation to IPC; it seems likely that there is multiple 
redundancy with respect to the triggering of RIPC with both a neural and humoral 
mechanism. When both mechanisms are intact then the threshold for induction of 
protection is exceeded earlier. However, if the neuronal pathway is blocked, 
protection may still be achieved by increasing the RIPC stimulus, through 
increasing the duration of ischaemia269 or the metabolic mass preconditioned. 
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5.1.4 Signal+transduction+in+RIPC+
In contrast to triggers of RIPC, there is limited data regarding the mechanism of 
signal transduction. 
 
5.1.4.1 Protein Kinase C (PKC) 
PKCε is thought to play a critical role in mediating the protective effect of IPC, 
Wolfrum and colleagues have also demonstrated a potential role for PKCε 
activation in RIPC. PKCε was found to be activated in response to bradykinin 
release from the distant organ and myocardial infarct size reduction associated 
with RIPC could be obviated by the PKC inhibitor chelerythrine.262 Weinbrenner 
et al obtained similar results in a rat model of infra-renal aortic occlusion (IOA); 
cardioprotection induced by IOA was PKC dependent. Furthermore, they were 
able to demonstrate a dose response relationship between the duration of IOA 
and the degree of myocardial protection. However, unlike many other studies, 
hexamethonium could not abolish the protection induced by the ‘highest dose’ of 
RIPC stimulus (15 min IOA, 10 min reperfusion).269 
 
5.1.4.2 Mitogen Activated Protein Kinases (MAPK) 
Several MAP kinases are thought to play a key role in the signalling cascades that 
mediate IPC. The role of MAP kinases in RIPC remains largely undetermined; 
administration of specific MAP kinase inhibitors SB203580, PD98059 and 
SP600125, which inhibit p38 MAPK, ERK1/2 and JNK1/2 respectively, prior to an 
RIPC protocol involving the mesenteric artery, appears to abolish the protection 
expected from RIPC.270 However, the same authors did not detect increased 
phosphorylation of the same MAPK in the myocardium following RIPC, whereas 
an increase in the phosphorylated forms of both ERK1/2 and JNK1/2 was seen 
following IPC of both the heart and mesentery. This data suggests that unlike IPC 
the MAPK may not play a direct role in transduction of the RIPC signal but 
perhaps have a significant role in the triggering of RIPC. The natural extension of 
Heidbreder and colleagues’ work would have been to administer the inhibitors 
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following the mesenteric ischaemia before coronary artery occlusion and see if 
protection was still abrogated. 
 
5.1.4.3 ATP gated potassium channels 
The current paradigm of IPC mediated protection is thought to involve the 
opening of ATP gated potassium channels in the sarcolemma and in particular, 
the mitochondrial membrane. Opening of these channels results in the generation 
of reactive oxygen species leading to either the activation of pro-survival kinases 
or inhibition of mitochondrial permeability transition and thus cytoprotection. 
Pharmacological blockade of KATP channels with 5-hydroxydecanoate (5-HD) 
prevents the infarct size limiting effect of a single cycle of renal preconditioning 
(10 min ischaemia, 10 min reperfusion)255 and a single cycle (15 min ischaemia, 
10 min reperfusion) of bilateral femoral preconditioning.271 Similar results were 
reported by Konstantinov et al252 in their model of orthoptic porcine heart 
transplant; four cycles (5 min ischaemia, 5 min reperfusion) of hind limb 
preconditioning resulted in significant myocardial protection which was 
prevented by pretreatment with glibenclamide. Likewise, in the isolated perfused 
rat heart model, administration of glibenclamide and 5-HD following the RIPC 
protocol but before the index ischaemia of the target organ, also abolished 
protection. The administration of diazoxide (a potassium channel ‘opener’) 
afforded similar protection to RIPC.272 Taken together these data suggest that intact 
potassium channel function in the target organ is required for RIPC induced 
protection. Moreover, potassium channels may be part of the ‘memory’ 
mechanism associated with RIPC as evidenced by the sustained protection 
conferred by diazoxide pretreatment. 
 
5.1.4.4 Nitric Oxide (NO) 
NO plays a central role in both early and delayed IPC. Inhibition of nitric oxide 
synthase with L-NAME has been shown to abrogate both early271 and late 
protection263 induced by RIPC. Furthermore, it appears not to be possible to limit 
infarct size through RIPC in inducible nitric oxide synthase knockout (iNOS-/-) 
mice.273 However, there are some conflicting reports.274 Infusion of L-arginine, the 
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substrate for nitric oxide synthase (NOS) has also shown to be protective and this 
protection can be abolished by concomitant administration of the potassium 
channel blocker 5-HD.271 
 
5.1.4.5 Reactive Oxygen Species (ROS) 
ROS are a twin edged sword in ischaemia-reperfusion injury. Whilst an excess of 
ROS is thought to be injurious, they are also vital signalling molecules. 
Weinbrenner et al260 demonstrated abolition of the infarct sparing effect of both 
classical and remote ischaemic preconditioning by N-2-mercaptopropionyl 
glycine (MPG). Shahid and colleagues271 have reported similar results with the 
free radical scavenger N-Acetyl Cysteine (NAC), which they found to attenuate 
the myocardial protection afforded by a single cycle of bilateral femoral artery 
occlusion (15 min ischaemia, 10 min reperfusion). They went on to show that 
diazoxide (a potassium channel opener) induced cardioprotection could also be 
abrogated by NAC, suggesting that the protection afforded by diazoxide was 
dependent upon ROS generation. 
 
5.1.4.6 Hypoxia inducible factor-1 alpha 
The transcription factor HIF-1α has also been implicated in remote ischaemic 
preconditioning. Working with an isolated perfused heart model, Kant and 
colleagues275 were able to reduce the size of myocardial infarction induced by 30 
min of global ischaemia. This was achieved by either renal preconditioning, 
consisting of four cycles of 5 min ischaemia 5 min reperfusion, or pretreatment 
with the prolyl-hydroxylase 2 (PHD2) inhibitor Ethyl-3,4-dihydroxybenzoate 
(EDHB). 
 
5.1.4.7 The mitochondrial transition pore 
The effector of reperfusion injury and the target of IPC and ischaemic post 
conditioning (iPost) is thought to be the mitochondrial transition pore. 
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5.1.5 +Remote+ischaemic+preconditioning+in+humans+
Kharbanda and colleagues248 were the first to demonstrate the effects of RIPC in 
humans. Using the response to acetylcholine infusion, assessed by venous 
occlusion plethysmography. They demonstrated improved endothelial 
responsiveness following 20 min of ischaemia of the non-dominant upper limb in 
subjects that had undergone an RIPC protocol consisting of 3 cycles of 5 min 
ischaemia 5 min reperfusion in the contralateral arm. 
 
The first successful clinical study of RIPC in humans was reported by Cheung et 
al.276 Employing 4 cycles of lower limb preconditioning with a blood pressure cuff 
inflated to 15 mmHg above the systolic arterial pressure they observed a 
significant reduction in postoperative troponin I (TnI) rise, inotrope requirements 
and airways resistance in children undergoing cardiopulmonary bypass (CPB) for 
the repair of congenital heart defects. 
 
Similar results were subsequently reported by Hausenloy et al;277 in a cohort of 
adult patients undergoing coronary artery bypass grafting they observed a marked 
reduction in the area under the curve for Troponin T (TnT) in patients receiving 
RIPC (three 5 min cycles of preconditioning of the upper limb using a BP cuff). 
 
A larger study conducted in the setting of elective repair of abdominal aortic 
aneurysm (AAA)278 has also demonstrated a beneficial effect of RIPC. Myocardial 
injury (defined as TnI >0.40 ng/mL), myocardial infarction and renal impairment 
(defined by a peak serum creatinine >177 µmol/L) were reduced by between 1/4 
to 1/5 following two cycles of 10 min iliac artery occlusion, 10 min reperfusion, 
performed sequentially. 
 
More recently a secondary analysis of two randomised controlled trials observed a 
substantial reduction in the risk of acute kidney injury (AKI) following coronary 
artery bypass grafting in patients who underwent an RIPC protocol.279 
 
Perhaps the most exciting demonstration of the utility of RIPC in a clinical setting 
was that reported recently by Botker et al. 280 In a study comprising 333 adults 
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presenting with a suspected first acute myocardial infarction 166 were randomly 
assigned to receive RIPC as an adjunct to primary percutaneous coronary 
intervention. RIPC, consisting of 4 cycles of intermittent arm ischaemia (for 5 min) 
with 5 min reperfusion, was delivered in the ambulance whilst the patient was 
conveyed to hospital. RIPC was associated with a 37% increase in the salvage 
index (the reciprocal of infarct size), as assessed by gated single photon emission 
CT (SPECT) at 30 days. In addition, RIPC appeared to confer the greatest benefit to 
those patients with the largest area at risk. 
 
However not all studies have demonstrated a benefit from RIPC.281 Clinical trials 
of RIPC, with a few exceptions, have largely been hampered by their small scale 
(few studies have enrolled more than 100 participants), short-term follow-up and 
by being underpowered to demonstrate differences in important clinical 
outcomes. 
 
5.1.6 The+effect+of+coImorbidity+on+remote+ischaemic+preconditioning+
To date; the majority of studies of RIPC have examined the nature of the stimulus 
which triggers protection. In contrast to classical and post conditioning, the effect 
of comorbidity on remote ischaemic preconditioning has not previously been 
investigated. 
5.2 Aim.
To assess the effect of chronic uraemia (induced by subtotal nephrectomy) on 
infarct size reduction by remote ischaemic preconditioning 
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5.3 Methods.9.Remote.preconditioning:..
Basic surgery and LAD ligation was carried out as previously described (pg 105).  
 
Following tracheostomy, cannulation of the internal jugular vein and carotid 
artery and thoracotomy with positioning of the suture to include the LAD, the left 
femoral artery was carefully dissected out and separated from the vein and nerve. 
A ligature was placed around the artery to assist in mobilisation. The femoral 
artery was occluded using a micro-vessel clip for 5 min. Ischaemia of the left hind 
limb was confirmed by pallor and reduced temperature of the paw. Reperfusion 
was signalled by hyperemia (of the toe pads) followed by restoration of normal 
colour and temperature. Three cycles of 5 min ischaemia followed by 5 min 
reperfusion of the left hind limb were employed. On completion of the third of 
cycle ischaemia-reperfusion (of the hind limb), the LAD was occluded for 25 min 
and reperfused for 120 min at the end of which the LAD was re-occluded, Evan’s 
blue dye injected and the heart excised for determination of infarct size, as 
previously described (pg 115). 
 
Blood samples were taken 15 min after the animals were placed on mechanical 
ventilation (for ABG analysis and biochemistry), immediately prior to the 
occlusion of the LAD (for ABG analysis) and at the end of the reperfusion period 
(for ABG analysis). 
 
Recordings of blood pressure and heart rate were made and subsequently 
analysed for evidence of arrhythmias as previously described (pg 176). 
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5.4 Results.–.Remote.ischaemic.preconditioning.
5.4.1 Arrhythmia+suppression+with+RIPC+
In contrast to IPC, the anti-arrhythmic effects of RIPC are not well described. It 
was hypothesised that RIPC would have a similar suppressive effect on ischaemia-
reperfusion induced arrhythmogenesis as IPC. 
 
The anti-arrhythmic effect of RIPC was examined. The definition of arrhythmia 
was as previously described (pg 176). 
 
Employing a 2-way ANOVA, a non-significant (p=0.099) trend towards a 
reduction in the duration of cardiac arrest was observed for the RIPC groups (see 
Figure 35). Given the relatively small sample size this result may be subject to 
type II error (failure to reject the nul hypothesis when it is infact false). 
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Figure 35 – Effect of RIPC on the duration of cardiac arrest. A non-significant trend towards 
reduced duration of cardiac arrest was seen in animals receiving RIPC. 
No difference in the timing of the onset of the first ischaemic arrhythmia (during 
i25), the duration of first ischaemic arrhythmia, the time to onset of reperfusion 
arrhythmias, the duration of arrhythmias during ischaemia or the total duration of 
all arrhythmias was found (see Figure 36). 
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Arrhythmia suppression by RIPC Sham Sham + RIPC SNx SNx + RIPC p
Time to first ischaemic arrhythmia
Duration of ischaemic arrhythmias
Duration of cardiac arrest
Time to first reperfusion arrhythmia
Duration of reperfusion arrhythmias
Total duration of ischaemic arrhythmias
Total duration of ischaemic arrhythmias
300 (260-343) 272 (223-350) 293 (243-370) 325 (279-454) 0.65
66 (33.5-131) 77 (27.5-103) 34 (22-120) 41 (14.5-74) 0.75
21 (0-34.5) 0 (0-1.5) 0 (0-2) 0 (0-1.5) 0.06
22 (18-30) 26 (18.5-35) 21 (20-24) 17.5 (16.3-21) 0.34
15 (8.5-21.5) 14 (7-17) 8 (7-19) 11 (5.5-13) 0.45
87 (37.5-190) 80 (27.5-103) 34 (22-122) 41 (14.5-75.5) 0.43
99 (45-221) 94 (44.5-110) 42 (30-142) 52 (25.5-83) 0.4
 
Figure 36 – Arrhythmia suppression by remote ischaemic preconditioning of the hind limb.  
No differences were seen in; (a) time to first ischaemic arrhythmia (i25), (b) duration of i25 arrhythmias, (c) total duration of ischaemic arrhythmias, (d) time to 
reperfusion arrhythmias, (e) duration of reperfusion arrhythmias or (f) total duration of all arrhythmias. Table shows p values from one-way ANOVA (Kruzkal-Wallis test). 
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5.4.2 Infarct,Size:,
There was a significant reduction in myocardial infarct size in both sham and SNx 
animals that underwent remote ischaemic preconditioning of the hind limb with 
three cycles of 5 min ischaemia and 5 min reperfusion (sham - RIPC 22.1% vs. 
sham - control 47.2% and SNx - RIPC 33.2% vs. SNx - Control 63.3%, 
respectively, p<0.001). 
 
Using 2 way ANOVA with Bonferroni post-test comparison, uraemia was not 
found to affect the ability of RIPC to reduce infarct size, no interaction between 
uraemia and RIPC was demonstrated (p=0.572), with the extent of the protection 
achieved with RIPC was comparable between the two groups (47.6% relative 
reduction [RR] in SNx animals, p=<0.001, 53.2% RR, sham animals, p=<0.01, 
see Figure 38a). However, uraemia was observed to significantly increase infarct 
size with a 25% relative increase in infarct size in uraemic animals (median 
infarct size in sham control group 47.2% [39.8 − 63.7%] vs. SNX control 63.3% 
[54.5 − 70.2%], p=0.026), corroborating the results of earlier experiments using 
the SNx model. The AAR was similar for all groups (see Figure 36d). 
 
5.4.2.1  Haemotological, biochemical and physiological variables 
 
The median creatinine for the SNx group was 3 fold higher than the sham group 
(90.70 µmol/L [83.6 − 138.7] vs. 34.0 µmol/L [32.5 − 36.0]) and the SNx group 
were significantly more anaemic, baseline mean haematocrit 28% (±5%) in the 
SNx group compared with 38.3% (±4.3%) in the sham group (see Figure 39e & f). 
 
For reasons that are not apparent there was a marked and highly significant 
difference in the baseline pO2 between both the control groups and both the 
intervention (RIPC) groups (Sham 22.8 kPa [20.9 − 60.4], Sham - RIPC 13.3 kPa 
[12.3 − 15.35], SNx 56 kPa [27.1 − 63.2], SNx - RIPC 15.7 kPa [12.6 − 19.55], 
p=0.0002), However, no statistically significant differences were observed at 
subsequent time points, including pre-occlusion (see Figure 37).  
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Figure 37 – pO2 for RIPC experiment. 
A marked difference in PO2 was seen at baseline (p=0.0002). However, there was no difference at 
subsequent time points. 
 
pH (Figure 38b), pCO2 (Figure 38c) and base excess (Figure 38f) were comparable 
between the groups. Mean arterial BP (MAP), heart rate (HR) and pressure rate 
product (PRP) were comparable for all groups (Figure 39a, b and c). 
 
RIPC Sham Sham + RIPC SNx SNx + RIPC p 
Animals (n)
Weight (g)
Haematocrit (%)
Creatinine (µmol/l)
Area at risk (%)
Infarct size (%)
12 6 15 9
430 [391-450] 391 [373-403] 380 [370-395] 300 [288-320] < 0.0001
39.0 [36.3-41.0] 39.5 [ 35.5-43.3] 27.0 [24.0-29.0] 30.0 [26.8-35.0] < 0.0001
34.4 [33.4-35.7] 31.4 [22.9-40.2] 89.8 [83.5-106] 107 [85.6-205] < 0.0001
50.9 [43.5-56.2] 40.5 [31.5-48.9] 44.6 [42.1-51.1] 42.9 [38.8-49.0] 0.116
47.2 [39.8-63.7] 22.1 [16.1-30.4] 63.3 [54.5-70.2] 33.2 [20.4-44.1] <0.0001
 
Table 10 - Hind limb RIPC provides protection against myocardial infarction in uraemic rats. 
Median [IQR]. 
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Figure 38 – Infarct size 
and ABG parameters. 
(a) Infarct size was 
significantly reduced by 
RIPC (RR 47.6% for SNx 
animals 53.2%). (d) AAR 
was similar for all groups. 
(b) pH, (c) pCO2 and (f) 
BE were similar for all 
groups. (e) Haematocrit 
was significantly lower in 
the SNx animals.
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Figure 39 – Biochemical, haematological and physiological variables for RIPC experiment. 
No significant differences in (a) MAP, (b) HR and (c) PRP were seen. Graphs show mean values 
with overlapping 95% CI. (d) The SNx animals that received RIPC were significantly lighter than 
the control group (SNx). (e) There was no significant difference in creatinine between the SNx 
groups (SNx and SNx –RIPC) or between the sham groups (Sham and Sham – RIPC). Haematocrit 
was lower for SNx animals (Graphs show median and IQR). 
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5.5 Discussion*
Although a trend towards a reduced length of cardiac arrest was seen in animals 
receiving RIPC, overall there appeared to be little effect of RIPC on ischaemia-
reperfusion induced arrhythmogenesis which was in marked contrast to the potent 
suppressive effect seen with IPC (see pg 178) and delayed RIPC induced by 
preconditioning of the kidney (see later pg 242). These findings may be subject to 
type II error, the sample size was similar to that used in the IPC experiements. 
However, as a general rule when employing a 2x2 factorial design, one should 
double sample size required for a 2-group design.282 
 
However, as the mechanism of arrhythmia suppression in IPC appears to be 
divorced from its cytoprotective effect,243 it is not inconceivable that RIPC, unlike 
IPC, may not provide protection against ischaemia-reperfusion induced 
arrhythmias. If this proved to be the case, it would have significant consequences 
for the effectiveness of RIPC to reduce mortality post AMI, particularly for patients 
with CKD/ ESRD who are recognized to have twice the risk of unexpected cardiac 
arrest.283 
 
Remote ischaemic preconditioning markedly reduced infarct size with a 
comparable effect to that seen in sham animals with normal renal function. This 
was despite a significantly greater degree of anaemia in the SNx animals, which 
might be predicted to impair oxygen delivery (VO2) and thus accentuate 
ischaemic injury. No difference in blood pressure was seen between SNx and 
sham animals (p=0.460). Studies carried out earlier to characterise the model 
suggest that; even in the absence of hypertension, the SNx animals will have left 
ventricular hypertrophy. These findings are consistent with the previous 
observations of the effect of chronic uraemia on infarct size reduction with 
classical preconditioning. 
 
 The effect of comorbidity on the efficacy of RIPC has not been previously 
investigated. This is the first report of the effect of chronic uraemia on myocardial 
infarct size reduction induced by remote ischaemic preconditioning. 
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The exciting results of the recently published clinical trial of remote ischaemic 
per-conditioning280 hold considerable promise for patients with CKD suffering an 
acute myocardial infarction. Botker et al reported an improvement in the salvage 
index for patients presenting with a first AMI, with the combination of primary PCI 
and remote ischaemic preconditioning compared with primary PCI alone (0.75 
[0.50–0.93] versus 0.55 [0.35–0.88], p= 0.033). Four cycles of RIPC (5 min 
ischaemia, 5 min reperfusion) were performed by inflating a blood pressure cuff 
on the upper arm whilst the patient was conveyed in the ambulance to the local 
cardiac centre. There was no difference in peak troponin-T concentration. 
However, troponin-T concentrations at 90–102 h after symptom onset were lower 
in the remote conditioning group than in the control group but did not reach 
statistical significance (median 1·66 µg/L, IQR 0·83–3·84 vs. 3·30 µg/L, 1·64–
5·49; p=0·06). Improved salvage index was mirrored by an earlier recovery of left 
ventricular ejection fraction (47% [39–54] versus 43% [36–51], p=0.022). A 
significant positive correlation was observed between area at risk and final infarct 
size in both the control (r2= 0·34, 95% CI 0·16–0·52, p<0·0001) and 
preconditioned (r2=0·36, 0·16–0·52, p<0·0001) groups. In the RIPC group, the 
slope of the regression line (0·34, 95% CI 0·27–0·41) was lower than in the 
control group (0·48, 0·41–0·55; difference 0·14, 95% CI 0·04–0·24, p=0·0080), 
suggesting that for a given area at risk, smaller infarcts were sustained by 
participants in the intervention group. 
 
The potential applications for RIPC to enhance the care of patients with CKD are 
many and varied. In light of my data and given the very limited risk associated 
with performing RIPC, I would hope to see a placebo controlled trial of RIPC as 
an adjunct to PCI and/ or coronary artery bypass grafting (CABG) in patients with 
CKD, with the prospect of conducting further studies in other elective settings.
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6 PHARMACOLOGICAL, PRECONDITIONING, USING, THE, HIF,
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6.1 Background*
Oxygen homeostasis is of critical importance to all eukaryotic organisms in order 
to maintain the production of compounds containing high-energy phosphate 
bonds (e.g. adenosine triphosphate) through oxidative phosphorylation and avoid 
cellular and nucleic acid damage by reactive oxygen species (ROS). The hypoxia 
inducible factors (HIF) are a family of three nuclear transcription factors (HIF-1, 
HIF-2 and HIF-3), which orchestrate the cellular response to hypoxia. The HIFs 
bind to a core DNA sequence (A/(G)CGTG) within the ‘hypoxia response element’ 
(HRE) of target genes.284 Hypoxia inducible factors are highly conserved across all 
metazoan species, even those without specialized cardio-pulmonary circulations, 
with >90% sequence homology between human, mouse and Rat HIF-1α. 
 
HIF-1 was originally identified as a result of the study of the transcriptional 
regulation of erythropoietin (EPO)285 but has subsequently been recognised to 
modulate the expression of hundreds of genes with functions as diverse as 
erythropoiesis, angiogenesis, vasomotor responses, cell proliferation and energy 
metabolism.286 However, these genes and their products share the common goals 
of increasing oxygen delivery and reducing cellular oxygen requirements thus 
restoring homeostasis. The particular genes that are regulated by HIF-1 vary 
according to cell type. 
 
HIF-1 is a heterodimer composed of two subunits, a constitutively expressed beta-
subunit (HIF-1β) and a regulated alpha subunit. Two further HIF isoforms have 
been identified; HIF-2α and HIF-3α. As with HIF-1α, both HIF-2α and HIF-3α are 
able to form heterodimers with HIF-1β.287 
 
Activation of the HIFs are implicated in the pathophysiology of a variety of human 
disease processes, from ischaemic/ hypoxic, neoplastic and metabolic diseases.288 
 
In contrast to HIF-1α, which is ubiquitously expressed by all cell types, HIF-2α 
displays a restricted pattern of expression. This diversity allows for variation in the 
response to hypoxia between various cell types engineered through the 
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differential expression of the alpha and beta subunits. The role of HIF-3α is less 
well understood, but it has been suggested that the alternative splice form of HIF-
3α binds to and inhibits transcriptional activity of HIF-1α.289 This may be an 
important negative feed back mechanism290 as, in contrast to HIF-1α and HIF-2α, 
transcription of HIF-3α is rapidly induced by hypoxia. 
 
Mice with the conditional deletion of both HIF-1α and HIF-2α have been 
generated to study their independent biological roles.291 These models suggest that 
HIF-1α may regulate many of the adaptive glycolytic metabolic responses to low 
oxygen. Whereas HIF-2α may play a larger role in regulating Epo expression and 
may be involved in embryonic stem cell biology.292,293
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6.1.1.1 Regulation of HIF 
Oxygen and HIF are tightly regulated, the mechanisms through which the actions 
of HIF are regulated are complex and our understanding of them is continually 
and rapidly changing. The regulation of HIF-1 is best described and understood. 
 
HIF-1 accumulates instantaneously under hypoxic conditions294 and is degraded 
rapidly upon re-oxygenation with a half-life, in vitro, of under 5 min.295 The 
kinetics of HIF-1 expression varies considerably between tissues; maximal 
expression is seen within the liver and kidney within 1 hour of exposure to 
hypoxia. In contrast, maximal expression in the brain is seen after 5 hours.296 
 
There are two principal mechanisms through which HIF-1 is regulated: 
1) The abundance of the HIF-1 heterodimeric transcriptional complex is 
regulated via the oxygen dependent degradation of the alpha subunit (HIF-
1α). 
2) Transcriptional activity of the HIF-1 heterodimer is also regulated in an 
oxygen dependent manner by factor inhibiting HIF-1 (FIH1). 
6.1.1.1.1 Oxygen*dependent*regulation*of*HIF*
6.1.1.1.1.1 Proline+hydroxylation+
Regulation of HIF is dependent upon proline hydroxylation to identify the protein 
targeted for destruction. 
 
The oxygen dependent proteolysis of HIF-1α is mediated by ubiquitination and 
carried out by the 26S proteosome. Hydroxylation of specific proline residues 
(positions 402 and/ or 564) contained in what is termed “the oxygen degradation 
domain” (ODD) constitutes the rate-limiting step in the degradation of HIF1-α.297 
This reaction is performed by a family of prolyl-4-hydroxylase enzymes (PHD1,2, 
and 3), bearing a conserved 2-histidine-1-carboxylate iron co-ordination motif. 
Proline hydroxylation promotes the binding of the Von Hippel-Lindau tumour 
suppressor protein (pVHL), which serves as the substrate recognition component 
for a ubiquitin-E3-ligase complex. These enzymes are similar to collagen prolyl-4-
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hydroxylases (C-P4Hs) in that they display preservation of three critical Fe2+ 
binding residues.298,299  
 
These enzymes utilise Fe2+, ascorbate and 2-oxoglutarate (alpha-ketoglutarate) as 
co-factors and display an absolute requirement for oxygen (O2). The three PHDs 
show 42-59% homology with each other. The PHD family has a highly conserved 
region responsible for co-ordinating the binding of iron within the active site. 
However, unlike haem-containing proteins, the Fe(II) in 2-oxoglutarate-dependent 
oxygenases (Both the PHDs and FIH1) can be chelated or substituted by Co(II) of 
Ni(II), rendering the enzyme inactive.300 This explains the long recognised 
property of cobalt and nickel salts as ‘hypoxia mimetics’.301 Most importantly, 
these prolyl hydroxylases have a relatively high Km for O2, which is slightly above 
atmospheric concentration, such that O2 is rate-limiting of their enzymatic activity 
under physiological conditions, this property permits these enzymes to act as 
‘oxygen sensors’.302 PHD2 activity primarily determines HIF-1a stabilisation303 and 
is required for embryonic development. 
 
6.1.1.1.1.2 The+Von+Hippel7Lindau+Tumour+Suppressor+Protein+(pVHL):+
Von Hippel-Lindau (VHL) Disease is an autosomal dominant inherited cancer 
syndrome characterised by the predisposition to develop highly vascularised 
tumours of the central nervous system, kidney, retina, pancreas, and adrenal 
gland and associated with mutations in the VHL gene, which result in loss of 
functional von Hippel-Lindau tumour suppressor protein (pVHL). Tumours 
derived from patients with VHL disease display a hypoxic phenotype with 
upregulation of vascular endothelial growth factor (VEGF) and erythropoietin 
(Epo). Maxwell and colleagues first described the interaction of pVHL with HIF-
1α.304 
 
The von Hippel-Lindau (pVHL) tumour-suppressor protein forms a heterotrimer 
with elongin B and C (VBC).305 pVHL contained within this ternary complex binds 
to hydroxylated Pro-564306 of the oxygen degradation domain (ODD) of HIF-1α. 
Additional proteins; cullin 2 (Cull2)307 and Ring box-1 (Rbx1)308 are recruited to 
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form a stable multimeric complex with E3 ubiquitin-protein ligase activity.309 This 
complex is capable of interacting with E1 and E2 enzymes and thereby facilitates 
poly-ubiquitination of HIF-1α310 and thus ear mark it for proteosomal destruction. 
 
Mutations in VHL are also associated with the majority (80%) of sporadic clear 
cell renal carcinomas (RCC).311 Many of these mutations disrupt the stability of the 
VBC complex.312 
 
In the absence of functional pVHL, the efficiency of proteosomal degradation of 
HIF-1α is significantly attenuated such that its half-life (in vitro) is increased more 
than 10 fold from ~5 min to ~60 min.304 
 
6.1.1.1.1.3 Factor+inhibiting+HIF+(FIH)+
A further, complementary, regulatory mechanism involves a second hypoxia-
sensing region, which functions as a hypoxia-inducible transactivation domain. 
Termed the carboxyl-terminal activation domain (CAD), it lies within a region of 
100 amino acids from the carboxyl-terminus of both HIF-1α and HIF-2α.313 
Asparagine residues at positions 803 (HIF-1α) and 851 (HIF-2α) are hydroxylated 
by an iron(II)-2-oxoglutarate-dependent dioxygenase.313  
 
When in solution it is thought that the CAD domain of both HIF-1 and HIF-2 is 
largely unstructured. Binding with p300 is associated with a conformational 
change of the CAD to form 3 alpha-helices. It is predicted that hydroxylation of 
Asn803 would interfere with binding to p300 and thus prevent transactivation.314 
 
Under hypoxic stress FIH, which as an iron(II)-2-oxoglutarate-dependent 
dioxygenase and displays an absolute requirement for dioxygen (O2) as a cofactor, 
fails to oxidise Asn803 (Asn851 in HIF-2α). Which in turn, permits the binding of 
HIF to the central integrating co-activator p300/CBP, via its cysteine/ histine rich 
domain (CH1) with the HIF-1α CAD and the recruitment of the accessory 
coactivators.315,316
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6.1.1.1.2 Oxygen*independent*regulation*of*HIF*
6.1.1.1.2.1 Receptor+ for+ Activated+ C7kinase+ 1+ (RACK1)+ and+Heat+ Shock+ Protein+ 90+
(HSP90)+
The competitive binding between RACK1 and HSP90 for the PAS-A domain of 
HIF-1a forms the cornerstone of an oxygen independent degradation pathway for 
HIF-1α.317 
 
RACK1 was originally identified as an anchoring protein for activated protein 
kinase C.318 However it is now understood to perform several other additional 
roles in such diverse biological processes as intracellular signal transduction319 
and assembly of the 80S ribosome from 40S and 60S subunits.320 
 
Using proteomic methods, Liu et al317 identified a novel interaction between HIF-
1α and RACK1. Co-transfection experiments demonstrated a marked reduction in 
HIF-1a expression with increasing RACK1 expression. They went on to determine 
that RACK1 was capable of recruiting Elongin C (the first component of the E3 
ubiquitin ligase complex) in an oxygen, PHD and VHL independent manner and 
facilitate ubiquitination. Whilst on the surface this would appear to be less 
efficient than having dedicated binding domains, as by chance only 50% of 
interactions will be HIF-1a:RACK1:RACK1:Elongin C, it allows for a further level 
of regulation. Phosphorylation of RACK1 favours homodimer formation 
conversely dephosphorylation by calcineurin inhibits dimerization.321 
 
HSP90 is a key member of a family of proteins (the heat shock proteins) which 
serve as molecular chaperones and through their ATPase activity prevent protein 
misfolding and other nonfunctional side reactions such as nonspecific 
aggregation. Thus in the broadest sense they act to maintain the stability of their 
client proteins.322 Binding of HSP90 to the PAS-A domain of HIF1-α protects it 
from RACK1 mediated degradation and thereby allows it to bind to CBP/P300. 
The HSP90 inhibitors, and potential anti-neoplastic agents, geldanamycin and 17-
allylaminogeldanamycin (17-AAG) compete with ATP for binding to HSP90 
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disrupting the interaction of HSP90 with HIF-1α323 resulting in enhanced RACK1 
dependent, proteosomal destruction of HIF-1α.
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6.1.1.1.3 Non;hypoxic*regulation*of*HIF*
Ischaemia is not only associated with the restricted availability of oxygen but also 
the other key substrates for energy metabolism namely glucose and of lesser 
importance fatty acids and ketone bodies. Therefore, it is logical to assess the 
impact of glucose deprivation on HIF activity. 
 
HIF-1α and HIF-1β mRNA levels, in the cerebral cortex, hypothalamus, lung, 
heart, liver and kidney, appear not be affected by the availability of glucose.324 In 
contrast, HIF-3α appears to be markedly upregulated at the transcriptional level 
by both insulin and glucoprivation with 2-deoxy-D-glucose (2-DG), a structural 
analogue of glucose. HIF-2a mRNA has also been shown to be mildly elevated in 
response to glucose deprivation in the heart and lung. This finding is of great 
interest given the potential use of 2-DG as an anti-neoplastic agent. 
 
Increased HIF-1α expression is evident in the mesangial cells of kidneys of 
diabetic mice (STZ and db/db). Moreover, high ambient glucose concentrations 
leads to an increase in HIF-1α in human mesangial cells (hMC) in a dose 
dependent manner, independently of oxygen tension and osmolality. Again, 
enhanced expression of HIF-1α appears to be mediated through increased 
transcription rather than the liberation of HIF-1α from proteolytic destruction. 
Binding of the transcription factor carbohydrate responsive binding protein 
(ChREBP) to the carbohydrate response element (ChRE) being the key mediator of 
this effect. In a display of tissue specificity this effect of high glucose seems to be 
predominantly seen in mesangial cells.288 
 
In addition, Interleukin-1b has been shown to induce both HIF-1α325 and HIF-
2α,326 in the absence of hypoxia, brought about by increased transcription but not 
stabilisation of HIF. 
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6.1.1.2  Evidence for HIF stabilisation as a cytoprotective strategy 
Animals exposed to chronic systemic hypoxia display increased cardiac 
ischaemia tolerance; as evidenced by earlier functional recovery following 
ischaemia-reperfusion327,328 Furthermore mice exposed to 5 cycles of acute 
systemic hypoxia (6% O2 in a hypoxic chamber, for 6 min), so called ‘hypoxic 
preconditioning’ had smaller myocardial infarcts 24 hours after systemic hypoxia 
in a manner analogous to that of delayed IPC. However, in mice exposed to acute 
hypoxia 30 min before ischaemia-reperfusion; there was no evidence of a 
beneficial effect, either in terms of recovery of left ventricular developed pressure 
(LVDP) or myocardial infarct size. 
 
It would be logical to assume a role for HIF activation in the cytoprotective 
mechanism of ischaemic preconditioning. In vivo repression of HIF-1α 
transcriptional activity with siRNA is associated with abolition of the myocardial 
protective effect of IPC.329 Furthermore hif-/+ partial knockout mice are unable to 
be classically preconditioned.330 Moreover HIF stabilisation using the pan-prolyl-
4-hydroxylase inhibitor dimethyloxaloglycine (DMOG), which also inhibits the 
aspariginyl hydroxylase, factor inhibiting HIF (FIH), is associated with a reduction 
in myocardial infarct size in a murine model of MI. Once again; the protective 
effect of DMOG could be abrogated by repressing HIF transcription through the 
co-administration of siRNA (specific to HIF-1α). Silencing PHD1 and PHD3 
neither led to an increase in HIF-1α levels nor a reduction in myocardial infarct 
size. Where as repression of PHD2 was associated with both an increase in HIF1-
α levels and a reduction in myocardial infarct size. Thus, from this data it would 
appear that the cardio-protective effects of HIF are dependent upon HIF-1α and 
PHD2.329 Unsurprisingly it seems that intact HIF-1α signally appears integral in 
mediating the cytoprotection afforded by both ischaemic and hypoxic 
preconditioning. 
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6.1.1.3  The development of pharmacological HIF stabilisers 
HIF stabilisation was first envisaged as a pharmacologic strategy to treat anaemia 
of renal disease, the present mainstay of which is recombinant human 
erythropoietin (Epo) or derivatives thereof. 
 
As erythropoiesis stimulating agents (ESA) prolyl-4-hydroxylase inhibitors have 
several potential advantages over Epo, which make them an attractive therapy for 
anaemia of CKD. 
♦ Oral bioavailability: all currently available ESAs require parenteral 
administration. 
♦ Oral absorption and mobilisation of iron: in order for elemental iron to 
be incorporated into haemoglobin there it must be absorbed across the 
apical surface of duodenal epithelia and then transported across the 
basolateral membrane into the circulation and transported to the bone 
marrow to be incorporated into haem.331,332 
♦ Reduced systolic BP333 
 
FibroGen Inc. (San Francisco, USA) was one of the first companies to develop 
orally active PHD inhibitors. I was given one such inhibitor, FG4497, in order to 
investigate its potential to ameliorate myocardial ischaemia-reperfusion injury. 
 
6.1.1.4  Evidence for FG4497 as a cytoprotective agent 
FG4497 is a small molecule inhibitor of PHD enzymes and has been described in 
patent filings US20040254215A1. It appears to be protective in a number of 
models of ischaemia-reperfusion injury and inflammatory disease. Robinson 
et.al.334 demonstrated a dose dependent improvement in severity markers in a 
murine model of colitis. 
 
Rosenberger et.al.335 demonstrated in an isolated perfused kidney (IPK) model that 
pretreatment (6Hrs before) by intravenous FG4497 (50mg/kg) was associated with 
a significant attenuation of functional decline, as evidenced by a higher renal 
PHARMACOLOGICAL PRECONDITIONING – FG4497 
212 
perfusate flow rate in the treated animals, and improved histomorphological 
markers of cellular injury following 90 minutes of perfusion. 
 
FG4497 has also been shown, in rodent allogenic renal transplant model, to 
improve both acute kidney injury as well as both short and long-term mortality. 
Bernhardt and colleagues336 gave FG4497 (40 mg/kg IV) 6 hours prior to 
performing an orthoptic allogenic renal transplant (Fisher-Lewis model). Animals 
were divided into 4 groups; 
Group 1 - Lewis recipient with Lewis donor (isograft) and pretreatment with 
vehicle. 
Group 2 - Lewis recipient with Fisher donor (allograft) and pretreatment with 
vehicle. 
Group 3 - Lewis recipient with Fisher donor (allograft) and pretreatment with 
FG4497 
Group 4 - Lewis recipient with Lewis donor (isograft) and pretreatment with 
FG4497. 
Grafts were perfused with University of Wisconsin (UW) preservation solution 
and stored for 24 h at 4oC prior to implantation. 
 
Each group included ‘acute’ and ‘chronic’ sub-groups. The acute group were 
bilaterally nephrectomised at the time of transplantation and did not receive 
immunosuppressants, thus rendering the animals critically dependent on the 
function of the graft for their survival. The chronic model underwent unilateral 
nephrectomy at the time of transplantation and then had the remaining native 
kidney removed 10 days later. In the acute model FG-4497 significantly improved 
survival from 23.1% to 53.3% (p=0.019), furthermore animals receiving a kidney 
form a donor pretreated with FG-4497 who survived to 10 days had a lower 
serum creatinine.
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6.1.2 Aim,
To investigate the ability of FG4497 to act as a pharmacological preconditioning 
agent and confer resistance to myocardial ischaemia reperfusion injury. In 
particular, I wished to investigate the possibility that HIF stabilisation might 
attenuate the increase in infarct size that was observed in SNx animals, in view of 
the suggestion that a possible explanation for the increased vulnerability of 
uraemic animals to IRI is due to a reduced capillary density in the uraemic heart. 
Capillary/ myocyte mismatch may be the result of an impaired response to 
hypoxia. Indeed there is evidence to suggest that senescence impairs responses to 
hypoxia337 and that patients with CKD manifest a phenotype of ‘premature 
ageing’.338
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6.1.3 Methods,–,FG4497,
6.1.3.1  Experimental Design 
To date only a transcriptional function has been ascribed to HIF. It was 
hypothesised that; as a strategy to reduce ischaemia reperfusion injury, HIF 
stabilisation would be most effective when achieved prior to the ischaemic insult. 
Thus it was proposed that FG4497 should be used as a pharmacological 
preconditioning agent. 
 
After discussion with the manufacturer of FG4497 (FibroGen Inc. San Francisco, 
USA), owing to a superior understanding of the pharmacokinetics, it was agreed 
that FG4497 should be administered intravenously. The most convenient method 
of administering an IV bolus to a rat is by cannulation of the tail vein. In order to 
facilitate this, one must vasodilate the tail vein. The usual method of doing this, in 
conscious animals, is to place the animal beneath a heating lamp, raising its core 
temperature and thus inducing vasodilatation of peripheral blood vessels. 
However, increasing body temperature is well recognised to induce 
cardioprotection in its own right.339 Even though this would be done to both test 
animals and control animals alike, it was feared that exposing both sets of animals 
to a preconditioning stimulus (heating) could potentially result in difficulties in 
data interpretation.  
 
Alternatively, the possibility of applying local heat by means of a water bath to 
anaesthetised animals was considered. However, the anaesthetic of choice for 
such a short-term procedure would be an inhalational agent such as isofluorane. 
Volatile anaesthetics themselves have been demonstrated to protect against IRI. 
Moreover, it has been suggested that their preconditioning effect is mediated 
through HIF stabilisation.340 Thus it was decided to anaesthetise the rats with 
sodium thiopentone and carry out the ‘basic surgery’, as previously described (pg 
105), in order to administer the FG4497 or a placebo (alkalinised 5% dextrose) 
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via the jugular vein. The animals would then be maintained under anaesthesia for 
4 hours before carrying out myocardial ischaemia reperfusion. 
6.1.3.1.1 *Experimental*protocol*
The animals were anaesthetised with an intraperitoneal (IP) injection of sodium 
thiopentone (sham - 88 mg/Kg [24 mg/ml]; SNx - 73 mg/Kg [20 mg/ml]) and basic 
surgery carried out as previously described (see pg 105) The animals were given 
intravenous FG4497 or vehicle and then maintained under anaesthesia for 4 
hours prior to undergoing LAD ligation, as described earlier (pg 112, employing 
25min ischaemia, 2h reperfusion. At the end of the 2h reperfusion period the 
surviving animals were sacrificed and infarct size determined. 
 
An excessive mortality was found to be associated with this initial experimental 
protocol (see results). It was felt that the excess mortality was predominantly 
attributable to the lengthy (nearly 4 hours) period of general anaesthesia and 
ventilation prior to inducing MI. Thus the experiment was redesigned. 
 
6.1.3.1.2 *Results*;*Intravenous*administration*of*FG4497*(Exp.1)*
A total of 25 animals were used for this experiment. Twelve animals had 
undergone a sub-total nephrectomy (SNx) and thirteen were sham-operated 
controls. Mortality in this first series of experiments was extremely high (56% 
overall mortality) with a relatively even split between SNx (57%) and sham 
animals. However, as a proportion of the group, mortality was greater, but not 
statistically different, in the SNx group (66% compared with 46% in the sham 
group, p= 0.43).  
 
Fifty percent of the animals in each group were lost either during the 4 hour 
period of ventilation prior to LAD occlusion or during the ischaemic phase, the 
remainder dying during reperfusion. Those animals that died during reperfusion (7 
in total) were split 3:4 FG4497 to vehicle treated. Thus it was concluded that 
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treatment with FG4497 was not associated with an increase in mortality. As half 
the animals died either before LAD occlusion or during the ischaemic phase it 
was felt that the most significant contributing factor to the high mortality was the 
lengthy period of anaesthesia that preceded myocardial ischaemia-reperfusion. 
Given the 2X2 factorial design the excess mortality resulted in insufficient 
numbers in each group to allow for any meaningful analysis. 
 
6.1.3.1.3 *Revised*experimental*design*
In redesigning the second experiment it was decided to only use sham-operated 
control animals on the basis that variability in infarct size and hence standard 
deviation may be less in the sham animals than uraemic (SNx) animals. The 
intention was to repeat the experiment with a 2X2 factorial design (with both SNx 
and sham operated control animals) if FG4497 pretreatment were to prove 
beneficial. 
 
To avoid the long period of mechanical ventilation prior to carrying out LAD 
ligation, it was decided to administer the test article (FG4497) by gavage. The 
change in route of administration necessitated an increase in the dose form 
50mg/Kg to 100mg/Kg. Additionally the time between dosing and LAD occlusion 
was increased from 4 to 6 hrs in order to allow sufficient time for the 
transactivation of HIF-1α regulated genes. 
 
Basic surgery, blood sampling and myocardial ischaemia-reperfusion were carried 
out as previously described (pg105, pg110, pg112), with the exception that in this 
second series of experiments the index episode of ischaemia was increased from 
25 to 30min. The duration of ischaemia was increased because in the preceding 
experiment a smaller than expected degree of injury had been observed. As 
previously discussed (pg 99) it is desirable when trying to demonstrate an 
improvement in infarct size in response to a treatment that the control group has a 
reasonably large infarct size. 
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6.1.3.2  Preparation of Drug and Vehicle 
6.1.3.2.1 Intravenous*preparations*
FG4497 was made up to a concentration of 10mg/mL. To 100mg of FG-4497, 
9.675 mL of 5% Dextrose was added followed by 325µL of 1N sodium hydroxide. 
The mixture was then sonicated until dissolved, if the drug failed to dissolve the 
pH was checked and if not >8.5 (desired pH range 8.5-9.2) further NaOH was 
added. The final preparation had a clear yellow colour and was then filtered 
through a 0.2µm filter. The drug was protected from light at all times. A vehicle of 
alkinised 5% dextrose was prepared by adding 1N NaOH to achieve a pH of 8.5-
9.2. 
6.1.3.2.2 *Oral*preparations*
The vehicle for oral administration of FG4497 was: 0.5% high-viscosity 
carboxymethylcellulose sodium (CMC-Na), 0.1% Polysorbate 80. 
1% high viscosity CMC-Na was prepared by adding 10g of CMC-Na to 990ml of 
distilled water (dH2O) in a 1L amber glass jar. A magnetic stirrer was used to 
ensure the CMC-Na completely dissolved. The final solution was stored at 2-8oC. 
A 0.2% solution of Polysorbate 80 (0.2% tween 80) was prepared by adding 998 
mL of dH2O to 2g of Polysorbate 80 (Tween 80) in an amber glass jar with a 
magnetic stirrer. The solution was stored at 2-8oC for no more than 19 days from 
the day of preparation. 
The test article was prepared by adding the 2 solutions in equal volumes to the 
drug to achieve a final concentration of FG4497 of 100 mg/mL. A sonicator was 
used to achieve a smooth suspension of drug particles 
The animals received either drug or vehicle by gavage 6h (median 6:12) prior to 
LAD occlusion.
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6.1.3.3  Cardiac biomarkers. 
One of the major drawbacks of both Planimetry and the NBT stained weight ratio 
method of measuring infarct size is the destruction of the tissue during the 
measurement process, rendering the heart unavailable for protein or gene 
expression studies. Additionally it was felt that biomarkers could be used to 
confirm and support the results of infarct size determined by the NBT method. 
 
Commonly used in the clinical setting for its specificity and prognostic 
significance, troponin I was a logical choice. 
 
Commercially available enzyme linked immunosorbent assay (ELISA) kits for: 
♦ Cardiac specific troponin I (cTNI) 
♦ Cardiac myosin light chain 1 (cMLC-1) 
Were purchased and performed in accordance with the manufacturer’s 
instructions. 
 
6.1.3.3.1 *Rat*Troponin*I*(TNI)*Assay*
A commercially available enzyme-linked immunosorbent assay (ELISA) kit for rat 
Troponin I (2010-20HSP) was supplied by Life Diagnostics Inc. (West Chester, PA, 
USA). The Assay was performed in accordance with the manufacturer’s 
instructions. 
 
This assay kit utilises the ‘sandwich’ technique employing one anti-cTNI antibody 
to achieve solid phase immobilization whilst a second antibody, conjugated to 
horseradish peroxidase (HRP) is used to detect bound TNI. A 
tetramethylbenzidine solution is used as the substrate for the HRP, when 
catabolised this gives rise to a blue coloured chromogen. The reaction was 
stopped after 20 minutes using sulphuric acid (Stop solution supplied with kit) 
resulting in a change of colour from blue to yellow. The plate was then read in a 
plate reader at 450 nm corrected for 650 nm to allow for imperfections in the 
plate.  
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Blood samples were obtained at the end of reperfusion, just before termination of 
the experiment. The blood was collected in heparinised syringes (P30, supplied 
by Radiometer UK, Crawley Surrey). 
 
Plasma samples were diluted prior to being assayed. We determined the optimal 
dilution of the samples to be 1:32. This dilution resulted in the majority of 
samples containing a concentration of troponin that would fall between the top 
and the bottom standard. A 1:32 dilution was achieved by first diluting the plasma 
samples with the ‘standard’ diluent supplied with the kit (1:8). A further 1:4 
dilution was performed using ‘plasma diluent’, as specified in the manufacturers’ 
instructions, giving a final dilution of 1:32. 
6.1.3.3.1.1 Results+
In preliminary work on stored plasma, Troponin I was found to be elevated at 
baseline in uraemic animals compared to non-uraemic animals (p=0.034, Figure 
40). Furthermore, plasma troponin I levels sampled after 2Hrs reperfusion, 
showed a robust correlation with infarct size (see Figure 41). This relationship 
held true for uraemic and non-uraemic animals alike. 
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Figure 40 – Baseline troponin levels 
Baseline troponin levels were elevated in uraemic (SNx) animals compared to non-uraemic sha-
operated control animals (p=0.034,*). 
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Figure 41 – Correlation of plasma troponin with infarct size.  
A robust correlation was seen with both absolute plasma troponin (b) and corrected for area at risk 
(a). This relationship held true for both non-uraemic animals (c&d) as well as uraemic animals 
(e&f). 
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6.1.3.4  Rat erythropoietin assay 
A commercially available enzyme-linked immunosorbent assay (Quantikine 
Mouse/ Rat erythropoietin assay, R&D Systems) was used to measure plasma 
erythropoietin levels, which was used as a surrogate marker of HIF stabilisation. 
The assay was carried out in accordance with the manufacturer’s instructions. FG-
4497 treated animals had plasma erythropoietin levels which exceeded the upper 
limit of detection in most cases such that a 1:8 dilution of the plasma samples was 
required in order to maintain the levels within the range of the standard curve. 
This was achieved by using the ‘calibrator diluent’ (RD67) supplied with the kit. 
 
6.1.3.5  VEGF assay 
As a second means of confirming the biological effect of FG4497 plasma VEGF 
levels were assayed using a specific rat VEGF ELISA (Rat VEGF Quantikine ELISA 
Kit, RRV00, R&D Systems, Abingdon, Oxon, UK). The assay was performed 
according to the manufacturers instructions on heparinised plasma samples 
obtained at the same time point as those used for the Epo ELISA (median of 5hrs 
31min [IQR 5hrs 2min - 5hrs 53min] after administration of FG4497). The 
samples were assayed neat and at a 1:10 dilution (diluted with Calibrator Diluent 
RD5-3 supplied with the kit).
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6.1.4 Results, –, Pharmacological, preconditioning,with, oral, administration, of,
FG4497,(Exp.,2),
In contrast to the first experiment, using intravenous (IV) FG4497, only 3 out of 31 
(9.7% vs. 50%) animals died prior to the completion of the experimental protocol. 
6.1.4.1  Infarct size 
Pretreatment with FG4497 6hrs (median 6:12, range 5:51-6:57) before induction 
of myocardial infarction by reversible LAD occlusion was associated with a small 
but significant reduction in infarct size (p=0.042, see Table 11) a relative 
reduction in infarct size of 18.7% (Figure 42a). The area at risk was also 
significantly smaller for the FG4497 treated animals (p=0.040, see Table 11 and 
Figure 42b). However, no correlation was observed between infarct size and area 
at risk for either the FG4497 or control groups, or for the experiment as a whole 
(see Figure 45). There was a non-statistically significant trend towards a lower 
level of plasma Troponin I (sampled at the end of reperfusion) in the FG4497 
treated group (p=0.079, see Table 11 and Figure 43c). 
Sample size (n)
Infarct size
Area at risk
Troponin I (ng/ml/g AAR)
Erythropoietin (pg/ml)
Haematocrit (%)
Control FG4497
Mean/ 
Median
SD/ IQR Mean/ 
Median
SD/ IQR p
11 13
76.3 10.1 66.0 19.8 0.042
57.9 6.55 49.9 10.6 0.040
1.14 0.775 0.646 0.369 0.079
1.64 0.84-8.06 15,201 13,541-15,763 0.001
39.8% 2.48 41.2% 4.55 0.409
 
Table 11 – Results of experiment 2: Infarct size reduction by pharmacological preconditioning 
with oral FG4497
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6.1.4.2  Plasma erythropoietin levels 
FG4497 increased plasma erythropoietin levels by almost 10,000 fold (control 
1.64 pg/mL [IQR 0.840-8.06] vs. FG4497 15,201 pg/ml [IQR 13,541-15,763]) at a 
median of 5hrs 31min (IQR 5hrs 2min - 5hrs 53min) after being administered by 
gavage. A significant inverse correlation between plasma erythropoietin levels and 
infarct size was observed in the FG4497 treated animals (r=-0.720 95%CI -0.902 
to -0.231, p=0.011, Figure 44a). Plasma erythropoietin levels were observed to be 
independent of AAR (see Figure 44b). 
 
6.1.4.3  Sub-group analysis by plasma erythropoietin (EPO) level 
The treatment group (FG4497) was subdivided around the median plasma 
erythropoietin level into ‘high Epo’ and ‘low Epo’ groups. Those animals in the 
high Epo group experienced a substantial reduction (42% absolute reduction, 
52.3% relative reduction, p=0.009) in the size of infarct they sustained (see Figure 
42c). The ‘Low’ EPO group had a median infarct size comparable to that of the 
untreated control group (‘Low’ EPO 80.3% [67.1-83.6] c.f. 74.1% [66.2-88.8%]). 
However, there was no difference in Troponin I levels between the treated 
(FG4497) and control groups (p=0.429, see Table 12 and Figure 43d). The 
attenuation in IR injury seen with FG4497 appeared to be independent of the area 
at risk, in that there was no significant difference in AAR in high and low Epo 
groups (Table 12 and Figure 42d). Using Spearman's rank, no correlation was 
found between Epo level and AAR for the treated group or the experiment as a 
whole (Spearman r = -0.056, p=0.863, Figure 44b). 
Infarct size (%AAR)
Area at risk (%LV)
Troponin I (ng/ml/mg AAR)
Low Epo High Epo
Mean/ Median SD/ IQR Mean/ Median SD/ IQR p
80.3% 71.0-83.4% 38.3% 35.6-63% 0.009
53% 37.4-61.5% 43.80% 40.3-59.3% 0.937
0.520 0.106-1.04 0.535 0.464-1.01 0.429
 
Table 12 – Results of sub-group analysis by high and low erythropoietin levels. 
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Figure 42 – Results of pharmacological pretreatment with the HIF stabiliser FG4497 
(a) Infarct size was reduced by approximately 20% following pretreatment with FG4497 
(p=0.042,*). (b) However, the area at risk was smaller for the FG4497 treated group (p=0.04,*). (c) 
Infarct size was substantially decreased (by more than 50%) in a sub-group analysis of those 
animals who achieved greater than the median plasma erythropoietin level (p=0.0087,**). (d) The 
area at risk was similar for both high and low erythropoietin groups.
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Figure 43 – Plasma erythropoietin and troponin levels 
(a) Plasma erythropoietin levels 6Hrs following treatment with FG4497 were almost 10,000 fold greater than untreated control animals (p=0.001,***). NB logarithmic 
scale. (b) There was no difference in HCT 6Hrs following treatment with FG4497. (c) There was a non-significant trend towards lower plasma troponin I levels, after 
2Hrs reperfusion, in the FG4497 treated animals (p=0.079). (d) Despite a marked reduction in infarct size there was no difference in plasma troponin I levels between 
the high and low Epo groups (p=0.429). 
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Figure 44 – Relationship between infarct size and plasma erythropoietin levels. 
(a) An inverse relationship was seen between plasma erythropoietin levels prior to LAD occlusion 
and subsequent infarct size (p=0.0082). (b) No relationship between erythropoietin level and area 
at risk was seen. (c) Standard curve for the erythropoietin assay.
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Figure 45 – The relationship between infarct size and area at risk (AAR). 
(a) No correlation was observed between IS and AAR in the experiment as a whole or for either 
(b) the control group or (c) the FG4497 treated group.
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6.1.4.4  Biochemical, haematological and physiological parameters 
The mean haematocrit was similar for both groups (Control 39.8 ±2.5% FG4497 
41.1 ±4.5%, p=0.409). 
 
After approximately 15 minutes mechanical ventilation (baseline) FG4497 treated 
animals were significantly more alkalotic (mean pH Control 7.46 ±0.047, FG4497 
7.51 ±0.066, p=0.031). However, an area under the curve (AUC) analysis 
revealed no significant differences (mean AUC Control 14.82 ±0.099 [n=13] vs. 
FG4497 14.89 ±0.124 [n=10]) and critically there was no significant difference in 
blood pH prior to occlusion of the LAD (Control 7.39 ±0.062 vs. FG4497 7.43 
±0.075, p=0.1468). 
 
To ensure consistency with previous work four animals were selected at random 
for biochemical analysis (median values with interquartile range are presented in 
Table 13). Median creatinine and phosphate was significantly lower in this 
experiment than the characterisation experiment. 
 
 Reference group FG4497/ Control P 
Haemoglobin 39.00 36.3-41.0 40.50 37.5-42.0 0.281 
Creatinine (µmol/L) 42.5 38.7-44.3 34.3 33.8-37.8 0.019 
Urea (mmol/L) 6.35 4.95-7.1 5.95 4.85-6.45 0.479 
Calcium (mmol/L) 2.52 2.45-2.58 2.51 2.48-2.53 0.777 
Phosphate (mmol/L) 2.54 2.18-2.78 1.80 1.74-1.98 0.006 
Albumin (g/L) 27.9 26.1-29.2 26.4 25.9-27.2 0.257 
 
Table 13 – Plasma biochemistry of 4 randomly selected animals.  
Comparison is made with sham operated control animals from experiment to characterise the 
models (see pg 83341).
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6.1.5 Discussion,–,Pharmacological,preconditioning,with,FG4497,
These data suggest a beneficial effect of therapeutic HIF stabilisation in 
myocardial ischaemia reperfusion injury. The results of this experiment should be 
interpreted with caution given the smaller area at risk in those animals that 
received FG4497. However, it should be borne in mind that no correlation was 
found between infarct size and area at risk for both groups either as a whole 
(vehicle and FG4497 groups combined) or for either group (control or FG4497) 
alone. The lack of correlation between infarct size and AAR casts doubt on the 
importance of this parameter in determining the results obtained. 
 
Excepting the area at risk, the two groups were well matched with respect to all 
other physiological variables that might be expected to influence tissue resistance 
to ischaemia-reperfusion injury. 
 
There appears to be a graded reduction in infarct size with increasing plasma 
erythropoietin levels. No relationship was observed between plasma Epo level 
and AAR, which would suggest that the correlation of Epo level to infarct size was 
independent of AAR. It is unclear whether this relationship reflects the extent of 
HIF up-regulation or whether the protective effect seen is mediated through Epo. 
A number of studies have demonstrated attenuation of ischaemia-reperfusion 
injury by pretreatment with recombinant erythropoietin.342 It is possible that 
animals that achieved high levels of plasma erythropoietin had superior 
absorption of FG4497 and thus benefited from increased HIF stabilisation.  
 
However, an arbitrary subdivision of the treated group at the median EPO level 
results in unequal groups and a potential for bias.  
 
Epo rises early and briskly in response to hypoxia with a significant increase in 
Epo concentration detectable after just 90 min341 However it takes several days 
PHARMACOLOGICAL PRECONDITIONING – FG4497 
230 
before this is manifested as an increase in haematocrit.343 The time course for 
other hypoxia regulated gene products e.g. VEGF, is less well described. I was 
unable to detect circulating VEGF. It is unclear whether the early rise in Epo 
occurs in order to provide sufficient lead time for an increase in red cell mass or 
whether, given that erythropoietin receptors are ubiquitously expressed, it 
represents part of an endogenous defence mechanism against hypoxic injury. 
 
Further work is required in order to both confirm the results obtained and to 
define the optimum timing and dosing schedule, for example would pretreatment 
24 hours in advance of the index ischaemic event be more efficacious, or even 
dosing at 24 hours and immediately before the ischaemic insult). It would be of 
interest to define the cardiac specific gene expression and proteomic changes and 
their time course in response to FG4497. 
 
In order to resolve the question of whether protection was mediated through Epo 
production or the direct effects on cardiomyocytes of HIF stabilisation, the study 
of an isolated heart preparation might prove useful.
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7 THE,EFFECT,OF,ACUTE,KIDNEY,INJURY,(AKI),ON,
MYOCARDIAL,INFARCT,SIZE
THE EFFECT OF AKI ON MYOCARDIAL INFARCT SIZE 
232 
7.1 Background.
CKD is a well established risk factor for adverse outcome following AMI.7 
However, the impact of acute kidney injury (AKI) upon prognosis post-AMI is less 
well described. 
 
The incidence of AKI appears to be increasing; studies in the late 1990s reported 
rates of between 8344 to 20345 per 100,000 population per year whereas more 
recent reports estimate the incidence of AKI between 288346- 500347 per 100,000 
population per year. The reason for this increase is unclear, but changing 
population demographics, improved reporting of events and changing definitions 
are all implicated. Depending on definition, AKI complicates between 10%348 and 
20%349 of admissions with AMI. 
 
In patients presenting with AMI, worsening of renal function, arbitrarily defined as 
an increase in serum creatinine of 44 µmol/L (≥0.5 mg/dl), is a strong predictor of 
both in hospital (OR 11.4) and one year (HR 7.2) all cause mortality. 348 Parikh et 
al349 stratified AKI into mild, moderate and severe. They observed that AKI 
displayed a strong, independent and graded association with both early (30 day) 
and late (10 year) mortality. Only 10% of patients who developed severe AKI 
were alive at 10 years compared with more than one third of patients who did not 
develop AKI. The association between AKI and long-term mortality was not 
altered by using relative or absolute values of SCr, suggesting that acute on 
chronic renal failure conveyed a similar risk of subsequent death. Indeed, AKI 
category (mild, moderate or severe) was comparable with other established risk 
factors, such as; left ventricular ejection fraction (LVEF), diabetes mellitus, CKD 
and anaemia. 349  
 
Newsome et al350 reported similar findings to Parikh and colleagues in a cohort of 
elderly patients. However, they also observed that even a minor increase of just 
0.1 mg/dl in peak SCr, in addition to a 14% increased risk of mortality, resulted in 
a 45% increased risk of ESRD at 10 years, raising the possibility that the outcome 
following AMI complicated by AKI was due to the risk of developing ESRD. 
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However, AKI occurring in the context of percutaneous coronary intervention 
(PCI) also appears to portend an increased risk of AMI351 and three times the risk 
of death at 1 and 5 years.352 
 
Szczech and colleagues353 reported an increased incidence of 90 day mortality, 
cardiac arrest and heart failure but no increase in rates of AMI in patients 
hospitalized for acute severe hypertension (one or more BP readings >180 mmHg 
systolic or >110 mmHg) complicated by AKI in contrast to patients with acute 
severe hypertension with CKD who were observed to experience an increased risk 
of NSTEMI. As others have previously reported, Szczech also found a strong and 
independent association between loss of GFR and in-hospital mortality (OR, 1.05; 
p=0.03 per 10-mL/min decline). 
 
7.1.1 The,cardioRtoxicity,of,acute,kidney,injury,
It is unclear whether the adverse outcome seen in patients who develop AKI in 
association with an AMI is due to a direct effect on the heart or merely identifies a 
subgroup of patients with more severe myocardial ischaemia. It is possible that 
the development of AKI alters the pathophysiologcal remodeling process. 
 
There is some evidence to support an indirect link between AKI and reduction in 
myocardial ischaemia tolerance. Blake et al354 demonstrated the presence of a 
negatively inotropic factor in the serum of patients with AKI and acute heart 
failure, which was not present in those with chronic kidney disease or those with 
chronic heart failure and mild CKD. 
 
Thirty min of bilateral renal ischaemia has been shown to result in a systemic 
increase in TNF-α and IL-1 and an increase in cardiac levels at 48 hours. This is 
associated with increased myocardial TUNEL staining, indicative of apoptotic cell 
death, together with evidence of neutrophil infiltration and activation (indicated 
by an increase in myeloperoxidase activity). Additionally, echocardiography has 
demonstrated functional alterations with decreased fractional shortening and 
increased left ventricular end systolic and end diastolic diameters.355 
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In the isolated perfused heart model, infusion of TNF-α has been shown to result 
in a reduction in left ventricular developed pressure and vasoconstriction.356 In 
vitro TNF-α and IL-1 upregulate adhesion molecules on endothelial cells and in 
vivo this facilitates immobilisation of leucocytes on the endothelium.357 In recent 
years systemic inflammation has been increasingly recognised as an important 
cardiovascular risk factor both in the general population358 and patients with 
ESRD.359 
 
Whilst it is easy to see how acute systemic inflammation might contribute to 
increased mortality in the short term, why differences in outcomes persist up to 10 
years after the index event and what constitutes this metabolic memory remains to 
be determined. Does AKI abrogate endogenous cardio-protective mechanisms? 
Does AKI induce a state of reduced ischaemia tolerance? 
 
Analysis of the human data is confounded by the fact that AMI with the resultant 
haemodynamic and inflammatory changes leads itself to an alteration of renal 
function. Because cardiac events are impossible to predict in humans it is unclear 
whether AKI in the context of AMI is a cause or effect.
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7.2 Aim.3.Myocardial*ischaemia/reperfusion*in*acute*kidney*injury.
The aim of the following experiment was to examine the effects of AKI on 
myocardial infarct size. It was hypothesised that, as in chronic uraemia, animals 
with acute kidney injury would sustain larger myocardial infarcts, possibly 
brought about as a result of the induction of a functional state of reduced 
ischaemia tolerance, inflammation or attenuation of endogenous cardio-
protective mechanisms.
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7.3 Methods.–.Myocardial*ischaemia/reperfusion*in*acute*kidney*injury.
7.3.1 Rodent,model,of,AKI,
6-week-old male Wistar rats (Charles River Laboratories UK, Margate, UK) were 
anaesthetized using ketamine (Ketaset, Fort Dodge Animal Health) at a dose of 
0.5ml/kg IP and xylazine 2% (Rompun, Bayer) 0.25ml/kg IP. In addition, 
analgesia in the form of 0.03ml SC of buprenorphine (Vetegesic, Alstoe Animal 
health) was given to all animals prior to the commencement of surgery. 
 
Anaesthetised rats were placed on a homoeothermic control blanket, with 
temperature maintained at 37oC ±1oC. Under aseptic conditions, bilateral flank 
incisions and externalization of kidneys were performed, in a manner similar to 
that described in the creation of SNx animals (pg 76). 
 
Once both kidneys had been exteriorized the rats were randomly allocated to one 
of two groups. Group 1 underwent 45 minutes of bilateral renal artery occlusion 
using arterial clips (AKI). Ischaemia was confirmed visually by pallor of the kidney 
and reperfusion by prompt restitution of the normal colour. The kidneys were 
returned to the retroperitoneal space. The second group (sham) were left with the 
kidneys exposed for 45 min but did not undergo bilateral renal artery occlusion 
and were treated identically in all other respects. 
 
Following renal ischaemia-reperfusion or a sham procedure, the kidneys were 
returned to the retroperitoneal space. The muscle layers were closed with 4-0 
polysorb braded suture (Syneture), and the skin closed using a disposable skin 
stapler (Precise Vista™, 3M, Bracknell, UK). The rats were left to recover under a 
warming lamp and returned to their cages when fully awake.
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7.3.2 Reversible,LAD,ligation,
24 hours after bilateral renal ischaemia-reperfusion, both groups of rats 
underwent an identical experimental protocol to that described for the earlier 
experiments with chronically uraemic animals (see pg 104). Briefly, both groups 
were anaesthetised, had arterial and venous lines inserted and a tracheostomy 
performed. They were ventilated and underwent a thoracotomy with reversible 
LAD ligation for 25 minutes with 2 hours reperfusion. At the end of this period the 
hearts were harvested for infarct size estimation. 
 
Cardiovascular parameters were recorded during the experiment. During the 25 
minutes of ischaemia the duration of ischaemic arrhythmias was noted for each 
group.
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7.4 Results.3.Myocardial.ischaemia3reperfusion.in.acute.kidney.injury.
By 24 hours following bilateral renal ischaemia (45 min), the AKI group had 
developed acute kidney injury as evidenced by significant elevations in SCr and 
urea (see Table 14). In addition, the AKI group also demonstrated significant 
derangements of other electrolytes, indicative of acute tubular dysfunction with 
higher serum potassium (p=0.07) and phosphate levels (p=0.02). Furthermore, 
serum AST, which is often used as a marker of renal ischaemia-reperfusion 
injury,360,361 was also significantly elevated (p=0.006). 
 
The area at risk was similar for the two groups (median 49.8% [45.6 - 53.7%] vs. 
45.8% [36.6 - 58.7%], p=0.485, see Figure 46c). However, contrary to 
expectation, infarct size was considerably reduced (RR 34%, p<0.02, Figure 46b) 
in animals that had previously undergone renal IRI (AKI Group). 
 
In addition, AKI induced by bilateral renal ischaemia reperfusion injury was 
associated with a significant reduction in the duration of ischaemia-induced 
arrhythmias (median 61.0 s [41.3-84.5] for sham group vs. 31.0 [6.00-45.0 s] for 
AKI group, p=0.035). Arrhythmias were recorded, defined and analysed as 
previously described (see pg 106 and pg 176). No difference in the time to first 
ischaemic arrhythmia, duration of cardiac arrest or duration of reperfusion 
arrhythmias was seen. 
 
Table 14 – weight and plasma biochemistry (median and [IQR]) for Sham and AKI groups. 
 Sham (n=6) AKI (n=8) P 
Weight (g) 278 (260-315) 315 (292.5-340) NS 
Serum albumin (g/l) 25.9 (25.4-27.8) 25.7 (25.1-26.9) NS 
Serum urea (mmol/L) 5 (4.14-5.75) 38 (31.9-41.5) 0.006 
Serum creatinine (mmol/l) 33.5 (27.2-41.4) 278.8 (163.2-335) 0.02 
Serum AST (IU/l) 75.3 (56.95-88.8) 291.4 (209.8-417.9) 0.006 
Serum sodium (mmol/L) 143.5 (141.4-145.7) 136.6 (133.1-145.2) NS 
Serum potassium (mmol/l) 4.2 (4-4.4) 4.9 (4.7-6.4) 0.07 
Serum chloride (mmol/l) 106 (102-1078) 100 (96.1-105) NS 
Serum phosphate (mmol/L) 3.12 (2.93-3.40) 3.8 (3.6-4.1) 0.02 
Serum calcium (mmol/l) 2.42 (2.275-2.64) 2.28 (2.16-2.32) NS 
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Figure 46 – Arrhythmia suppression and infarct size reduction by acute kidney injury (AKI). 
(a) Animals with AKI displayed a marked reduction in the total duration of ischaemia induced 
arrhythmias (p= 0.035,*). (b) Infarct size significantly reduced in animals with AKI induced by 45 
minutes of bilateral renal ischaemia (p=0.014,*). (c) The area at risk for both groups was similar 
(p=0.485). 
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7.5 Discussion.3.Myocardial.ischaemia3reperfusion.in.acute.kidney.
injury.
The only real explanation for the unexpected finding of reduced infarct size in the 
setting of AKI induced by renal ischaemia-reperfusion injury (IRI), is that renal 
ischaemia had induced a ‘preconditioned state’ in the myocardium, analogous to 
that seen with remote ischaemic preconditioning (RIPC). 
 
Similar to ischaemic preconditioning (IPC), RIPC is a phenomenon whereby brief 
periods of ischaemia-reperfusion of one organ/ tissue confers resistance to 
subsequent prolonged ischaemic injury in another organ distant or remote to it. 
As with IPC, RIPC also has an early and late phase or second window of 
protection which appears from around 24 hours after the preconditioning event.362 
 
However this data constitutes the first demonstration that an episode of 
ischaemia-reperfusion, of sufficient duration to result in organ dysfunction may 
also convey a preconditioning stimulus to distant or remote organs. 
 
Takaoka et al268 demonstrated that 10 minutes of renal ischaemia followed by 20 
minutes reperfusion led to a significant cardioprotection following 40 minutes of 
coronary occlusion and 120 minutes reperfusion. Remote ischaemic 
preconditioning is more often thought of as induced by episodes of ischaemia 
reperfusion of insufficient duration to result in organ dysfunction (non-lethal). 
However, it seemed that the most likely explanation for the infarct sparing effect 
in this model of AKI was delayed remote Ischaemic preconditioning. Additional 
experiments were designed to investigate this hypothesis further.
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7.6 Renal.Remote.Ischaemic.Preconditioning.
In order to demonstrate that lethal renal ischaemia-reperfusion injury (induced by 
45 min bilateral renal ischaemia and 24 hours reperfusion) conferred an 
equivalent protective effect on the myocardium as RIPC and in order to 
investigate the mechanism through which this protection was achieved, a further 
series of experiments were designed and executed. 
 
7.6.1 Methods,R,Renal,Remote,Ischaemic,Preconditioning,
As an additional arm to the previous experiment, eight animals underwent 
bilateral renal ischaemic preconditioning, consisting of 3 cycles of 5 min 
ischaemia followed by 5 min reperfusion, with the intention of inducing delayed 
remote ischaemic preconditioning of the myocardium. The surgery was performed 
as described earlier for the induction of AKI (pg 236). 
 
Twenty-four hours after renal ischaemic preconditioning, myocardial ischaemia-
reperfusion was carried out as previously described (pg 104) and the hearts 
harvested for determination of infarct size.
THE EFFECT OF AKI ON MYOCARDIAL INFARCT SIZE 
242 
7.6.2 Results,–,Renal,Remote,Ischaemic,Preconditioning,
Serum creatinine was marginally higher in the delayed RIPC group compared with 
the Sham group (Sham 33.5 µmol/L [27.2 − 41.4 µmol/L] vs. RIPC 44.0 µmol/L 
[40.4 − 70.9 µmol/L]. This difference was not statistically significant with Dunn’s 
multiple comparison test and of borderline significance when tested by Mann-
Whitney (p=0.071). 
 
A graded reduction in the duration of ischaemia-induced arrhythmias occurring 
during 25 minutes of myocardial ischaemia was seen, 61 seconds for the sham, 
31 seconds for the AKI and 13 seconds for the IPC group (p=0.01, see Figure 47c). 
 
No differences in mean arterial blood pressure (MAP) were seen throughout the 
duration of myocardial ischaemia-reperfusion.  
 
7.6.2.1 Infarct size 
Delayed RIPC proved to afford superior protection against myocardial IRI 
compared to that induced by acute kidney injury. Median infarct size for delayed 
RIPC was 23.5% [14.3 − 44.7%] vs. 34.0% [22.6 − 45.0%] for the AKI group and 
51.3% [49.7 − 58.4%] for the sham group. One-way ANOVA demonstrated that 
these differences were highly significant (p=0.0043). However, with Dunn’s post 
hoc test, only RIPC was significantly different from the Sham group, in contrast to 
the results of the Mann-Whitney test of Sham versus AKI (p=0.014). There was no 
significant difference demonstrated between the AKI and the RIPC group with 
either Dunn’s post comparison test or a Mann-Whitney test. 
 
The AAR for the groups was similar with no differences seen when tested with 
either one-way ANOVA and Dunn’s post comparison test or Mann-Whitney tests.
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Figure 47 – Effect of RIPC on infarct size in chronic uraemia. 
(a) Infarct size reduction was maximal with RIPC. Reduction in infarct size by AKI was no longer statistically significant when analyzed by one-way ANOVA with Dunn’s 
post-test comparison. (b) Area at risk was similar for all groups. (c) As with infarct size, RIPC appeared to result in a graded reduction in the duration of ischaemic 
arrhythmias, again the AKI group was no longer significantly reduced in comparison to Control when analysed by one-way ANOVA. (d) There was no demonstrable 
difference in the BP, HR or PRP for the duration of the experiment. 
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7.7 Mechanism,of,RIPC,and,Lethal,Renal,IRI,induced,cardio9protection,
To investigate the mechanism of lethal renal IRI induced cardio-protection and 
specifically the role played by components of the ‘RISK pathway’, a further 
experiment was carried out. 
7.7.1 Methods+ –+ Mechanism+ of+ RIPC+ and+ Lethal+ Renal+ IRI+ induced+ cardio;
protection+
Six-week-old male Wistar rats were divided into 6 groups (see Table 15). Groups 
1 and 4 underwent unilateral renal ischaemia-reperfusion injury (45 min 
ischaemia), Groups 2 and 5 were subjected to a sham procedure (as previously 
described on pg 236) and Groups 3 and 6 were subjected to unilateral renal 
ischaemic preconditioning (3 cycles of 5 min ischaemia, 5 min reperfusion). 
 
Organs (kidneys and hearts) were harvested at two hours (Groups 1, 2 and 3) and 
twenty four hours (Groups 4, 5 and 6) and immediately snap frozen in liquid 
nitrogen and stored at −80oC for later determination of the phosphorylation state 
of the ‘RISK pathway’ components. 
 
Table 15 – Experimental groups for immunoblot studies. 
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7.7.1.1  Immunoblot analysis of RISK pathway components 
Extracellular signal-regulated kinases (ERK) 1/2 (p42/ 44) and Akt, which represent 
two key components of the RISK pathway were selected for study by immunoblot. 
 
Tissues for Western blotting were triturated in a pestle and mortar under liquid 
nitrogen. The powder was weighed and 1ml of RIPA buffer, with 1% v/v protease 
inhibitor cocktail (Sigma), added for every 100mg of tissue. The suspension was 
polytron-homogenised (3x 30sec bursts with 1min intervals on ice). 
 
The tissue homogenate was incubated for 10 minutes on ice and then centrifuged 
at 5,000g for 10 minutes at 4oC. The supernatant was aliquoted and stored at -
80oC until required. Protein concentrations were determined using the 
Bicinchoninic Acid assay (BCA, Pierce), with bovine serum albumin (BSA, Sigma) 
as the protein standard. Each sample was diluted down to a concentration of 
1µg/µl. 30µl of homogenate was denatured with 10µl of NuPage loading buffer 
in a thermocycler. 
 
A SureLock mini-cell vertical electrophoresis system (Invitrogen) was assembled, 
with two NuPage 10% Bis-Tris polyacrylamide gels (Invitrogen). The mini-cell 
system was filled with MOPS SDS running buffer (Invitrogen). 25µl of the 
denatured buffered homogenate was added to the wells with 7.5µl of a molecular 
weight standard at one end (Cruz Marker). The gels were run at 200 mV for one 
hour after which the gels were removed and the blotting membrane prepared by 
immersion in methanol for 30 seconds before soaking the membrane in 20% 
NuPage Transfer Buffer (Invitrogen). The gel was removed from its housing and 
the membrane was placed over the gel and into the blot module (Invitrogen). The 
blotting module was filled with transfer buffer and connected to a 30V power 
supply for 1 hour. After the hour the membrane was removed and washed in Tris-
Buffered Saline and Tween (TBST) three times. The primary antibody was diluted 
according to manufacturers instructions in 10ml of blocking buffer (Invitrogen). 
The primary antibody was added to the washed membrane and incubated over 
night on a rocking platform at 4oC. Following incubation with the primary 
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antibody, the membrane was washed three times in TBST before the secondary 
antibody was applied. The membrane and secondary antibody were incubated for 
one hour after which time the membrane was again washed in TBST (three times).  
 
The protein bands on the membrane were detected using the ECLplus 
chemiluminescence detection kit (Amersham Pharmacia). The following 
antibodies (from Cell Signaling) were used: rabbit anti-phspho-p44/p42 ERK1/2 
(Thr202/Tyr204), rabbit anti-p44/p42 (total ERK), mouse anti-phospho Akt 
(Ser473), rabbit anti-Akt (total Akt).
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7.7.2 +Results+–+Immunoblots+of+‘RISK’+pathway+components+in+RIPC+
Western blots of homogenates made from the hearts showed no differential 
upregulation of ERK 1/2 or Akt at 2 or 24 hours post renal reperfusion (see Figure 
48 panels A&B). Kidney homogenates revealed increased phosphorlyation of ERK 
1/2 and Akt in both the AKI and renal IPC groups at 2 hours (Figure 48 panel C). 
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Figure 48 – Immunoblots of homogenates made from the kidney and hearts of rats undergoing 
kidney ischaemic preconditioning or remote ischaemic preconditioning of the heart. 
Panel A demonstrates phospho-Erk1/2 and total Erk1/2 together with phospho Akt and total Akt in 
the myocardium following 2 hours reperfusion. Panel B shows phospho-Erk1/2 and total Erk1/2 in 
the heart following 24 hours reperfusion. Panel C demonstrates increased phosphorylation of both 
Erk1/2 and Akt in the kidneys after 2 hours reperfusion. A similar degree of phosphorylation is 
seen following 45 min ischaemia and renal preconditioning. 
THE EFFECT OF AKI ON MYOCARDIAL INFARCT SIZE 
248 
7.8 ,Discussion,
Both the AKI and the delayed RIPC (Kidney) groups share common features; both 
involve renal ischaemia and reperfusion, inhibit arrhythmogenesis during 
subsequent myocardial ischaemia-reperfusion, upregulate members of the RISK 
pathway in the kidney and both confer a cardio-protective effect against 
myocardial IRI. 
 
These data suggest that lethal renal ischaemia-reperfusion injury results in 
myocardial protection in a manner analogous to that of delayed remote ischaemic 
preconditioning and if true represents the first report that lethal (sufficient to 
induce organ dysfunction) ischaemia-reperfusion injury can confer a 
cytoprotective effect. 
 
The immunoblot studies suggest that members of the RISK pathway are 
upregulated in the preconditioned organ (in this case the kidneys) and that this 
occurs to a comparable degree in lethal renal ischaemia reperfusion but not in the 
remote organ (the heart). Thus it seems likely that the RISK pathway is not 
responsible for transducing the RIPC stimulus. However, there are a number of 
caveats; only two time points were examined (2 hrs and 24 hrs), it is possible that 
changes in the phosphorylation state in the remote organ follow a different time-
course. 
 
The immunblots represent the basal phosphorylation state of these kinases, there 
is data to suggest that both ERK 1/2 and Akt display a biphasic response to 
ischaemia reperfusion with increased phosphorylation during early ischaemia 
which subsequently diminishes with a further increase upon reperfusion.220 
 
Heidbreder et al,270 have subsequently reported similar findings to these. Utilising 
the small intestine to remotely precondition the heart, they first confirmed that 
they could induce myocardial protection, consistent with the published literature. 
An increase in phosphorylated ERK 1/2 and c-Jun N-terminal kinases (JNKs) was 
observed in the preconditioned organ (intestine) but no alteration in levels in the 
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remotely preconditioned organ (heart). Interestingly they found that inhibition of 
the MAP kinases before the intestinal preconditioning protocol not only abolished 
upregulation of the intestinal MAP kinases but also abrogated the myocardial 
protective effect of intestinal RIPC. This suggests that activation of MAP kinases in 
the directly preconditioned organ is necessary to confer protection to the remote 
organ. 
 
7.8.1.1.1 %Future%work%
The original hypothesis was that acute renal failure would induce a state of 
reduced ischaemia tolerance in the heart resulting in an increase in infarct size. 
Although not statistically significant, delayed RIPC did appear to afford superior 
cardio-protection then that induced by lethal renal IRI, suggesting that factors 
related to acute renal dysfunction may have been antagonising the protective 
effect of remote renal IRI. 
 
It would seem that the model of AKI chosen to investigate this hypothesis was not 
appropriate. Future studies should examine other models of AKI e.g. Bilateral 
ureteric obstruction, or models of toxic injury. Additionally, bilateral nephrectomy 
and or permanent ligation of the renal arteries would be interesting arms to add to 
this experiment. 
 
Furthermore the administration of specific MAP kinase inhibitors prior to renal IRI 
might confirm whether the same mechanisms are at play in lethal renal IRI as 
renal IPC. In addition it would be interesting to administer ganglion blockers (e.g. 
hexamethonium), prior to renal IRI, to investigate the possible requirement for an 
afferent sensory neural signal in mediating the cardio-protective effect of lethal 
renal IRI.
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8 SUMMARY+AND+CONCLUSIONS
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8.1 Summary,
 
The results of the experimental data presented in this thesis may be summarised as 
follows: 
 
8.1.1 Reduced+ischaemia+tolerance+in+chronic+uraemia+
The previously reported increase in myocardial infarct size sustained by animals 
rendered chronically uraemic as a result of subtotal nephrectomy135 was 
replicated. However, the same effect was not observed in an alternative model of 
chronic uraemia induced by adenine diet. This was despite a significantly greater 
degree of renal dysfunction, as evidenced by serum creatinine and urea and more 
profound anaemia. The cause of this discrepancy remains to be elucidated and 
should form the basis of future study. However, it does not appear to be due to an 
expansion in the nucleotide pool. 
 
8.1.2 Ischaemic+preconditioning+in+chronic+uraemia+
It was shown in the fourth chapter that in all models (SNx, AD and WO), chronic 
uraemia was not a barrier to IPC induced myocardial protection. Moreover, not 
only did uraemia not reduce the efficacy of IPC in protecting the heart, but in the 
SNx model there appeared to be enhanced protection from IPC, with a superior 
reduction in infarct size compared with that seen in sham operated control 
animals. 
 
In addition to infarct size reduction, IPC was shown to have a marked suppressive 
effect on ischaemia-reperfusion induced arrhythmias in both uraemic (SNx) and 
non-uraemic (sham) animals. 
 
Immunoblots demonstrated increased phosphorylation of STAT3 and ERK 1/2 
following three cycles of IPC, levels were qualitatively similar for both uraemic 
and non-uraemic animals. These findings are consistent with previously published 
mechanistic studies in non-uraemic animals and suggest that the IPC induced 
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protection remains dependent on the major intracellular signaling pathways (RISK 
and SAFE) described in the literature. 
 
8.1.3 The+ effect+ of+ uraemia+ on+ infarct+ size+ reduction+ afforded+ by+ remote+
ischaemic+preconditioning+(RIPC)+
The effect of uraemia on RIPC induced infarct size reduction was explored. As 
with IPC, RIPC induced by three cycles of femoral artery occlusion provided 
substantial cardioprotection, manifest as reduced infarct size. The magnitude of 
infarct size reduction was comparable between both uraemic (SNx) and non-
uraemic (sham) animals. This is the first time the effect of comorbidity upon the 
efficacy of infarct size reduction through RIPC has been studied. 
 
However, unlike IPC, RIPC did not appear to suppress ischaemia-reperfusion 
induced arrhythmias. 
 
8.1.4 Pharmacological+ preconditioning+ with+ HIF+ prolyl;4;hydroxylase+ (PHD)+
inhibitors+
The potential of HIF stabilisation as a pharmacological preconditioning strategy 
was investigated in the seventh chapter. A significant reduction in infarct size was 
observed in animals treated with the PHD2 inhibitor FG4497 six hours prior to 
myocardial ischaemia reperfusion injury. Infarct size reduction was observed to 
be proportional to plasma erythropoietin (Epo) levels, suggesting a possible role 
for Epo in mediating the cardio-protective effect observed. 
 
8.1.5 The+impact+of+acute+kidney+injury+on+myocardial+infarct+size+
The paradoxical finding of reduced myocardial infarct size in the setting of acute 
kidney injury, induced by 45 min of renal ischaemia, was described. It is believed 
that this tissue protective effect is analogous to that of delayed remote ischaemic 
preconditioning and represents the first report that ‘lethal’ ischaemia-reperfusion 
injury, of sufficient duration to cause organ dysfunction, may still induce 
cardioprotection. 
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8.2 Conclusions,
8.2.1 Ischaemia+tolerance+in+uraemia+
An improved understanding of the pathophysiology of uraemic heart disease may 
identify novel therapeutic targets to improve the long-term outcome for 
individuals with CKD and ESRD. To this end, a further and more detailed 
comparison of the adenine diet and sub-total nephrectomy models, in order to 
identify the reasons for increased infarct size in SNx rats, may provide valuable 
insights. 
8.2.2 Ischaemic+ preconditioning+ and+ remote+ ischaemic+ preconditioning+ in+
chronic+uraemia+
These data represent a comprehensive assessment of the effects of chronic 
uraemia on ischaemic conditioning and demonstrate that, unlike in diabetic,236-238 
dyslipidaemic239,363 and senescent animals,234,236 chronic uraemia does not appear 
to attenuate the effect of ischaemic preconditioning, remote ischaemic 
preconditioning. Indeed uraemic animals appear to derive greater protection than 
non-uraemic animals from protocols that involve manipulating the blood supply 
of the target organ directly (i.e. IPC). 
 
The reduction in infarct size for uraemic animals subjected to IPC was 
significantly greater than non-uraemic animals subjected to IPC. This observation 
may be the result of Type 2 error. However, it should also be noted that there was 
a non-significant trend towards a smaller area at risk in the SNx animals that 
received a single cycle of preconditioning. Alternatively, It is possible that as a 
result of a lower haematocrit, the uraemic animals had less “no-reflow” and thus 
the effect of IPC was enhanced by being combined with more extensive 
reperfusion, resulting in smaller myocardial infarcts in these animals compared to 
the less anaemic sham operated (non-uraemic) animals. Of note, uraemic animals 
treated with RIPC faired no better than their sham-operated counterparts. It is 
interesting to compare these results with those of Gritsopoulos364 who found that 
remote post-conditioning was a more potent cytoprotective strategy than classical 
post-conditioning, suggesting that further direct interference with the dependent 
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vascular bed, which had experienced the index ischemic episode, was not 
entirely without consequence. 
 
Given that ageing, diabetes and a variety of other metabolic disturbances have 
been acknowledged to reduce the efficacy of conditioning in both animal and 
human models. It is somewhat of a surprise that renal dysfunction does not appear 
to have a similar effect. We examined the effect of IPC in two different models of 
chronic uraemia, the sub-total nephrectomy (SNx) model, which is the most 
commonly used model to study the pathophysiology of impaired renal function, 
and adenine diet (AD) induced uremia. In our hands, SNx animals are typically 
hypertensive with LVH and have more significant anemia in comparison to those 
animals with renal dysfunction induced by AD. However, animals with AD may 
be considered to be more uremic in that the median serum creatinine is 
approximately 8 times that of controls, where as in SNx animals the median 
serum creatinine is usually around 3 times greater. Despite this apparent disparity 
in the degree of renal dysfunction, AD animals that received preconditioning had 
infarct sizes that were nearly 50% smaller. We believe that this agreement in 
results obtained from experiments employing these two different models is 
mutually supportive. 
 
8.2.3 Lost+in+translation+
It is nearly a quarter of a century since Murray and colleagues17 made their 
seminal discovery of ischaemic preconditioning and yet despite the widespread 
acknowledgement that ischaemic conditioning represents the most powerful 
cytoprotective strategies yet discovered, with overwhelming animal data to attest 
to the benefit of conditioning, it has failed to gain acceptance within the broader 
medical community or to be adopted into routine clinical practice. This is 
possibly due to a perceived, comparative lack of efficacy of conditioning in 
humans. Human trials conducted to date have mostly been small scale, usually 
from a single center, with limited length of follow-up, thus being underpowered to 
demonstrate mortality differences. They have therefore employed surrogate 
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outcome measures, such as the magnitude of rise in biomarkers of cardiac 
ischaemia.365  
 
Animal models that are used to evaluate cytoprotective strategies usually employ 
healthy, juvenile animals. This is in marked contrast to human disease, which 
rarely occurs in the absence of comorbidities. Such comorbid conditions may 
influence the efficacy of experimental treatments.366 Furthermore animal studies 
typically compare treated with untreated animals whereas in clinical trials, a new 
treatment, in addition to existing therapy, is compared to existing therapy alone. 
Thus animal studies may overestimate the benefit of a therapy. 
 
Renal dysfunction is a common comorbidity in those presenting with AMI and 
engenders an adverse prognosis. It may also modulate the risk benefit relationship 
for existing therapies. The fundamental purpose of these studies was to examine 
the effect of impaired renal function on conditioning strategies. 
 
It has been suggested that reperfusion therapy alone is sufficient to maximally 
limit infarct size for the majority of patients. However, it is estimated that one 
quarter of patients still sustain myocardial infarcts of >75% of the area at risk.193 In 
a recently published clinical trial of remote ischemic conditioning, 280 for a given 
area at risk, patients that received remote ischaemic conditioning had a smaller 
infarct size. This effect was most marked for those with the largest area at risk. A 
similar effect was seen in small clinical trial of iPost as an adjunct to primary 
PCI.367 Infarct size is a major risk factor for the development of post AMI heart 
failure and therefore long-term prognosis. With this in mind, a contributing factor 
to the apparently disappointing results of human trials of conditioning may be the 
result of poor patient selection. The highest risk groups, with the largest area at 
risk, should be targeted to receive adjuvant cardioprotective therapies. 
 
The higher event rate seen in patients with CKD and ESRD could in theory allow 
for trials, sufficiently powered to detect differences in mortality, to be conducted 
with a smaller sample size. It would be desirable to corroborate the results of the 
animal experiments in this thesis in human subjects with CKD and ESRD. 
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In conclusion, there is an urgent and at present unmet need to improve the 
prognosis of patients with CKD suffering AMI. Stratergies to reduce cardiovascular 
risk have done little to improve outcomes for patients with CKD. An alternative, 
but complimentary, stratergy to primary and secondary prevention is to attempt to 
reduce case fatality through the application of adjuvant myocardial protective 
therapies to early reperfusion. The routine exclusion of individuals with impaired 
renal function from clinical trials impedes the advancement of the care of these 
patients. The experimental work contained in this thesis provides the preclinical 
data to justify conducting clinical trials of preconditioning in patients with CKD. 
These individuals may derive benefits from preconditioning over and above that 
seen in patients without CKD.
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Figure 49 – Constituents of normal chow. 
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Notes
1. All values are calculated using a moisture basis of 10%.
Typical moisture levels will range between 9.5 - 11.5%.
2. a. Vitamin A includes Retinol and the Retinol equivalents of β-carotene
b. Retinol includes the Retinol equivalents of β-Carotene.
c. 0.48 µg Retinol = 1 µg β-carotene = 1.6 iu Vitamin A activity
d. 1 µg Retinol = 3.33* iu Vitamin A activity
e. 1 iu Vitamin A = 0.3 µg Retinol = 0.6 µg β-carotene
f. The standard analysis for Vitamin A does not detect β-carotene
3. 1µg Cholecalciferol (D3) = 40.0 iu Vitamin D
4. 1 mg all-rac-α-tocopherol = 1.1 iu Vitamin E activity
1 mg all-rac-α-tocopherol acetate = 1.0 iu Vitamin E activity
5. 1 MJ = 239.23 Kcalories = 239.23 Calories = 239,230 calories
6. These nutrients coming from natural raw materials such as cereals may have
low availabilities due to the interactions with other compounds.
7. Based on in-vitro digestibility analysis.
8. AF Energy = Atwater Fuel Energy = ((CO%/100)*9000)+
((CP%/100)*4000)+((NFE%/100)*4000)/239.23
9. Supplemented nutrients from manufactured and mined sources.
15. Calculated.
NUTRIENTS Total Supp (9)NUTRIENTS Total Supp (9)
Proximate Analysis
Moisture (1) % 10.00
Crude Oil % 2.71
Crude Protein % 14.38
Crude Fibre % 4.65
Ash % 6.00
Nitrogen Free Extract % 61.73
Digestibility Co-Efficients (7)
Digestible Crude Oil % 2.47
Digestible Crude Protein % 12.92
Carbohydrates, Fibre and Non Starch Polysaccharides (NSP)
Total Dietary Fibre % 17.05
Pectin % 1.52
Hemicellulose % 10.17
Cellulose % 4.32
Lignin % 1.68
Starch % 44.97
Sugar % 4.05
Energy (5)
Gross Energy MJ/kg 14.74
Digestible Energy (15) MJ/kg 11.90
Metabolisable Energy (15) MJ/kg 10.74
Atwater Fuel Energy (AFE)(8) MJ/kg 13.75
AFE from Oil % 7.42
AFE from Protein % 17.49
AFE from Carbohydrate % 75.09
Fatty Acids
Saturated Fatty Acids
C12:0 Lauric % 0.02
C14:0 Myristic % 0.14
C16:0 Palmitic % 0.31
C18:0 Stearic % 0.04
Monounsaturated Fatty Acids
C14:1 Myristoleic % 0.02
C16:1 Palmitoleic % 0.09
C18:1 Oleic % 0.77
Polyunsaturated Fatty Acids
C18:2(ω6) Linoleic % 0.69
C18:3(ω3) Linolenic % 0.06
C20:4(ω6) Arachidonic % 0.13
C22:5(ω3) Clupanodonic %
Amino Acids
Arginine % 0.91
Lysine (6) % 0.66 0.07
Methionine % 0.22 0.04
Cystine % 0.24
Tryptophan % 0.18
Histidine % 0.35
Threonine % 0.49
Isoleucine % 0.54
Leucine % 0.98
Phenylalanine % 0.66
Valine % 0.69
Tyrosine % 0.49
Taurine %
Glycine % 1.11
Aspartic Acid % 0.67
Glutamic Acid % 3.17
Proline % 1.20
Serine % 0.56
Hydroxyproline %
Hydroxylysine %
Alanine % 0.16
Macro Minerals
Calcium % 0.73 0.63
Total Phosphorus % 0.52 0.04
Phytate Phosphorus % 0.24
Available Phosphorus % 0.28 0.04
Sodium % 0.25 0.19
Chloride % 0.38 0.32
Potassium % 0.67
Magnesium % 0.23
Micro Minerals
Iron mg/kg 159.30 82.50
Copper mg/kg 11.50 1.94
Manganese mg/kg 72.44 19.22
Zinc mg/kg 35.75
Cobalt µg/kg 634.10 550.00
Iodine µg/kg 1202.69 1085.00
Selenium µg/kg 298.99 100.00
Fluorine mg/kg 10.49
Vitamins
β-Carotene (2) mg/kg 0.16
Retinol (2) µg/kg 2566.38 2400.00
Vitamin A (2) iu/kg 8554.27 8000.00
Cholecalciferol (3) µg/kg 15.54 15.00
Vitamin D (3) iu/kg 621.70 600.00
α-Tocopherol (4) mg/kg 76.45 56.82
Vitamin E (4) iu/kg 84.10 62.50
Vitamin B1 (Thiamine) mg/kg 8.58 1.96
Vitamin B2 (Riboflavin) mg/kg 4.33 2.94
Vitamin B6 (Pyridoxine) mg/kg 4.81 0.98
Vitamin B12 (Cyanocobalamine) µg/kg 7.49 6.00
Vitamin C (Ascorbic Acid) mg/kg 2.59
Vitamin K (Menadione) mg/kg 10.17 9.36
Folic Acid (Vitamin B9) mg/kg 0.79
Nicotinic Acid (Vitamin PP) (6) mg/kg 61.32 2.45
Pantothenic Acid (Vitamin B3/5) mg/kg 20.17 5.80
Choline (Vitamin B4/7) mg/kg 1080.14 366.60
Inositol mg/kg 2369.59
Biotin (Vitamin H) (6) µg/kg 277.13
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cycle arrest and resistance to apoptosis were shown to increase following individual drug 
treatment but the co-treatment abrogated these EMT associated gene changes.
 )79087'32?618,)%&-0-8=3*7	%2( %4%1='-2 83'%97)"-2
cells, however, our results have shown a possible protective role for co-treatment with 
Rapamycin in CsA-mediated EMT.
Disclosure of Financial Relationships: nothing to disclose
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
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!$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!	
of Renal Diseases  Shigeru Inomata, Minoru Sakatsume, Yuichi Sakamaki, 
Xingzhi Wang, Masakazu Wada, Takayoshi Miura, Yoshikatsu Kaneko, 
Shin Goto, Ichiei Narita, Fumitake Gejyo.  Division of Clinical Nephrology 
 Rheumatology, Niigata University Graduate School of Medical & Dental 
Sciences, Niigata, Japan.
Purpose: SM22A, a 22 kDa protein, is abundantly expressed in smooth muscle tissues 
and has been established as a novel marker of injured glomerular epithelial cells in the 
rat anti-glomerular basement membrane (GBM) nephritis by our previous studies (Ogawa 
A et al. Nephron Exp Nephrol 2007). In this study, we investigated the pathological 
7-+2-?'%2')3*!A)<46)77-32-238,)613()073*6)2%0(-7)%7)779',%78,)-7',)1-%
6)4)6*97-32 13()08,)2)4,6)'831=13()0%2(8,)49631='-2)%1-2329'0)37-()
(PAN) nephrosis.
Methods: Renal ischemia was induced by clamping left renal pedicle for 45min in 
male Sprague Dawley (SD) rats. The kidney was harvested at 0, 6, 12 hours  and 1, 2, 7 
(%=7%*8)66)4)6*97-322)4,6)'831=;%74)6*361)(&=6)13:-2+8,)6-+,8/-(2)=%2(
two poles of the left kidney in male SD rats. The kidneys were harvested after 1, 2, 4, 8 
weeks. PAN nephrosis was induced in male Wistar Kyoto rats by an intravenous injection 
3*%8%(37)3*	1+/+",)/-(2)=;%7,%6:)78)(%8%2(
(%=7%*8)68,)-2.)'8-32
Immunohistochemical studies were performed by using the mouse monoclonal antibody 
for SM22A.
 )790872 13()0!A was inducibly expressed in peri-tubular cells after 12 
hours reperfusion, and increased with the passage of time, but was not detected in any 
+031)690%6')007!-1-0%60=-8;%7)<46)77)(-24)6-89&90%6')0073*8,)2)4,6)'831=
model. In PAN nephrosis, it was preferentially expressed in glomerular epithelial cells 
after 7 days.
Conclusions: SM22A was expressed in injured renal parts not only in anti-GBM 
nephritis, but in other models of renal diseases. SM22A is a unique phenotypic marker 
of injured kidney cells and may be expressed in directly and strongly injured cells in the 
kidney.
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Tamm-Horsfall Protein Deficient Mice Are Susceptible to Chronic 
Pyelonephritis by Type 1 Fimbriated Escherichia coli  James M. Bates, Jr,1 
%.%13,-())2! %*?1 Zoltan Laszik,2 Satish Kumar.1  1Medicine/Nephrology, 
University of Oklahoma & VA Medical Center, Oklahoma City, OK; 2Pathology, 
University of California San Francisco, San Francisco, CA.
We have previously shown in short term (7days) studies that Tamm-Horsfall protein 
()?'-)281-') " %6)136) 4632) 83 '=78-8-7 &= 8=4) 
?1&6-%8)(E. coli (JASN 
14:377A, 2003). In this long term (30 days) study, we quantitated the local (bladder) and 
7=78)1-'-2@%11%836=6)74327)%2(8,)():)0341)283*4=)032)4,6-8-7-2" mice 
-2(9')(&=8=4)
?1&6-%8)(E. coli.
Twenty five microliters of an inoculum containing 108 E. coli was introduced 
transurethrally into THPand THP mouse bladders. Urine and blood were collected. 
Leukocytes (WBC) were measured in blood and urine at baseline, 12 hours and on days 1, 
3 and 7. IgG and IgA were measured in urine at baseline, and on days 1, 3, 7, 21 and 31. 
Bladders and kidneys were removed on day 32 for histomorphometric examination.
Urinary leukocytes (mean WBC x 10-3103*96-2)+ SE) were increased in the THP-
 mice at 12 hrs (THP1503 + 65 vs THP3900 + 1162, p = 0.036) and on day 1 (THP
1192 + 199 vs THP 3000 + 580, p = 0.007). Blood leukocytes (log10#903*&033(
+ SE) were higher in the THP mice at 12 hrs (THP3.73 + 0.04 vs THP3.91 + 0.09, 
p = 0.046), on day 1 (THP3.75 + 0.04 vs THP3.96 + 0.011, p = 0.047) and on day 3 
(THP3.88 + 0.05 vs THP4.03 + 0.06, p = 0.042). Neutrophils (%) were higher in the 
THPmice on day 1 (THP25 + 4 vs THP39 + 6, p = 0.034). Urinary IgG was greater in 
the THP mice on day 31 (THP
9+10+ 0.85 vs THP
	9+10+ 4.4, p = 0.042). 
Urinary IgA was similar in both groups. Cystitis and chronic pyelonephritis occurred in 
both groups but the area affected by chronic pyelonephritis (as measured on histologic 
sections) was much greater in the THP mice (THP0.85 mm2 + 0.28 vs THP 13.21 + 
4.40 mm2 , p = 0.007).
27911%6=8=4)
?1&6-%8)(E. coli)0-'-8)(%78632+)603'%0%2(7=78)1-'-2@%11%836=
response and led to more extensive pyelonephritis in THP mice. These data suggest that 
THP acts as a defense factor against both cystitis and pyelonephritis.
Disclosure of Financial Relationships: nothing to disclose
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Hemolysis Induced by A-Hemolysin from Escherichia coli Requires P2X 
Receptor Activation  Helle A. Praetorius,1 Niklas R. Jorgensen,2 Jens Leipziger,1 
Marianne Skals.1  1Inst. of Physiology and Biophysics, The Water and Salt 
Reseaech Center, University of Aarhus, Aarhus, Denmark; 2Dept. of Clinical 
Biochemistry, Roskilde Hospital, Roskilde, Denmark.
Escherichia coli-78,)(31-2%28*%'908%8-:)&%'8)6-91-28,)2361%0-28)78-2%0@36%
E.coli is, however, also responsible for the majority of serious urinary tract infections. 
There are distinct serotypical differences between the facultative and invasive E.coli-strains. 
Invasive strains frequently produce virulence factors as A-hemolysin (HlyA), which induces 
intracellular Ca2+ oscillations in renal epithelia and lysis of red blood cells by forming 
pores in the plasma membrane. The present study reveals that this pore-formation per se 
-723879*?'-)2883463(9'),)130=7-7",)0=8-')**)'83*0=6)59-6)7-28%'8496-2)6+-'
signaling in red blood cells.
Methods: HlyA was collected from the supernatant of E.coli strain ARD6. Haemolysis 
;%759%28-?)(&=348-'%0()27-8=	1)%796)1)2873*8,))6=8,63'=8)794)62%8%28
or by time laps microscopy.
Surpricingly, non-selective ATP-receptor (P2) antagonists (PPADS, suramin) and 
ATP scavengers (apyrase, hexokinase) abolished HlyA-induced lysis of equine, murine 
%2(,91%2)6=8,63'=8)7",)7)?2(-2+7'%2&)+)2)6%0->)(8338,)6436)*361-2+83<-27
as A-toxin from Staphylococcus aureus. The pattern of responsiveness to more selective 
P2-antagonists indicate that the relevant P2 receptor is the P2X7 receptor in human -, and 
a combination of P2X7 and P2X1-2196-2)%2()59-2))6=8,63'=8)7",)7)?2(-2+7;)6)
:)6-?)(-2)6=8,63'=8)7*631$7 mice. In addition, our results also implicate that pore-
protein, pannexin1 is necessary for HlyA-induced hemolysis, as various non-selective 
-2,-&-83673*8,-7',%22)07-+2-?'%280=6)(9')(,)130=7-7-2%008,6))74)'-)7
In conclusion, activation of P2X-receptors is required for hemolysis induced by the 
bacterial toxins, HlyA and A83<-2",)7)?2(-2+7,%:)'0)%6'0-2-'%04)674)'8-:)7%7
antagonists may ameliorate symptoms during gram negative urosepsis and offer the time 
window needed for the antibiotic treatment to become effective. This is especially interesting 
in the light of new P2X antagonists under current clinical trails.
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	$ %!#!
in the Rat Model of Coronary Artery Ligation  Conor Byrne, Kieran 
McCafferty, Julius Keiswich, Magdi Yaqoob.  Dept Translational Medicine  
Therapeutics William Harvey Research Institute, Charterhouse Sq, London, 
United Kingdom.
The presence of CKD is well recognised as an important predictor of poor outcome in 
survivors of acute myocardial infarction, and is included as a variable in several prognostic 
models e.g. GUSTO-1. However, it is unknown whether AKI has a bearing on prognosis. 
Emerging data suggests that even small, in hospital elevations in serum creatinine confer 
%4336)6 032+ 8)61463+237-7 8 -792/23;2;,)8,)6 8,)7)3&7)6:%8-3276)@)'8+6)%8)6
7):)6-8=3*36;,)8,)68,)46)7)2')3*-2@9)2')78,)4%8,34,=7-303+=3*
altering the prognosis. Animal models of AMI in the context of CKD have demonstrated 
an increase in infarct size in uraemic animals.
#),=438,)7-7)(8,%88,)-2@%11%836=1-0-)98,%8)<-787*3003;-2+/-(2)=-7',%)1-%
reperfusion (IR) injury might exacerbate cardiac IR injury.
Methods:
Male Wistar rats aged 7-8 weeks, underwent either bilateral renal ischaemia under 
/)8%1-2)$=0%>-2)%2%)78,)7-%*361-27*3003;)(&=,39676)4)6*97-3236%7,%1
procedure where both kidneys were decapsulated.
24 hours after renal IR the animals underwent cardiac IR employing reversible LAD 
ligation, 25 minutes ischaemia followed by 2 hours reperfusion, at the end of which the 
%2-1%07;)6)7%'6-?')(%2(8,)-2*%6'87->);%71)%796)()<46)77)(%7%4)6')28%+)3*
the area at risk.
Results:
Both groups were similar in terms of  blood pressure, weight and haematocrit. The 
6)2%0 +6394,%(7-+2-?'%280=,-+,)6'6)%8-2-2)8,%28,)7,%1+6394:90
(p=0.006)
Paradoxically we found a decrease in the size of myocardial infarction in the renal IR 
group compared with the sham operated group
We believe this observation is the result of the phenomenon of remote pre-conditioning. 
Further work is required to determine the underlying mechanism.
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Dietary Salt Intake Induces Peritoneal TGF-B"!	%#('#"
and Fast Transport Status in Rats  Anneleen Pletinck,1 Claudia Consoli,2 Maria 
Van Landschoot,1 Nick Topley,2 Raymond Vanholder,1 Wim Van Biesen.1  1Renal 
Division, University Hospital Ghent, Ghent, Belgium; 2Institute of Nephrology, 
Wales College of Medicine, Cardiff, United Kingdom.
Background
3/>+<C=+6>38>+5/2+=,//86385/.>9/82+8-/.-+<.3+-+8.</8+6G,<9=3=,C?:</1?6+>398
of TGF-B mRNA, but its impact on the peritoneal membrane has not been evaluated.
Methods
12 healthy non-uremic Wistar rats were randomised to NS (normal salt) or HS (high 
salt). They received normal rat chew. NS rats had free access to tap water, HS rats had 
only free access to NaCl 2% as drinking water. After two weeks, rats were subjected 
to an abbreviated rat PET test. Samples of dialysate (D) and plasma (P) were taken for 
determination of sodium, glucose and urea. Next, Visceral (VP) and parietal (PP) peritoneum 
A/</=+7:6/.09<;?+8>3G-+>39890(B mRNA by using the 7900HT Fast Real-Time 
system, and for histology.
Results
TGF-B° +8. !EE7&#A/</ =3183G-+8>6C79</ ?:</1?6+>/. 38 >2/' <+>=
compared to NS rats taken as standard. (°2.4 times higher, p=0.015 for VP and 1.6 times 
2312/<:			
09<%%EE>37/=2312/<:			
09<)%+8.>37/=2312/<:		

for PP)
#'@='%?</+A+=	F		@=		F		:		+>	+8.	F		@=
	F		:			+>
	738?>/=#9=3183G-+8>.300/</8-/A+=09?8.09<>2/9>2/<
:+<+7/>/<=3=>96913-+66CA/=+A38'<+>==3183G-+8>79</G,<9=3=38>2/)%:			

and a thicker PP (p=0.035).
Conclusion
An enhanced dietary salt intake in non uremic rats for a short period induced an 
?:</1?6+>39890:/<3>98/+6(,/>++8.!7&#/B:</==398>23=A+=+--97:+83/.
by an increase in small solute transport.
$?<.+>+0?<>2/<=?11/=>>2+>=+6>69+.3813=89>986C:<9G,<9>3->2<9?12(B, but also 
:<938H+77+>9<C>2<9?12!>2//00/->90=+6>>91/>2/<A3>2+8//.09<79</2C:/<>983-
.3+6C=+>/= >9-9:/A3>2H?3.9@/<69+.-9?6.2+@/+-?7?6+>3@/./><37/8>+6 37:+->98
peritoneal membrane structure so that salt restriction might be important in a dual way to 
preserve peritoneal function in PD patients. Further studies are planned considering the 
combined impact of salt intake and hypertonic dialysate.
Disclosure of Financial Relationships: nothing to disclose
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A Role of Wnt/B-Catenin Signaling in the Pathogenesis of Renal Interstitial 
Fibrosis  Weichun He, Chunsun Dai, Gang Zeng, Satdarshan P.S. Monga, 
Youhua Liu.  Department of Pathology, University of Pittsburgh, Pittsburgh, 
PA.
Wnt proteins are a family of signaling regulators that play an essential role in embryonic 
53.8/C./@/69:7/8>29A/@/<>2/3</B:</==39838+.?6>53.8/C3=>29?12>>9,/=36/8-/.8
this study, we report a comprehensive analysis of the expression and regulation of Wnts, 
>2/3<0<3DD6/.D.</-/:>9<=+8.+8>+1983=>=3889<7+6+8.G,<9>3-53.8/C=+0>/<9,=><?->3@/
injury. The vast majority of 19 different Wnts and 10 Fzd receptor genes were expressed 
at various levels in mouse adult kidney. Except Wnt5b, Wnt8b and Wnt9b, all members of 
>2/*8>0+736CA/</?:</1?6+>/.A3>2.3=>38->.C8+73-=38G,<9>3-53.8/C+0>/<?836+>/<+6
ureteral obstruction. The expression of most Fzd receptors and Wnt antagonists was induced 
as well. A dramatic accumulation of B-catenin in renal tubular epithelial cell cytoplasm 
and nuclei was observed after obstructive injury, indicating the activation of the canonical 
:+>2A+C90*8>=318+6381#?7/<9?=*8>B-catenin target genes, such as c-Myc, Twist, 
!
+8.G,<98/->38A/</38.?-/.+8.>2/3</B:</==398A+=-69=/6C-9<</6+>/.A3>2</8+6
B-+>/838+,?8.+8-//63@/<C90*8>+8>+1983=>3-559:0
1/8/=3183G-+8>6C</.?-/.
renal B-+>/838+--?7?6+>398+8.3823,3>/.>2//B:</==39890*8>B-catenin target genes. 
?<>2/<79</1/8/>2/<+:CA3>23-559:0
3823,3>/.7C9G,<9,6+=>+->3@+>398=?::</==/.
>C:/-966+1/8+8.G,<98/->38/B:</==398+8.</.?-/.>9>+6-966+1/8-98>/8>3879?=/
79./6909,=><?->3@/8/:2<9:+>2C(2/=/</=?6>==?11/=>+:3@9>+6<96/90*8>B-catenin 
=318+638138>2/:+>291/8/=3=90</8+6G,<9=3=>2/</09</>+<1/>381>23==318+6:+>2A+C7+C
,/+89@/6=><+>/1C09<>2/<+:/?>3-38>/<@/8>39890G,<9>3-53.8/C.3=9<./<=
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"#"#(& "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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%#$',  Bruce 
L. Riser,1,2 Feridoon Najmabadi,1 Bernard Perbal,3 Darryl R. Peterson,1 JoAnn 
Rambow,1 Herman Yeger,4 Melisa L. Riser,1 Sarah C. Riser.1  1Physiology and 
Biophysics, Rosalind Franklin Univ. of Medicine and Science, North Chicago, 
IL; 2Renal Division, Baxter Healthcare, McGaw Park, IL; 3Biochemistry and 
Virology, University of Paris, 7, Paris, France; 4Lab. Medicine and Pathobiol, 
Univ. Toronto, Hospital for Sick Children, Toronto, Canada.
Fibrosis is a major cause of end stage renal disease (ESRD), and although factors 
responsible for its initiation are being elucidated, a lack of understanding of the downstream 
</1?6+>9<C:+>2A+C=2+=:</@/8>/../@/69:7/8>90=:/-3G-+8>3G,<9>3->2/<+:3/=#
(CTGF) has emerged as a critical molecule acting both downstream and independent of 
TGF-B>9.<3@/38-</+=/./B><-/66?6+<7+><3B">?<89@/<+8.G,<9=3=7+53813>+8
attractive therapeutic target. However, attempts to suppress CCN2 activity have been 
.30G-?6>*//B+738/.>2/:9==3,363>C>2+>##$)+89>2/<#0+736C7/7,/<
with different reported biological activities, might act as an endogenous negative regulator 
90#A3>2>2/-+:+-3>C>96373>>2/G,<9>3-</=:98=/*/./798=><+>/09<>2/G<=>>37/
?=381+838@3><979./690</8+6G,<9=3=>2+>,9>2/B91/89?=></+>7/8>+8.><+8=0/->398A3>2
the over-expression of the CCN3 gene in mesangial cells markedly down-regulates CCN2 
activity and blocks collagen type I protein production and promoter activity stimulated by 
TGF-B. Conversely, TGF-B treatment decreases endogenous CCN3 expression allowing 
increased CCN2 activity along with enhanced collagen gene and protein expression, 
38.3-+>381+:9>/8>3+66C37:9<>+8>89@/6C38C+81/00/->8:</63738+<C+837+6=>?.3/=
?=381>2/.,.,79?=/79./690.3+,/>3-</8+6G,<9=3=#A+==29A8>9,/?:</1?6+>/.
late in the course of disease, at a time when disease progression is greatly limited and CCN2 
activity is returning to normal. CCN3 then, as a negative regulatory molecule of CCN2 
and the effects of TGF-B7+C+->8+>?<+66C>96373>G,<9=3=in vivo, and therefore provide 
opportunities for novel endogenous-based therapy.
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Cells: The Role of TonEBP  Christopher J. Rivard, Miguel A. Lanaspa, Ana 
Andres-Hernando, Tomas Berl.  Renal Diseases and Hypertension, University 
of Colorado Health Sciences Center, Denver, CO.
FSP1, also known as S100A4, expression is a marker of epithelial-mesenchymal 
><+8=09<7+>398+8.3=+==9-3+>/.A3>238-</+=/.38>/<=>3>3+6G,<9=3=*/</-/8>6C./798=><+>/.
that FSP1 is also an osmotic response protein in the kidney. While the functional role of 
FSP1 in the osmotic stress response has yet to be elucidated, the present study examines 
the transcriptional regulation of this protein in kidney cells. Analysis of the FSP1 promoter 
3./8>3G/.-98=/8=?==/;?/8-/=09<=/@/<+6><+8=-<3:>3980+->9<=38-6?.381(!#KB 
+8.(98%#((2/?=/90=:/-3G-6?-30/<+=/</:9<>/<-98=><?->=09<(+8.#KB 
revealed substantial transcriptional activity in IMCD3 cells under isotonic conditions with 
89 =3183G-+8> -2+81/A2/8-/66=A/</ /B:9=/.+-?>/6C >92C:/<>983- =></==9A/@/<
inhibition of TCF or NFKB activity independently by either pharmacological inhibitors 
or dominant negative or mutated constructs abolished the hypertonic expression of FSP1 
in IMCD3 cells suggesting that their respective transcriptional activity is necessary for 
FSP1 expression. In contrast to TCF and NFKB, luciferase reporter assays for TonEBP 
revealed only minor activity under isotonic conditions with a 2.8 fold increase under acute 
hypertonic stress. Employing the TonEBP inhibitor rottlerin at 5 – 10 MM or silencing 
TonEBP expression using a shRNA construct completely abolished S100A4 expression 
under hypertonic stress. These data therefore support a mechanism whereby TCF, NFKB 
and TonEBP transcription factors are all necessary for FSP1 expression under hypertonic 
stress but only TonEBP provides regulatory control under these conditions. We postulate 
that this could partially explain the greater propensity of medullary structures to develop 
38>/<=>3>3+6G,<9=3=
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Fibrogenesis  Shinong Wang,1 Edward Leof,2 Raimund Hirschberg.1 
1Nephrology, LABioMed at Harbor-UCLA Medical Center, Torrance, CA; 
2Biochemistry  Molecular Biology, Mayo Clinic College of Medicine, 
Rochester, MN.
TGFB3=+7+49<7/.3+>9<90</8+638>/<=>3>3+6G,<91/8/=3=+8.38>/<=>3>3+6G,<9,6+=>=
are its major target. We showed previously that TGFB38.?-/=:<9630/<+>39890G,<9,6+=>=
through a non-smad pathway involving abl downstream of PAK2 whereas transition to 
>2/7C9G,<9,6+=>:2/89>C:/3=7/.3+>/.,C>2/=7+.:+>2A+C' 



		
8-?6>?</.G,<9,6+=>=,?>89>/:3>2/63+6-/66=(B also activates mTORC1 (through 
tuberin), and we tested the hypothesis that the abl inhibitor Imatinib (Im) as well as the 
7($&
3823,3>9<&+:+7C-38&+:/+-2+8.38-97,38+>398+</+8>3G,<91/83-&+>=
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patients with FSGS and MCD destroyed the cytoskeleton and tight junction of podocyte. 
Injection of the sera caused proteinuria in rats as fast as 8h (0.5±0.03mg/ml vs 0.2±0.01mg/
ml control sera, p<0.01), renal tissue obtained at this point showed podocyte foot process 
effacement. CF presented in 16.3% of FSGS and 12.2% of MCD patients, while CF was 
not detected in other nephrotic patients (IgAN, MN, MPGN, lupus nephritis, diabetic 
nephropathy). Although decomplement, removed lipoproteins and IgG, the positive sera 
still contained the CF activity. Coincubation of serum with homologous urine and normal 
serum could not neutralize the activity of CF, it did not support the missing factor hypothesis. 
CF positive sera activated STAT6, p-38 MAPK and RhoA signal pathways. We concluded 
9/(9</0*/<(886,*0?*09>67,8,4*,046(90,498<09/$$(4+!+07,*92>(*954
podocytes. Multiple signal pathways involved in the effect of CF on podocytes. Our study 
provides a new approach to detect the CF in patients with FSGS, and paved the road to 
further explore the CF in patient based studies.
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Urinary Biomarkers for Distinguishing Subjects with Class IV from Class 
V Lupus Nephritis  Michiko Suzuki,1 M. Bennett,1 L. Das,1 K. Hanes,2 M. 
Klein-Gittelman,3 J. Olson, K. Onel,5 K. O’Neil,6 E. Silverman,7 L. Tucker,8 
N. Singer,9 M. Wyder,10 K. Greis,10 H. Brunner,1 P. Devarajan.1  1Cincinnati 
Children’s Hospital, Cincinnati, OH; 2Hackensack University; 3Children’s 
Memorial Hospital, Chicago, IL; 4Medical College of Wisconsin; 5University 
of Chicago; 6Oklahoma University; 7Hospital for Sick Children, University of 
Toronto; 8British Columbia Children’s Hospital, Vancouver, Canada; 9Case 
Western University, Cleveland, OH; 10University of Cincinnati.
The ISN/RPS class IV and V Lupus nephritis (LN) show different histological features 
and differ in prognosis. In this study we aimed to identify non-invasive biomarkers which 
differentiate between class IV and V LN. Urine samples from 6 children with class IV LN, 
<09/*2(88& "(4+<09/$$*549752<,7,89:+0,+22 "8(362,8<,7,*522,*9,+
within 60 days of a kidney biopsy. Subjects with overlapping features were not included. 
Two complementary proteomic methods were employed: 2 dimensional gel electrophoresis 
(4+$ %#!$',-5:4+6759,04880.40?*(492>5;,7,=67,88,+04*2(88
&;8*2(88&)>! %#!$	!$(4(2>8080+,490?,+9/,8,6759,048(8/:3(4
serum albumin fragments (25kDa) and A-1-B glycoprotein (60kDa). In SELDI-TOF-MS, 
we used four different types of ProteinChips and analyzed the spectra with ProteinChip 
Data Manager 3.07. The most robust and reproducible peaks are shown in the Table. These 
+,?4,(80.4(9:7,5-:704(7>)053(71,789/(9*2,(72>+08904.:08/),9<,,4*2(88&(4+*2(88
& "%/,8,?4+04.8/(;,,45735:803620*(90548459542>-57)053(71,7+08*5;,7>):9
also for differential pathogenic mechanisms for LN subclasses.
SELDI-TOF-MS peaks in LN
Class IV vs V * Control vs class IV ** Control vs Class V **
CM 10 7807 3273, 3323
NP 20 3266, 3278 
7787, 23119 23119
H 50 


25835, 28101






IMAC 30 
 

 7035, 15096, 15298
* Peaks (Da) with fold change >2, ** Peaks (Da) with fold change > 10
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Ischemic Preconditioning of the Uremic Heart Limits Myocardial Infarct 
Size  Kieran McCafferty, Conor J. Byrne, Julius Kieswich, Martin J. Raftery, 
Magdi M. Yaqoob.  Translational Medicine and Therapeutics, William Harvey 
Research Inst, London, United Kingdom.
Background
Direct ischemic preconditioning (dIPC) and remote ischemic preconditioning (rIPC) 
are processes by which brief nonlethal periods of ischemia in a remote tissue in the case of 
rIPC or in the dependant tissue in the case of dIPC, render that tissue resistant to subsequent 
lethal injury. There is evidence that additional co-morbidities, such as senescence  diabetes 
may render hearts more resistant to the effects of preconditioning. There is no published 
data examining the effects of uremia on preconditioning.
Methods and results
Male Wistar rats underwent subtotal nephrectomy (SNx) or a sham procedure (Sham 
SNx).
A preconditioning cycle consisted of 5 min arterial occlusion (LAD or femoral) 
followed by 5 min reperfusion.
3 experiments were performed:
Methods and Results
Subjects Preconditioning (x cycles)
Ischaemia 
duration 
(mins)
Reperfusion 
duration 
(mins)
Median infarct 
size 
(% of AAR)
p value
Expt 1 SNx No preconditioning 25 120 61.2 <0.005
SNx IPCx3 25 120 7.5
Expt 2 SNx IPCx1 35 120 16.8 <0.01
Sham SNx IPCx1 35 120 
Expt 3 SNx RIPCx3 25 120 33.2 NS
Sham SNx RIPCx3 25 120 22.1
Discussion
Exp.1: demonstrates that the uremic heart can be preconditioned.
Exp.2: suggests that there is no increase in resistance to dIPC in the uremic heart.
Exp.3: suggests that chronic uremia does not render hearts resistant to rIPC. When 
compared to control experiments the relative reduction in infarct size was comparable 
between sham and SNx groups (Sham SNx 50.8% v SNx. 52.9%)
Conclusions
This study suggests that clinical trials using rIPC or dIPC in uremic patients could 
improve outcomes following cardiac interventions and that CKD patients should not be 
excluded from future trials.
Disclosure of Financial Relationships: nothing to disclose
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Impact of Chronic Kidney Disease on Risk of Incident Congestive Heart 
Failure and Subsequent Survival in Medicare Patients  Charles A. Herzog, 
Shuling Li.  CVSSC, USRDS, Minneapolis, MN.
Introduction: Congestive heart failure (CHF) is a major cause of morbidity and 
mortality in elderly pts and CKD is a multiplier of risk.
Methods:',0+,490?,+
698(.,67,;(2,49		
049/,,4,7(2
Medicare database (CHF and ESRD excluded) and followed through 12/31/07. The risk of 
developing CHF was assessed in a Cox model adjusting for demographics, comorbidity, 
and CKD stage (from ICD-9 codes 585.1-585.5, 585.9). Age-adjusted survival of CHF pts 
was estimated by Kaplan-Meier method.
Results:%/,67,;(2,49

*5/579<(83(2,</09,(.,
(.,
(.,(.,
(4+(.,>89(.,45

89(.,89(.,&89(.,:4145<4>89(.,04*0+,49
occurred in 5.3% no CKD, 12.7% stage I-II, 15.0% stage III-V, 12.3% stage unknown. The 
Table shows predictors of CHF (age 66-69, male, white, no CKD, no comorbid conditions 
is reference) with hazard ratio (HR) and survival of CHF pts.
Conclusion: CKD stage is a predictor of incident CHF and subsequent risk of death in 
elderly pts. Medicare pts with CKD and CHF have high one year mortality.
Predictors of CHF
Variable HR (95%CI) P   
.,
 
 <.0001   
Age 75-79 1.75 (1.70,1.80) <.0001   
.,
 
 <.0001   
., 3.82 (3.71,3.93) <.0001   
Female 0.95 (0.93,0.96) <.0001   
Black 1.21 (1.18,1.25) <.0001   
Anemia  <.0001   
Diabetes 1.57 (1.55,1.60) <.0001   
Atherosclerotic heart disease 
 <.0001   
Dysrhythmia 
 <.0001   
CKD Stage I-II  <.0001   
CKD Stage III-V 1.68 (1.61,1.75) <.0001   
CKD (Stage unknown) 1.27 (1.22,1.32) <.0001   
     
Survival (Mos) CKD Stage    
 No CKD I-II III-V Stage Unknown
1 95.6  93.0 87.3
6 88.6 83.1 82.5 
12 83.2  75.1 67.1
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Abstract 4841: The Impact of Chronic Uremia on
Ichemic Preconditioning of the Myocardium
Kieran Mccafferty ; Conor Byrne ; Julius Kieswich ; Magdi Yaqoob
William Harvey Rsch Inst, London, United Kingdom
Background Ischemic Preconditioning (IPC) is a process by which brief non lethal
periods of ischemia render the dependant tissue resistant to subsequent lethal
injury. This process has been extensively studied in animal models and this has
led to human clinical trials. There is evidence to suggest that additional co-
morbidities may render hearts more resistant to the effects of IPC. There is no
published data examining the effects of chronic uraemia on IPC. This is of clinical
importance due to the burden of cardiovascular disease in CKD patients.
Hypothesises
1. Can uremic hearts respond to an IPC stimulus 
2. Can uremic hearts respond to an IPC stimulus as well as non uremic hearts 
Methods The 5/6 nephrectomy model (SNx) in male Wistar rats was used as a
model of chronic uraemia. We performed 2 experiments to test the hypothesises.
Expt 1: SNx rats were divided into 2 groups. The control group (n=15) underwent
myocardial ischemia using reversible LAD artery ligation. The LAD was occluded
for 25 minutes and reperfused for 2 hours. The IPC group (n=4) had 3 cycles of 5
minutes LAD ligation and 5 minutes reperfusion followed by 25 min occlusion
and 120min reperfusion. Expt 2: SNX animals (n=8) and Sham controls (n=6)
underwent x1 cycle of IPC as above with 35minutes ischemia 2 hours reperfusion.
At the end of the experiment the animals were sacrificed and the infarct size was
measured and expressed as a percentage of the area at risk (AAR).
Results Expt 1: Median Infarct size was 61.2% and 7.5% in the control and IPC
groups respectively (P=0.003) Expt 2: Median infarct size was 16.8% and 43.7% in
the SNX and sham SNx groups respectively. (P=0.008) The AAR was not
significantly different in any of the groups studied.
Discussion This is the first evidence that unlike ‘old’ hypertensive rats and
diabetic rats, uremic rats can respond to a preconditioning stimulus. Furthermore
it appears that the preconditioning may confer greater protection in uremic
animals than controls. We hypothesize that the significantly lower haemoglobin in
the uremic animals reduces microvascular occlusion which may occur during IPC.
Work is underway to quantify this finding.
Conclusion This study suggests that clinical trials using IPC in uremic patients
could improve outcomes following cardiac interventions.
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Male Wistar rats were fed a diet containing 0.75% adenine for 4 weeks or underwent 
a 2 stage sub-total nephrectomy or a sham procedure. The animals were allowed 4 weeks 
to develop a uremic phenotype. Myocardial infarction was induced by occluding the left 
anterior descending artery for 25 min followed by 2 hrs reperfusion at the end of which 
6*'#0+/#.59'4'5#%4+>%'&#0&+0(#4%65+<'&'6'4/+0'&
 '47/%4'#6+0+0'9#55+)0+>%#06.;*+)*'4+06*'#0+/#.59+6*#&'0+0'+0&7%'&4'0#.
failure (median 145 v 86 v 34.7 µmol/l; p=0.0001). Despite this there was no difference in 
+0(#4%65+<'$'69''04#659+6*#&'0+0'+0&7%'&74#'/+#145*#/#0+/#.5('&%10641.&+'6
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	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
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
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higher mean arterial blood pressures (MAP) compared with the other groups (141 +/- 17 
v 150 +/- 12.4 v 143 +/- 19.7 mmHg), they also had the lowest mean haemoglobin of the 
3 groups (11.4 +/- 1.84 v 13.8 +/- 1.85 v 8.7 +/- 1.68 g/dl).
In these animal models of chronic kidney disease, the degree of uremia per se does not 
#22'#461*#8'#5+)0+>%#06+/2#%610/;1%#4&+#.+0(#4%65+<';2'46'05+10#0&&')4''1(
#0#'/+#/#;9'..2.#;#/14'5+)0+>%#0641.'+0&'6'4/+0+0)+0(#4%65+<'746*'4914-+5
4'37+4'&61+&'06+(;6*'(#%6145%1064+$76+0)61.#4)'4+0(#4%65+<'+06*' :/1&'.
Disclosure of Financial Relationships: nothing to disclose
SA-PO2382
Ischemic Preconditioning Protects the Heart in the Adenine Model of Severe 
Chronic Uremia  Kieran Mccafferty, Conor Byrne, Julius Edward Kieswich, 
Martin J. Raftery, Magdi Yaqoob.  William Harvery Research Institute, Queen 
Mary university London, London, United Kingdom.
Ischemic preconditioning (IPC) is a process by which brief episodes of ischemia 
and reperfusion to an organ render that tissue resistant to subsequent ischemic injury. 
Comorbidities such as diabetes and senescence attenuate the effects of IPC. We have 
previously shown that the uremic heart can be preconditioned (ASN 2009 PO1228). 
However, the sub-total nephrectomy model(SNx) is a model of mild-moderate CKD. It is 
still unknown whether severe CKD limits the effects of IPC.
Male Wistar rats were given 4 weeks of 0.75% Adenine diet to induce severe uremia. 
Animals then underwent either an IPC protocol of 3cycles of 5 minutes ischaemia/
reperfusion to the left anterior descending artery (LAD), or sham IPC protocol before 
undergoing an acute myocardial infarction (AMI) of 25 minutes LAD ligation and 2 
hours reperfusion.
Results
Control Adenine SNx p
Weight (g) 419 (35) 223 (20) 389 (29) 0.0001
Creatinine (umol/l) 32.1 (4.8) 252.6 (52.4) 133.5 (79.7) 0.0001
Hematocrit (%) 41.6 (3.1) 29.8 (7.3) 28 (5.7) 0.0001
"#.7'55*190#5'#0 #0&#0#.;<'&75+0)"
Adenine animals are anemic, growth restricted, have twice the plasma creatinine of 
the SNx model, and 7 times the creatinine of a non uremic control group. (Data shown 
from previous work)
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following IPC compared to Sham IPC animals.
Conclusions
These data in conjunction with our past work in the SNx model, suggests preconditioning 
affords protection across the spectrum of CKD.
CKD patients have poor outcomes following AMI and have been routinely excluded 
from trials in IPC. Our work suggests CKD patients should not be excluded from trials 
and have much to gain from future work in preconditioning.
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1,25-Dihydroxyvitamin D Is Associated with Cardiac Structure but Not 
Function in Patients with CKD  William G. Petchey, Brian A. Haluska, 
Erin Howden, Rodel Leano, David W. Johnson, Nicole M. Isbel.  CCRE - 
Cardiovascular Disease and Metabolic Disorders, Brisbane, Australia.
Background Patients with Chronic Kidney Disease (CKD) experience a greatly 
increased risk of cardiovascular events. Vitamin D status is inversely related to 
cardiovascular morbidity, both in the general and CKD populations. Animal models suggest 
this risk may be related to cardiac hypertrophy and dysfunction in states of hypovitaminosis 
D. CKD patients are at increased risk of hypovitaminosis D, due to an impaired ability to 
generate active 1,25-dihydroxyvitamin D (1,25-OHD), irrespective of substrate availability 
(25-hydroxyvitamin D, 25-OHD).
Hypothesis 1,25-OHD but not 25-OHD is negatively associated with cardiac mass 
and early diastolic dysfunction in patients with CKD.
Methods Patients with stages 3-4 CKD were recruited. Cardiac structure was assessed 
echocardiographically by: left ventricular (LV) mass (indexed to height2.7, LVMI); septal 
and posterior wall thickness (SWT and PWT respectively). Diastolic dysfunction was 
&'>0'&#5/+64#.+0?19&'%'.'4#6+106+/'
/5'%14
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left atrial enlargement (>20cm2).
Results Population characteristics (n=104); age 59±10 years, 60% male, eGFR 39±9ml/
min, BP 135±14/77±7mmHg. Whilst there was no association between cardiac structure 
and 25-OHD, 1,25-OHD correlated negatively with SWT (r=-0.22, p=0.032), PWT (r=-
0.22, p=0.029), and LVMI (r=-0.26, p=0.011), and the effect was independent of eGFR. 
+#561.+%&;5(70%6+109#524'5'06+0
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with either 25-OHD or 1,25-OHD concentrations. In multivariate analysis, higher LVMI 
was independently associated with a history of coronary artery disease, LV preload (end 
diastolic volume), BMI, systolic BP and inversely with 1,25-OHD (adjusted R2=0.40, 
p<0.0001). In this model, every 6.7pmol/L increase in serum 1,25-OHD predicted an 
average decrease in LV mass of 1g/m2.7 (p=0.004).
Conclusion LV mass is negatively correlated with 1,25-OHD in patients with 
CKD, however there is no association with LV diastolic function. Whether 1,25-OHD 
supplementation can regress LV mass in pre-dialysis CKD patients should be the subject 
of future work.
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Molecular Cardiology
Ischemic Conditioning Protects the Uremic Heart in a
Rodent Model of Myocardial Infarction
Conor J. Byrne, MBBS, BSc*; Kieran McCafferty, MBBChir, MA*; Julius Kieswich, BSc;
Steven Harwood, PhD; Petros Andrikopoulos, PhD; Martin Raftery, MBBChir;
Christoph Thiemermann, PhD**; Muhammad M. Yaqoob, MD**
Background—Outcomes after acute myocardial infarction in patients with chronic kidney disease are extremely poor.
Ischemic conditioning techniques are among the most powerful cytoprotective strategies discovered to date. However,
experimental data suggest that comorbidity may attenuate the protective effects of ischemic conditioning.
Methods and Results—We conducted investigations into the effects of chronic uremia on myocardial infarct size and the
protective effects of ischemic preconditioning (IPC), remote ischemic preconditioning, and ischemic postconditioning
in 2 rodent models of chronic uremia. In addition, a limited investigation into the signaling mechanisms involved in
cardioprotection after IPC was performed in both uremic and nonuremic animals. Myocardial infarct size was increased
in uremic animals, but all 3 conditioning strategies (IPC, remote IPC, ischemic postconditioning) proved highly
efficacious in reducing myocardial infarct size (relative reduction, 86%, 39%, and 65% [P!0.005, P!0.05, and
P!0.05], respectively). Moreover, some protocols (IPC and ischemic postconditioning) appeared to be more effective
in uremic than in sham (nonuremic) animals. Analysis of the signaling mechanisms revealed that components of both
the reperfusion injury salvage kinase and survivor activating factor enhancement pathways were similarly upregulated
in both uremic and nonuremic animals after an IPC stimulus.
Conclusion—Conditioning strategies may present the best opportunity to improve outcomes for patients with chronic
kidney disease after an acute coronary syndrome. (Circulation. 2012;125:1256-1265.)
Key Words: ischemia ! ischemic postconditioning ! ischemic preconditioning ! myocardial infarction
! renal insufficiency
Cardiovascular disease is the leading cause of death forpatients with moderate to severe chronic kidney disease
(CKD; stages 3–5), and remains among the commonest
causes of death for recipients of renal allografts.1,2 Although
most cardiovascular deaths are due to heart failure or sudden
cardiac death, the rate of acute myocardial infarction (AMI)
among patients with CKD is more than twice that of patients
without CKD.3
Editorial see p 1215
Clinical Perspective on p 1265
There is a graduated risk of death for patients with kidney
disease after AMI. Hospital mortality is in the order of 26%
to 32%,4,5 some 15 times the rate for patients without CKD
(2% in-hospital mortality) and greater than twice the risk of
diabetic patients without CKD. One-year survival for dialysis
patients after MI is a little over 40%,6 and despite significant
advances in the management of AMI over the last 30 years,
there has been little change in the prognosis for patients with
CKD after AMI.
Patients with an eGFR !60 ml/min/1.73 m2 make up
between a quarter to nearly one third of patients presenting
with an acute coronary syndrome.4,7,8 Despite making up a
sizeable proportion of patients presenting with both ST-
segment–elevation and non–ST-segment–elevation myocar-
dial infarction, these patients are routinely excluded from
clinical trials,9,10 resulting in a dearth of prospective data on
which to base clinical practice guidelines.
A consistent feature of observational studies has been the
recognition that patients with CKD are less likely to receive
reperfusion or revascularization therapies. The underuse of
such treatments, so-called therapeutic nihilism, was thought
to explain much of the excess mortality seen after AMI in
patients with impaired renal function; indeed, this maybe a
contributing factor.4 However, emerging data from a number
of registry studies suggest that, even when they are optimally
treated, outcomes for patients with CKD receiving primary
percutaneous coronary intervention (PCI) for AMI remain
poor. Even those patients with relatively mild CKD (stage 3;
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estimated glomerular filtration rate, 30–59 mL/min) have
roughly 7 times the rate of in-hospital mortality as patients
without CKD.7 Furthermore, reperfusion therapy seems to
have little impact on in-hospital mortality for patients with
CKD, and PCI for those with the most severe degrees of renal
dysfunction may actually be harmful.8,11 However, in recip-
ients of reperfusion therapy who survive to hospital dis-
charge, the long-term prognosis appears to be improved by
primary PCI and early revascularization.4 Additionally, in
patients with stable coronary artery disease, PCI does not
improve outcomes for patients with mild CKD over optimal
medical management.12 The factors determining outcomes
for patients with CKD remain largely unstudied.
The cause of the excess mortality seen in patients with
CKD after AMI is likely to be multifactorial. Individuals with
CKD are at increased risk of bleeding, and several studies
have highlighted the risk of increased hemorrhagic compli-
cations after PCI associated with CKD.13 However, even
when bleeding episodes are corrected for, the outcome for
patients with CKD remains significantly worse,14 suggesting
that additional factors specific to patients with impaired renal
function may be of importance. Patients with CKD are
significantly more likely to experience postinfarction heart
failure and cardiac arrest.15
Discovered by Murry and colleagues16 in 1986, ischemic
preconditioning (IPC) describes the phenomenon whereby a
brief episode or episodes of “sublethal” ischemia (ie, of insuffi-
cient duration to result in tissue damage) followed by reperfu-
sion confer resistance to a subsequent, more prolonged or lethal
episode of ischemia/reperfusion. Subsequently, Przyklenk et al17
reported that vascular beds adjacent to the preconditioned
territory were also rendered resistant to ischemia reperfusion
injury. It was later determined that this cytoprotective effect was
also seen between organs, and the term remote IPC (RIPC) was
coined to describe this phenomenon. In 2003, Zhao et al17a
extended the scope of conditioning when they discovered ische-
mic postconditioning (iPost). By interrupting reperfusion with
three 30-second episodes of ischemia, they were able to achieve
a substantial reduction in myocardial infarct size.
IPC, RIPC, and iPost, which we refer to together as
conditioning strategies, are arguably the most powerful car-
dioprotective therapies yet discovered and may be considered
benchmarks against which to determine the relative efficacy
of potential drug therapies. Data from both animal models
and small-scale human studies suggest that the effect of
conditioning may be attenuated by diabetes mellitus18–20 and
senescence21,22 as result of perturbations in the signal trans-
duction mechanism.23 However, the effect of uremia on the
response to conditioning stimuli is unknown.
We conducted a series of experiments to investigate the
effects of chronic renal failure on the efficacy of a variety of
conditioning protocols.
Methods
All experiments were approved by our institutional ethics committee
and performed under license granted by The Home Office (United
Kingdom) in accordance with the Animals (Scientific Procedures)
Act 1986. Male Wistar rats were used for all experiments (Charles
River Laboratories UK, Margate, UK).
Models of Chronic Uremia
Subtotal Nephrectomy
Animals first underwent a 2-stage subtotal nephrectomy (SNx) or a
sham procedure in a manner similar to that previously described.24–26
In brief, animals were anesthetized with isoflurane (Animalcare,
York, UK) and nitrous oxide (BOC, UK) with analgesia (buprenor-
phine, Reckitt Benckiser Healthcare UK Ltd, Hull, UK; 0.04 mg/kg).
Via a flank incision, the left kidney was decapsulated and approxi-
mately two thirds resected. Hemostasis was achieved with direct
compression, after which the kidney was returned to the retroperi-
toneal space. Before closure, 0.5 mL saline was instilled into the
peritoneal cavity. The incision was closed in layers with 4-0 vicryl
for the muscle layers and surgical clips (Precise Vista 3M, Bracknell,
UK) for the skin. The animals were allowed 14 days to recover
before undergoing the second stage of the procedure, right total
nephrectomy, which was performed via a flank incision as above.
Sham animals had the appropriate kidney decapsulated only. Cre-
ation of SNx animals was carried out by a single operator to reduce
variability in serum creatinine.
The animals were allowed 4 weeks after the second stage (right
total nephrectomy) to recover and to develop the uremic phenotype
before undergoing myocardial ischemia/reperfusion.
Adenine Diet
After a week of acclimatization, a diet containing 0.75% (by weight)
adenine (AD; Special Diet Services, Essex, UK) was fed to 6-week-
old male Wistar rats for 4 weeks, as described previously by
Yokozawa et al.27 At the end of the 4 weeks, the animals had
developed a marked degree of uremia and were used for left anterior
descending artery ligation experiments. A control group was fed
normal chow for 4 weeks.
Myocardial Ischemia/Reperfusion
Myocardial ischemia/reperfusion was carried out in a manner similar
to that described previously.28 Animals were anesthetized with an
intraperitoneal injection of sodium thiopental (73 mg/kg for SNx
animals, 88 mg/kg for sham animals; LINK Pharmaceuticals, Hor-
sham, UK); a tracheostomy was performed; and an arterial line to
monitor pulse and blood pressure was inserted into the right carotid
artery. Another line was inserted into the right jugular vein to
administer maintenance anesthesia and fluids.
The animals were ventilated with small-animal ventilator (Harvard
Apparatus, Kent, UK). Ventilatory parameters were adjusted in
response to arterial blood gas analysis (ABL77, Radiometer Ltd,
Crawley, UK).
A left parasternal incision was performed with electrocautery
(PromhoVet, Barcelona, Spain); the ribs and thymus were retracted;
and the pericardium was resected. A 6-0 silk suture was placed
through the myocardium at the approximate level of the left anterior
descending artery. A piece of polythene tubing (Portex, Smiths
Medical, Watford, UK), flared at 1 end, was placed over the free
ends of the suture to form a snare.
Determination of Infarct Size
As previously described,28 at the end of reperfusion, the left anterior
descending artery was reoccluded, and Evans blue dye was injected
via the right jugular vein to delineate the area at risk. The heart was
excised and immersed in ice-cold 0.9% saline to achieve cardiople-
gia and then sliced in transverse sections to the level of the suture.
The right ventricle was dissected from the left, and then the blue
perfused portion of the left ventricle was separated from the undyed
area at risk. The 2 portions of tissue were weighed, the ratio
indicating the proportion of the left ventricle that was at risk. The
tissue from the ischemic zone was then diced into small pieces
(!1 mm3) and incubated in nitro blue tetrazolium (0.5 mg/mL) for 30
minutes. Nitro blue tetrazolium is reduced to a dark blue/purple azole in
the presence of reducing compounds, enabling the necrotic tissue to be
distinguished from viable tissue. The tissue was divided into 2 aliquots
based on the presence of purple staining. Infarct size was given by the
ratio of the weights of these 2 quantities of myocardium.
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Cardiac Troponin I Assay
A cardiac-specific rat troponin I ELISA (Life Diagnositics, West
Chester, PA) was used. Blood was drawn into a heparinized syringe
after 2 hours of reperfusion. The blood was immediately separated in
a centrifuge; the plasma was aspirated and snap-frozen in liquid
nitrogen before being stored at !80°C until assayed. The assay was
performed in accordance with the manufacturer’s instructions with
the only modification being a 1:8 dilution of the plasma samples
performed with the standard diluent contained in the kit. A further 1:4
dilution was performed with plasma diluent, as specified in the manu-
facturer’s instructions, giving a final dilution of 1:32. This was done to
maintain the optical density within the range of the standard curve.
Conditioning Protocols
Ischemic Preconditioning
One or 3 cycles of 5 minutes of left anterior descending artery
occlusion (ischemia) were followed by 5 minutes of reperfusion
before either 25 minutes (standard) or 35 minutes of sustained
ischemia (threshold experiment; see Figure 1).
Remote Preconditioning
The left femoral artery was carefully dissected out and separated
from the femoral vein and nerve. A ligature was placed around the
artery to assist in mobilization. A microvessel clip was used to
Figure 1. Diagrammatic representation of conditioning protocols.
Figure 2. Uremic rats sustain larger myocardial
infarcts compared with sham-operated controls.
A, Uremic animals (SNx) sustained myocardial
infarcts that were approximately one third larger
than those of sham-operated controls (32%;
*P"0.033). B, The area at risk was similar for both
groups (P"0.235). C, Uremic animals were signifi-
cantly more anemic, as evidenced by a lower
hematocrit, 27% as opposed to 39%
(***P"0.0003). D, Median serum creatinine was
34.4 !mol/L in the sham animals and 91.0 !mol/L
in the uremic (SNx) animals (****P#0.0001). Box
and whisker plots: whiskers indicate minimum and
maximum values; box, interquartile range (IQR);
line, median; and $, mean.
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occlude the artery. Pallor and a reduction in the temperature of the
paw confirmed occlusion. Reperfusion was confirmed by hyperemia
followed by restoration of normal color and temperature. Three
cycles of 5 minutes of ischemia followed by 5 minutes of reperfusion
were used.
Postconditioning
Left anterior descending artery occlusion (ischemia) for 25 minutes
with 5 cycles of 10 seconds of reperfusion/10 seconds of ischemia
on reperfusion was followed by an 1 hour 58 minutes 20 seconds of
reperfusion (ie, 2 hours of reperfusion in total). At the end of the final
reperfusion period, the animals were euthanized, and their hearts
were harvested for determination of infarct size.
Immunoblotting and Protein Extraction
Hearts from sham-operated or uremic animals subjected to the IPC
protocol detailed above were excised, washed once in ice-cold PBS,
snap-frozen in liquid N2, and stored at !80°C until further use. A
total of 20 rats (10 SNx, 10 sham-operated controls) split into 4
groups of 5 were used to study the response to a preconditioning
stimulus in the subtotal nephrectomy model. Another 15 rats were
used to investigate signal transduction in the AD model (8 control
animals split into 2 groups of 4 and 7 AD animals, 3 of which were
preconditioned).
Tissues for western blot were triturated with a mortar and pestle
under liquid N2 and subsequently polytron homogenized (30-second
bursts with 1-minute intervals on ice 3 times) in a mammalian
protein extraction buffer (GE Healthcare; 10:1 vol/wt) supplemented
with the following inhibitors: 1 mmol/L EDTA, 0.5 mmol/L DTT,
1% vol/vol protease inhibitor cocktail (Sigma), 1 mmol/L NaF,
5 !mol/L fenvalerate (Calbiochem), 1 mmol/L Na3VO4, and 1%
vol/vol phosphatase inhibitor cocktails I and III (Sigma). The tissue
homogenate was incubated for 10 minutes on ice and then centri-
fuged at 5000g for 10 minutes at 4°C. The supernatant was divided
into aliquots and stored at !80°C until further use. Protein concen-
trations were determined with the bicinchoninic acid assay (Pierce)
with BSA (Sigma) as the protein standard.
Lysates (40 !g protein) were subjected to SDS-PAGE with the
NuPAGE electrophoresis system (Invitrogen) under reducing condi-
tions as previously described.29 The ECLplus chemiluminescence
detection kit (Amersham Pharmacia) was used to visualize protein
bands. The following antibodies (supplied by Cell Signaling) were
used: rabbit anti–phspho-p44/p42 MAPK (Thr202/Tyr204), rabbit
anti-p44/p42 (total ERK), mouse anti–phospho-AKT (Ser473), rab-
bit anti-AKT (total AKT), mouse anti–phospho-STAT3 (Tyr705),
rabbit anti-STAT3 (total STAT3), and peroxidase-conjugated sec-
ondary antibodies.
Densitometry was performed with Image J software on the
immunoblots obtained. The method used was described previously.30
Statistical Analysis
Data were analyzed with GraphPad Prism software (San Diego, CA).
Given the relatively small sample size in some of the experiments,
nonparametric statistical analysis was used when possible, and the
data are presented as median with interquartile range (IQR). Two-
way ANOVA with Bonferroni posttest comparison was used to
analyze the results of experiments with a 2"2 factorial design
(immunoblot studies, RIPC, and iPost); a 2-tailed Mann-Whitney U
test was used to test for significance in all other experiments.
Results
Determination of Myocardial Infarct Size in
Uremic Animals: Reduced Ischemia Tolerance?
In our first series of experiments, we sought to replicate
previously published data suggesting that uremic animals
sustain larger myocardial infarctions than nonuremic sham-
operated controls.31 We were able to demonstrate a modest
but statistically significant increase in myocardial infarct size
in uremic rats compared with sham animals (sham, 47.2%
[IQR, 39.8%–63.7%] versus SNx, 62.3% [IQR, 53.5%–
69.5%]; relative increase, 32%; P#0.03; Figure 2). The
increase in infarct size was remarkably similar to that
Figure 3.Ischemic preconditioning (IPC) markedly reduced
infarct size in uremic animals and was more effective in uremic
than nonuremic animals. A, Three cycles of IPC (5 minutes is-
chemia/5 minutes reperfusion) is highly effective in protecting
the uremic heart (SNx model) against ischemia/reperfusion injury
(****P#$0.0001). Area at risk (AAR; P#0.305) and median creat-
inine were similar for the 2 groups (84 and 90 !mol/L, respec-
tively; P#0.182). B, The same protocol proved efficacious in an
alternative model of chronic uremia (adenine diet [AD] model)
despite substantially worse renal function. The median creati-
nine was the similar for both groups (250 and 285 !mol/L,
respectively; P#0.902). C, A single cycle of IPC was more effec-
tive in limiting myocardial infarct size in uremic animals after 35
minutes of ischemia (2 hours of reperfusion) than in sham-
operated control animals (P#0.031). Box and whisker plots:
whiskers indicate maximum and minimum; box, interquartile
range; line, median; and %, mean.
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reported by Dikow and colleagues31 (33% relative increase in
infarct size). The area at risk was similar for both groups
(sham, 50.9% [IQR, 43.5%–56.2%] versus SNx, 44.8% [IQR,
42.2%–51.4%]; P!0.24).
Uremic (SNx) animals had a median serum creatinine that
was roughly 3 times that of the sham animals (91 !mol/L
[IQR, 83.7–116 !mol/L] versus 34.4 !mol/L [IQR, 33.4–
35.7 !mol/L]) and were significantly more anemic (SNx
hematocrit, 27% [IQR, 24% to 31%] versus sham, 39% [IQR,
36.3% to 41%]; P!0.0003).
IPC of Uremic Animals
Using a preconditioning protocol consisting of 3 cycles of 5
minutes of ischemia and 5 minutes of reperfusion, we were
able to achieve significant myocardial protection with an
absolute reduction in infarct size of "50% (control, 61.2%
[IQR, 54.2%–70.5%] versus IPC, 7.7% [IQR, 6% to 10%];
relative reduction [RR], 86%; P!0.002; Figure 3A); the area
at risk was similar between the 2 groups (control, 44.4%
[IQR, 41.3%–49.5%] versus IPC, 42.2% [IQR, 37.5%–
47.3%]; P!0.447), as was serum creatinine (control,
83.5 !mol/L [IQR, 74 –93.3 !mol/L] versus IPC,
89.7 !mol/L [IQR, 87.6–92.2 !mol/L]; P!0.211).
Using the same protocol, we performed an additional
experiment (Figure 3B) with an alternative model of chronic
uremia (AD). These animals have significantly greater renal
dysfunction (median serum creatinine #8 fold higher than in
controls and #3-fold greater in SNx than sham animals).
However, we still observed an RR in median infarct size of
#50% (median infarct size, 50.6% [IQR, 34.9%–75.8%] in
control animals versus 29.4% [IRQ, 7.7%–32.1%] in the IPC
group; P!0.014).
Threshold for IPC in Uremic Animals
Having established convincingly that uremic animals could
be preconditioned, we sought to determine whether there was
an increase in the threshold for eliciting cytoprotection with
IPC in uremic animals. Because nearly maximal protection
was seen with 1 cycle of IPC and 25 minutes of sustained
ischemia, we increased the period of sustained ischemia to 35
minutes for this series of experiments.
In contrast to diabetic and senescent animals, far from
seeing a blunting of the effect of a single cycle of precondi-
tioning in uremic animals, we demonstrated a significant
reduction in the infarct size of uremic (SNx) animals receiv-
ing 1 cycle of IPC compared with nonuremic (sham) animals
receiving a single cycle of IPC (median, 18.1% [IQR,
7.2–23.6] and 32.1% [IQR, 22.9–46.6], respectively;
P!$0.02; Figure 3C).
Remote Preconditioning
RIPC markedly attenuated myocardial ischemia/reperfusion
injury (P$0.0001, 2-way ANOVA). The absolute reduction
in infarct size achieved with RIPC was comparable between
Figure 4. Remote ischemic preconditioning (RIPC) of the hind limb reduces myocardial infarct size in experimental chronic uremia. A,
RIPC was associated with a significant reduction in infarct size (****P$0.0001). The relative reduction in infarct size was similar for both
uremic and nonuremic animals (P!0.456, unpaired t test). B, The area at risk was similar for all 4 groups (P!0.466, Kruskal-Wallis test).
C, Plasma creatinine was significantly higher in uremic (SNx) animals (****P$0.0001). Hematocrit was significantly lower in SNx animals
(****P$0.0001); there was no within-group difference. Box and whisker plots: whiskers indicate maximum and minimum; box, interquar-
tile range; line, median; and %, mean.
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the 2 groups (sham, 32.3% [P!0.001] versus SNx, 30.9%
[P!0.0001], Bonferroni multiple comparison). However, the
RR in infarct size was substantially but not significantly
greater in nonuremic sham-operated rats (59.3% RR in sham
versus 48.3% RR in SNx; P"0.328, Mann-Whitney; see
Figure 4). There was a trend toward an increased infarct size
in uremic animals that was of borderline statistical signifi-
cance (P"0.062). No interaction between uremia and RIPC
was demonstrated (P"0.572, 2-way ANOVA).
Ischemic Postconditioning
A postconditioning protocol consisting of 5 cycles of 10
seconds of reperfusion and 10 seconds of ischemia begun
after a 25-minute episode of sustained ischemia was used (see
Figure 5). As with all other conditioning protocols, a substan-
tial and statistically significant reduction in myocardial in-
farct size was observed (47% RR for nonuremic animals,
65% RR for SNx animals; P"0.0014, 2-way ANOVA). No
evidence of an interaction was seen between renal function
and response to iPost; ie, iPost had an equivalent effect on
infarct size reduction regardless of the presence of uremia.
Although uremic animals had a greater RR in infarct size, this
was not statistically significant (Mann-Whitney). The area at
risk was similar for all groups.
These results were mirrored by a reduction in the levels of
cardiac troponin I in postconditioned animals (P"0.0043,
2-way ANOVA; see Figure 5D). No interaction was observed
(P"0.7312).
Western Blots
In light of previous reports of altered signal transduction
associated with comorbidity18 and senescence,32 a limited
study of signaling mechanisms was undertaken in both the
SNx and AD models. A marked increase in both phosphor-
ylated STAT3 (SNx, P"0.001; AD, P"0.02) and ERK1/2
(SNx) was consistently demonstrated after 3 cycles (5 min-
utes of ischemia, 5 minutes of reperfusion) of IPC (see
Figures 6 and 7). The increase in phospho-STAT3 and
phospho-ERK1/2 was similar in uremic and nonuremic ani-
mals (SNx, P"0.034; AD, P"0.002). However, we were
unable to demonstrate a consistent result with respect to the
phosphorylation of Akt in response to the preconditioning
protocol.
Discussion
These data represent a comprehensive assessment of the
effects of chronic uremia on ischemic conditioning and
demonstrate that, unlike in diabetic,18–20 dyslipidemic,33,34
and senescent animals,21,22 chronic uremia does not appear to
attenuate the effect of IPC, RIPC, or iPost. Indeed uremic
animals appear to derive greater protection than nonuremic
animals from protocols that involve manipulating the blood
supply of the target organ directly (ie, IPC and iPost). In the
context of chronic uremia, the IPC signal appears to be
conducted through the same pathways.
Furthermore, we confirm the previously published obser-
vation of increased myocardial infarct size in uremic ani-
Figure 5. Ischemic postconditioning (iPost) reduces infarct size in uremic (SNx) animals. A, iPost resulted in a significant reduction in
myocardial infarct size in both uremic and nonuremic animals (****P!0.0001, 2-way ANOVA). B, The area at risk was similar for all 4
groups (P"0.444, Kruskal-Wallis test). C, Plasma creatinine was significantly higher in the SNx animals compared with the sham-
operated controls (****P!0.0001). There was no difference in creatinine between the SNx groups (P#0.05, Bonferroni multiple compari-
son). D, Plasma troponin after 2 hours of reperfusion was significantly less in postconditioned animals (**P"0.0043). Box and whisker
plots: whiskers indicate maximum and minimum; box, interquartile range; line, median; and $, mean.
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mals.31 Larger myocardial infarctions may in part explain the
greater mortality, particularly the increased incidence of heart
failure, seen in patients with CKD after AMI. Left ventricular
hypertrophy is a key feature of the uremic cardiac phenotype
and is extremely common in individuals with end-stage renal
disease35 and experimental models of uremia.36 However, in
contrast to patients with left ventricular hypertrophy with
normal renal function, left ventricular hypertrophy occurring
in the context of uremia appears to result in a greater degree
of intermyocyte fibrosis and capillary rarefaction.37 Thus,
there is the potential for a simultaneous increase in oxygen
demand (as a result of myocyte hypertrophy) and reduction in
oxygen delivery consequent to reduced capillary density and
increased oxygen diffusion distance. The cardiomyocyte in
the uremic heart is thus closer to the brink of ischemia.
The reduction in infarct size for uremic animals subjected
to IPC was significantly greater than in nonuremic animals
subjected to IPC, and a substantial difference of borderline
statistical significance was seen in animals that received
iPost. These observations might be the result of a type 2 error.
However, it should also be noted that there was a nonsignif-
icant trend toward a smaller area at risk in the SNx animals
that received a single cycle of preconditioning. Alternatively,
it is possible that, as a result of a lower hematocrit, the uremic
animals had less no reflow, and thus the combination of either
IPC or iPost and more extensive reperfusion resulted in even
smaller infarcts in these animals compared with the less
anemic sham-operated (nonuremic) animals. Of note, uremic
animals treated with RIPC fared no better than their sham-
operated counterparts. It is interesting to compare these
results with those of Gritsopoulos et al,38 who found that
remote postconditioning was a more potent cytoprotective
strategy than classic postconditioning, suggesting that further
direct interference with the dependent vascular bed, which
had experienced the index ischemic episode, was not entirely
without consequence.
Given that aging, diabetes mellitus, and a variety of other
metabolic disturbances have been acknowledged to reduce
the efficacy of conditioning in both animal and human
models, it is somewhat surprising that renal dysfunction does
not appear to have a similar effect. We examined the effect of
IPC in 2 different models of chronic uremia, the subtotal
Figure 6. Immunoblots for phosphorylated (p) ERK, total (tot) ERK, pSTAT3, and tot-STAT3. A, Representative immunoblot. B, A signifi-
cant increase in pERK was seen in both uremic and nonuremic animals after 3 cycles of ischemic preconditioning (IPC; *P!0.034). C,
No differences in total ERK levels were seen in either uremic or nonuremic animals. D, The ratio of pERK to tot-ERK was significantly
increased after IPC but did not differ in magnitude between uremic and nonuremic animals (*P!0.013) E, Levels of pSTAT3 were signif-
icantly increased by IPC (**P!0.0014). F, There was no significant difference between the 4 groups in the levels of total STAT3. G, The
ratio of p-STAT3 to tot-STAT3 was significantly increased after IPC but did not differ between uremic and nonuremic animals
(***P!0.0001). Bar charts show mean with SEM (n!5 for each group).
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nephrectomy (SNx) model, the most commonly used model
to study the pathophysiology of the uremic state, and AD-
induced uremia. In our hands, SNx animals are typically
hypertensive with left ventricular hypertrophy and have more
significant anemia compared with those animals with renal
dysfunction induced by AD. However, animals with AD may
be considered more uremic in that the median serum creati-
nine is !8 times that of controls, whereas the median serum
creatinine is !3-fold greater in SNx animals. Despite this
apparent disparity in the degree of renal dysfunction, the
infarcts in AD animals that received preconditioning were
nearly 50% smaller. We believe that this agreement in results
obtained from experiments with these 2 different models is
mutually supportive.
In addition, we have provided evidence that 3 cycles of IPC
(5 minutes of ischemia, 5 minutes of reperfusion) are asso-
ciated with a robust and reproducible increase in phospho-
Stat3 and phospho-ERK1/2 representing key components of
the 2 putative signal transduction mechanisms: the reperfu-
sion injury salvage kinase (RISK) pathway and the survivor
activating factor enhancement (SAFE) pathway.
IPC is thought to be triggered by a number of factors,
including adenosine, bradykinin, and endogenous opioids.
Two major intracellular signaling cascades have been pro-
posed as mediators of the preconditioning stimulus, the RISK
pathway and the SAFE pathway. In addition, both these
pathways have been implicated in mediating the infarct
size–limiting effects of iPost.
The RISK pathway is considered to consist of 2 arms, 1
arm involving MEK1/2 and ERK1/2 and the other involving
PI3 kinase and Akt. Both arms are thought to be triggered by
the binding of specific ligands with G-protein–coupled re-
ceptors and terminate on glycogen synthase kinase-3-! to
reduce the likelihood of mitochondrial permeability transition
pore opening and thus attenuate reperfusion injury.39
The SAFE pathway was first identified as the mediator of
cardioprotection induced by tumor necrosis factor-".40 How-
ever, JAK/Stat signaling, which is at the heart of the SAFE
pathway, is now recognized to be important in the transduc-
tion of a number of other infarct size–limiting therapies and
has been implicated in IPC (both the early and late phases41),
iPost,42 and RIPC. As with the RISK pathway, it is thought
that inhibition of the mitochondrial permeability transition
pore is the end effector of this pathway.
It has been nearly a quarter of a century since Murry and
colleagues16 made their seminal discovery of IPC, but despite
the widespread acknowledgement that ischemic conditioning
represents the most powerful cytoprotective strategy yet
discovered with overwhelming animal data to attest to the
benefit of conditioning, it has failed to gain acceptance within
the broader medical community or to be adopted into routine
clinical practice. This is possibly due to a perceived compar-
ative lack of efficacy of conditioning in humans. Human trials
conducted to date have mostly been small scale, usually from
a single center, with limited follow-up and thus have been
underpowered to demonstrate mortality differences. They
have therefore used surrogate outcome measures such as the
magnitude of rise in biomarkers of cardiac ischemia.43
Figure 7. Immunoblots of phosphorylated (p) ERK, total (tot)
ERK, pSTAT3, and tot-STAT3 in adenine diet (AD) animals. A,
Representative immunoblot. B, A significant increase in pERK
was seen in both uremic and nonuremic animals after 3 cycles
of ischemic preconditioning (IPC; **P"0.018). C, No differences
in tot-ERK levels were seen in either uremic or nonuremic ani-
mals. D, The ratio of pERK to tot-ERK was significantly
increased after IPC but did not differ in magnitude between ure-
mic and nonuremic animals (**P"0.0077). E, Levels of pSTAT3
were significantly increased by IPC (*P"0.02). F, There was no
significant difference between the 4 groups in the levels of tot-
STAT3. G, The ratio of pSTAT3 to tot-STAT3 was significantly
increased after IPC but did not differ between uremic and non-
uremic animals (****P#0.0001). Bar charts show mean with SEM
(n"4 for each group except AD-IPC, for which n"3).
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Animal models that evaluate cytoprotective strategies usu-
ally use healthy, juvenile animals. This is in marked contrast
to human disease, which rarely occurs in the absence of
comorbidities. Such comorbid conditions may influence the
efficacy of experimental treatments.44 Furthermore, animal
studies typically compare treated with untreated animals,
whereas in clinical trials, a new treatment in addition to
existing therapy is compared with existing therapy alone.
Renal dysfunction is a common comorbidity in those
presenting with AMI and engenders an adverse prognosis. It
may also modulate the risk-benefit relationship for existing
therapies. The fundamental purpose of our studies was to
examine the effect of impaired renal function on conditioning
strategies.
It has been suggested that reperfusion therapy alone is
sufficient to maximally limit infarct size for the majority of
patients. However, it is estimated that one quarter of patients
still sustain myocardial infarcts of!75% of the area at risk.45
In a recently published clinical trial of remote ischemic
conditioning,46 for a given area at risk, patients who received
remote ischemic conditioning had a smaller infarct. This
effect was most marked for those with the largest area at risk.
A similar effect was seen in a small clinical trial of iPost as
an adjunct to primary PCI.47 Infarct size is a major risk factor
for the development of post-AMI heart failure and therefore
long-term prognosis. With this in mind, we speculate that a
major reason for the apparently disappointing results of
human trials of conditioning may be poor patient selection;
we should be targeting patients at the highest risk of an
adverse outcome to receive adjuvant cardioprotective thera-
pies. Therefore, we would envisage that post-AMI outcome
might be improved for patients with CKD by the addition of
a conditioning strategy to early reperfusion.
The higher event rate seen in patients with CKD and
end-stage renal disease could in theory allow trials suffi-
ciently powered to detect differences in mortality to be
conducted with a smaller sample size. It would be desirable to
corroborate our findings in human subjects with CKD and
end-stage renal disease.
Conclusions
We report for the first time that conditioning strategies
provide powerful cardioprotection in the setting of experi-
mental uremia. There is an urgent and at present unmet need
to improve outcomes for patients with CKD suffering from
AMI. The routine exclusion of individuals with impaired
renal function from clinical trials impedes the advancement
of the care of these patients. Patients with CKD may derive
benefit from conditioning strategies over and above that seen
in patients without CKD.
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CLINICAL PERSPECTIVE
Ischemic conditioning encompasses a number of established experimental techniques that provide powerful protection for
an organ or vascular bed against ischemia/reperfusion injury. However, by and large, clinical trials have not delivered on
the promise of preclinical studies undertaken in animals. A number of comorbid conditions such as diabetes mellitus and
dyslipidemia have been demonstrated in animal models to attenuate the efficacy of ischemic conditioning. Up to one third
of patients presenting with an acute coronary syndrome have chronic kidney disease. These patients have a particularly
poor prognosis after acute myocardial infarction that has not been improved by enhanced reperfusion rates. Moreover,
patients with chronic kidney disease are frequently excluded from clinical trials. The present study demonstrates that renal
dysfunction per se is not a barrier to achieving substantial myocardial protection with ischemic preconditioning, remote
ischemic preconditioning, and ischemic postconditioning. The survival pathways thought to be important in transducing the
protective effect of ischemic preconditioning, remote ischemic preconditioning, and ischemic postconditioning appear to
be preserved and activated to the same degree in 2 different models of experimental renal failure. This study provides the
preclinical data to justify the inclusion of patients with chronic kidney disease in future clinical trials of ischemic
conditioning as adjuvant therapy to reperfusion in the setting of acute myocardial infarction.
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